



2024 No. 158

Analysis of Practice for the Physical Therapy Profession: Report Memo 2024

Prepared for: Federation of State Boards of
Physical Therapy
124 West Street South
Alexandria, VA 22314

Date: November 15,
2024

Authors: Nicholas Howald
Jessica L. Harris
Teresa Bui

Analysis of Practice for the Physical Therapy Profession: Report Memo 2024

Table of Contents

Background and Executive Summary	1
Summary of Practice Analysis Survey Changes.....	2
Sample Selection and Administration	2
Data Cleaning and Screening	3
Response Rates and Final Analysis Sample	3
Sample Description and Representativeness	4
Work Activity and Knowledge and Skill Requirements: Data Analytic Strategy	5
Work Activity and Knowledge and Skill Requirements: Results Summary	7
Recommendations for Future Practice Analysis Survey Cycles	27
References	28
Appendix A. Summary of Background Questionnaire Responses	1
Appendix B. Summary of Work Activity and Knowledge and Skill Requirements Survey Responses	1
Appendix C. Notable Mean Differences Across Years.....	1

List of Tables

Table 1. Data Quality Screens	3
Table 2. Survey Distribution and Response Rates	4
Table 3. Estimates of Interrater Consistency and Agreement.....	6
Table A.1. Descriptive Statistics for the 2024 Background Questionnaire	A-1
Table B.1. PT Work Activity Survey Results	B-2
Table B.2. PTA Work Activity Survey Results	B-25
Table B.3. PT Knowledge and Skill Requirements Survey Results.....	B-44
Table B.4. PTA Knowledge and Skill Requirements Survey Results	B-64
Table C.1. Notable Mean Differences Across Years	C-2

Table of Contents (Continued)

List of Figures

Figure 1. WA Importance Scale	1
Figure 2. KSR Importance Scale	2
Figure 3. PT KSR Blood-flow Restriction by State	12
Figure 4. PT WA Blood-flow Restriction by State	13
Figure 5. PTA KSR Blood-flow Restriction by State	14
Figure 6. PT KSR Cupping by State	15
Figure 7. PT WA Cupping by State	16
Figure 8. PTA KSR Cupping by State	17
Figure 9. PT WA Dry Needling by State	18
Figure 10. PT WA Dry Needling by Setting	19
Figure 11. PT KSR Telehealth by State	20
Figure 12. PTA KSR Telehealth by State	21
Figure 13. PT KSR Regenerative Medicine (Neuromuscular and Nervous System) by State	22
Figure 14. PT KSR Regenerative Medicine (Musculoskeletal Disease) by State	23
Figure 15. PT WA Negative Pressure Wound Therapy by Setting	24
Figure 16. PTA WA Negative Pressure Wound Therapy by Setting	25
Figure 17. PT WA Sharp Debridement by Setting	26

Analysis of Practice for the Physical Therapy Profession: Report Memo 2024

Background and Executive Summary

This memo summarizes the process and results of the analysis of practice for the physical therapy profession conducted by the Federation of State Boards of Physical Therapy (FSBPT) in partnership with the Human Resources Research Organization (HumRRO). The study documented in this memo was conducted between January and July 2024 and represents the seventh data collection cycle in the multi-year practice analysis methodology through 2024.

The methodology enables FSBPT to (a) monitor on-going and emerging trends in entry-level requirements, (b) respond quickly to changes in the profession that necessitate adjustments to the licensure examinations (e.g., removing test questions that assess skill areas of decreasing importance; increasing the numbers of test questions that assess skill areas of increasing importance), and (c) enhance awareness among current and prospective PTs and PTAs of FSBPT's mission, purpose, and the services it provides.

The approach to conduct the analysis of physical therapy practice in 2024 was similar to that taken in recent years (e.g., Howald et al., 2023; Harris, Rogers, & Caramagno, 2021).

- In February 2024, HumRRO collected input on existing lists of work activities (WAs) and knowledge and skill requirements (KSRs) from the FSBPT. HumRRO also reviewed feedback on this list obtained from the Exam Committee Chairs in 2023.
- HumRRO used this input to modify the online survey used to gather ratings of the WAs and KSRs from a large sample of PTs and PTAs across 53 licensing jurisdictions comprising FSBPT's membership. The survey had two sections: a set of questions about the demographic characteristics of the sample and a set of WAs or KSRs that respondents evaluated using a five-point Likert-type importance rating scale (see Figures 1 and 2).
- HumRRO analyzed the response data, compiled the results in summary tables and charts, and shared the results with FSBPT and the Exam Committee Chairs.
- HumRRO reviewed the results of the survey on July 12, 2024, with the Exam Committee Chairs. The results are described in detail in this memo.

Figure 1. WA Importance Scale

How important is it for you to perform this work activity to provide safe and effective care?					
0	1	2	3	4	5
I have not performed this work activity	Not important	Minimally important	Moderately important	Very important	Extremely important

Figure 2. KSR Importance Scale

How important is this knowledge or skill for an entry-level physical therapist (<i>physical therapist assistant</i>) to provide safe and effective care?				
1	2	3	4	5
Not important	Minimally important	Moderately important	Very important	Extremely important

Summary of Practice Analysis Survey Changes

Prior to administering the survey, FSBPT and HumRRO reviewed the previous year's Exam Committee Chairs' feedback of the 2023 survey to determine whether adjustments to the wording of items or the addition of new items was warranted. In 2024, the majority of background questions, WAs, and KSRs were unchanged from 2023, although some very minor changes were made to a few items (changes are in bold; strikethrough text indicates text that was removed):

- PT KSR
 - Function, implications, contraindications and related precautions of mechanical circulatory devices (e.g. extracorporeal membrane oxygenation ~~{[ECMO]}~~, intraaortic balloon pump ~~{[IABP]}~~, ventricular assist devices ~~{[VAD]}~~)
 - Adverse effects or complications on the integumentary system from physical therapy and medical/surgical interventions **used** on the integumentary system
- PTA WA
 - Perform tests and measures of body composition (e.g., percent body fat, lean muscle mass, body mass index ~~{[BMI]}~~)

Sample Selection and Administration

- FSBPT selected participant samples from a list of licensure candidates who had passed the National Physical Therapy Exam (NPTE) stratified by exam level, year of licensure, and initial licensure jurisdiction.
- HumRRO sent email invitations starting on April 11, 2024. All respondents were sent periodic reminder emails for the duration of the survey.
- The survey closed on June 6, 2024.
- Consistent with previous years, respondents completed either the WA or KSR survey based on their years of professional experience. Individuals with two or fewer years of experience were assigned to the WA survey. Individuals with three or more years of experience completed the KSR survey. The PT KSR survey also incorporated branching logic to redirect respondents who indicated that they routinely supervise PTAs and have

a good understanding of the knowledge and skills PTAs need to provide safe and effective care.¹

Data Cleaning and Screening

To ensure data quality, HumRRO:

- Examined the raw data to identify unexpected responses, such as duplicates.
- Applied data screens to remove careless responder data based on flat, hasty, or missing response patterns, as well as ineligible employment status. The respondents screened out at this step are summarized in Table 1.

Table 1. Data Quality Screens

Data Screen	PT KSR		PTA KSR		PT WA		PTA WA	
	A	B	A	B	A	B	A	B
Flat Responding	16	30	11	19	18	5	9	3
Hasty Responding	3	2	4	3	3	0	1	1
Missing >90% of responses	119	61	51	30	49	35	24	15
Employment Status								
Retired	5	3	7	6	--	1	--	--
Unemployed and <i>not</i> looking for work as a PT or PTA	14	18	21	26	2	3	6	5
Total	153	110	87	77	68	41	36	22

Note. Flat Responding includes individuals who selected the same response value an unreasonably high number of times in a row. Hasty Responding includes individuals who completed the survey too quickly to have been paying adequate attention to the survey questions. The values in the “Total” row account for overlapping across the data screens and identify the absolute number of cases that were excluded (i.e., no double-counting).

Response Rates and Final Analysis Sample

Table 2 summarizes the response rates for the 2024 practice analysis surveys.

- The “Responded” count is the number of individuals who started the survey and completed at least the background questions.

¹ In prior years, the branching logic was “turned off” during survey administration once an adequate sample of PT KSR participants completed the PTA KSR survey. Starting in 2020, HumRRO programmed two separate PT KSR background questionnaires—one with branching logic and one without branching logic (i.e., questionnaires were the exact same except for the branching logic). FSBPT randomly selected 20% of PT KSR participants to be assigned to the background questionnaire containing the branching logic. This ensured an adequate sample of PT KSR participants completed the PTA KSR survey without needing to adjust any aspects of the survey during administration.

- The “Usable” count reflects the number of respondents who provided response data of acceptable quality based on the data screens noted above. The rates of usable responses are notably about half of what they were in 2023.
- The final analysis sample included data from 2,246 respondents across all survey forms.

Table 2. Survey Distribution and Response Rates

Sample	Invited	Responded			Usable	
		Form A	Form B	Total		
PT KSR	32,961	678	636	1,314	1,051	3.2%*
PTA KSR	18,447	331	360	691	527	2.9%*
PT WA	12,396	294	296	590	481	3.9%
PTA WA	5,493	117	128	245	187	3.4%

*Note. *120 PT KSR respondents were reassigned to the PTA KSR survey based on responses to the background question regarding supervision of PTAs.*

Sample Description and Representativeness

HumRRO calculated descriptive statistics for all items in the background questionnaires. Below, we provide an overview of the respondents' demographic characteristics for key variables. The complete results of the background questionnaire are presented in Appendix A.

- The majority of survey respondents identified as female (70.5% PT WA, 73.2% PT KSR, 75.9% PTA WA, 71.2% PTA KSR), White (70.2-77.2%), and employed as a physical therapist or physical therapist assistant full-time by an employer other than oneself (88.4% PT WA, 71.8% PT KSR, 84.5% PTA WA, 70.8% PTA KSR).
- The majority of the PT WA respondents (91.7%) and PT KSR respondents (75.7%) held Doctor of Physical Therapy (DPT) or clinical doctorate degrees while the majority of the PTA WA respondents (73.8%) and PTA KSR respondents (52.8%) held associate's degrees.
- Respondents to the PT WA and PT KSR surveys reported spending more than 50% of their time in private outpatient facilities (38.7% and 22.7%, respectively), health system or hospital-based outpatient facilities (26.8% and 19.6%), acute care hospitals (8.1% and 11.9%), home health or home care facilities (2.5% and 12.0%), and skilled nursing facilities (4.0% and 6.9%).
- Respondents to the PTA WA and PTA KSR surveys reported spending more than 50% of their time working in private outpatient facilities (42.8% and 24.3%, respectively), hospital-based outpatient facilities (18.7% and 17.3%), skilled nursing facilities (13.9% and 19.2%), home health or home care facilities (3.2% and 14.2%), acute care hospitals (5.9% and 6.1%).
- The majority of PTs and PTAs (55.6-67.6%) reported having only one employment position/job in the past 12 months, although many reported holding two to three positions (29.2-42.2%).

- The majority of PTs and PTAs (74.5-94.1%) reported spending more than three-fourths of their time in direct patient care.

Work Activity and Knowledge and Skill Requirements: Data Analytic Strategy

Analysis of the WA and KSR survey data consisted of computing descriptive statistics to examine the distribution and mean of respondents' ratings and interrater agreement indices to evaluate the degree of agreement and consistency in the response sets.

In 2023, the following changes were made to the calculation of Percent Perform and Percent Important metrics.

- We discovered that the calculation of Percent Perform from 2018-2022 included missing respondents in the numerator (i.e., effectively counting them as performing the WA) due to a syntax error. This resulted in an overestimate of a given WA's Percent Performance to the extent that respondents were missing data for that WA. In 2023, we corrected this mistake so that missing respondents are no longer counted in the numerator for Percent Perform. We reviewed the differences in the previous calculations with the Exam Chairs Committees and determined that there were no WAs that were significantly impacted by the error such that the WA would have been resulted in a different inclusion status on the 2024 NPTE Content Outlines.
- We changed how we define "usable responses" (i.e., the denominator) for both Percent Perform and Percent Important. From 2018-2022, missing respondents for a given WA or KSR were included in the denominator (given that they were not screened out of the overall analysis sample for missing over 90% of data). This had the effect of slightly lowering Percent Perform and Percent Important for a given WA or KSR. Beginning in 2023, we have calculated these metrics using only data for people who responded to a given WA or KSR. In other words, missing data is no longer included in the denominator (or the numerator, per the previous bullet point) for these metrics.

HumRRO conducted the following analyses for WAs and KSRs:

- For each WA statement, HumRRO computed:
 - Sample size: number of usable respondents.
 - Percent perform ($\%_{\text{Perf}}$): Sum of responses for scale points 1 through 5, divided by the total number of usable respondents.
 - Percent important ($\%_{\text{Imp}}$): Sum of responses for scale points 2 through 5, divided by the total number of usable respondents.
 - Mean importance (M): Based on responses for scale points 1 through 5. Mean WA importance ratings exclude respondents who selected the option *I have not performed this WA*.
 - Standard deviation of importance (SD): Based on responses for scale points 1 through 5.
- For each KSR statement, HumRRO computed:
 - Sample size: number of usable respondents.

- Percent important (%_{Imp}): Sum of responses for scale points 2 through 5, divided by the total number of usable respondents.
- Mean importance (M): Based on responses for scale points 1 through 5.
- Standard deviation of importance (SD): Based on responses for scale points 1 through 5.
- For select WA and KSR statements, HumRRO also compared ratings by work setting and state and provided graphs depicting these differences.
- Two types of intraclass correlation coefficients (ICCs; McGraw & Wong, 1996; Shrout & Fleiss, 1979) were computed to estimate the degree of consistency and agreement among the survey respondents. Results are indicated in Table 3.
 - Consistency refers to the extent to which the patterns of ratings between raters are similar (i.e., the rank ordering of statements is similar between raters). Agreement refers to the extent to which the absolute value of ratings are similar to each other. For example, consider a situation where two raters gave the following ratings:
 - Rater 1:
 - Statement 1: 1
 - Statement 2: 3
 - Rater 2:
 - Statement 1: 3
 - Statement 2: 5

In this situation, the raters have perfectly consistent ratings, but they do not have perfect agreement.

For both types of intraclass correlations, we computed both “1-rater” and “observed” estimates, where:

- The 1-rater estimates indicate the level of consistency (or agreement) to be expected between the ratings provided by any single rater with any other randomly selected single rater, and
- The observed estimates indicate the degree of consistency (or agreement) to be expected between the average among the sample of survey participants and the average that would be obtained if another random sample were to be drawn from the population.

Table 3. Estimates of Interrater Consistency and Agreement

Survey	Form	Number of Items	Type of ICC			
			Consistency		Agreement	
			1-rater	Observed	1-rater	Observed
PT KSR	A	81	.69	.99	.66	.99
	B	78	.68	.99	.62	.99
PTA KSR	A	72	.73	>.99	.70	.99
	B	69	.72	.99	.68	.99
PT WA	A	118	.66	>.99	.62	.99
	B	124	.61	.99	.55	.99
PTA WA	A	99	.68	>.99	.64	.99
	B	102	.60	.99	.54	.99

Note. Consistency and agreement ICCs estimated for a single rater (1-Rater) and for the total number of raters (Observed).

Work Activity and Knowledge and Skill Requirements: Results Summary

Descriptive statistics for all PT and PTA WAs and KSRs are presented in Appendix B. To keep tables concise, we report only the most recent five years of analyses (2020 to 2024). We refer interested readers to previous project reports (Howald et al., 2023; Harris, Caramagno, & Rogers, 2022a; Harris, Caramagno, & Rogers, 2022b) for descriptive statistics from prior years. Based on the descriptive statistics, HumRRO flagged statements that:

- 1) fell at, just above, or below the “criticality threshold” for mean importance (2.50),
- 2) increased or decreased in mean importance by greater than 0.50 between 2020 and 2024 or between 2023 and 2024, or
- 3) were of particular interest to FSBPT given current trends, changes in the field, or desire to track data by work setting or state.

Findings for each of these three categories of statements are presented in Appendices B and C and are summarized below.

- **Statements at, just above, or below the mean importance criticality threshold.**
 Using the criticality threshold of 2.50, which represents halfway between scale points 2 (Minimally Important) and 3 (Moderately Important), HumRRO extracted statements that received mean importance ratings at, just above (between 2.50 and 3.00), or below (<2.50) this threshold (see red and orange highlighted statements in Appendix B).
 - **PT KSR:** Overall, eight PT KSR statements fell below the criticality threshold (<2.50), indicating relatively low mean importance ratings. These included:
 - Knowledge of:
 - dry heat thermotherapy (e.g., Fluidotherapy)
 - laser light therapy
 - diagnostic electrophysiology (EMG/NCV) using needle insertion
 - physical therapy ultrasound imaging of the genitourinary system
 - Knowledge of applications, indications, contraindications, and precautions of:
 - LED light therapy
 - phonophoresis
 - shockwave therapy
 - diathermy

The mean importance ratings for these statements ranged from 2.14 to 2.48. These results are consistent with previous practice analysis survey results, with the mean importance of each of these statements falling near or below the criticality threshold in recent years.

- **PTA KSR:** Of the PTA KSR statements, three fell below the criticality threshold. These included:
 - Applications, indications, contraindications, and precautions of:
 - diathermy

- LED light therapy
- phonophoresis

These results ranged in mean importance from 2.37 to 2.44. This is consistent with the decreasing trend in importance ratings for these statements in the past few years (2021-2023). However, this is the first year that the mean importance ratings ($M = 2.44$; $M = 2.42$; $M = 2.37$) have dropped below the criticality threshold.

- **PT WA:** Of the PT WA statements, 14 fell below the criticality threshold. All except three statements were associated with “Therapeutic Modalities.” The other statements were associated with “Integumentary Repair & Protection Techniques,” “Manual Therapy Techniques,” and “Anthropometric Tests and Measures.” The 14 PT WA statements included:

- Perform and/or train patient/client/caregiver in:
 - postural drainage
 - hyperbaric therapy
 - apply taping for edema management
 - hydrotherapy using contrast baths/pools
 - paraffin bath thermotherapy
 - ultrasound procedures
 - iontophoresis
 - phototherapy (laser light)
 - phonophoresis
 - monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])
 - shockwave therapy
 - dry heat thermotherapy (e.g., Fluidotherapy)
 - diathermy
- Select and perform tests and measures of body composition (e.g., percent body fat, lean muscle mass, body mass index [BMI])

These statements ranged in mean importance from 1.77 to 2.48. These results are consistent with previous practice analysis survey results, with the mean importance of each of these statements falling near or below the criticality threshold in recent years.

- **PTA WA:** Eight PTA WA statements fell below the criticality threshold. These included:

- Perform and/or train patient/client/caregiver in:
 - hyperbaric therapy
 - negative pressure wound therapy (e.g., vacuum-assisted wound closure)
 - shockwave therapy
 - perform sharp debridement (e.g., removal of specific areas of devitalized tissue)
 - phototherapy (laser light)
 - phonophoresis

- monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])
- Perform tests and measures of body composition (e.g., percent body fat, lean muscle mass, body mass index [BMI])

These statements ranged in mean importance from 2.15 to 2.48. For most of these statements, the mean importance rating in 2024 does not greatly differ from that of recent years. However, “Perform tests and measures of body composition...” did have a large change from 2023, decreasing by 0.53.

- **Statements with mean differences greater than 0.50.** HumRRO computed the difference between mean importance ratings across years and highlighted values that indicated an increase or decrease in mean importance of more than 0.50 occurring between 2024 and 2023 (i.e., within the past year) or between 2024 and 2020 (i.e., over the past four years). See Appendix C for the full table of these results.

– PT KSRs

- Two PT KSRs decreased in mean importance by more than 0.50 since 2020
 - Applications, indications, contraindications, and precautions of:
 - dry heat thermotherapy (e.g., Fluidotherapy)
change since 2020: **-1.22**; change since 2023: -0.22)
 - LED light therapy
(change since 2020: **-0.55**; change since 2023: -0.05)

– PTA KSRs

- Seven PTA KSRs decreased in mean importance by more than 0.50 since 2020:
 - Applications, indications, contraindications, and precautions of:
 - dry heat thermotherapy (e.g., Fluidotherapy)
(change since 2020: **-1.66**; change since 2023: -0.18)
 - iontophoresis
(change since 2020: **-0.61**; change since 2023: -0.10)
 - laser light therapy
(change since 2020: **-0.58**; change since 2023: -0.05)
 - LED light therapy Error! Bookmark not defined.
(change since 2020: **-0.75**; change since 2023: -0.09)
 - phonophoresis
(change since 2020: **-0.74**; change since 2023: -0.26)
 - ultrasound modalities, excluding phonophoresis
(change since 2020: **-0.62**; change since 2023: -0.12)
 - diathermy
(change since 2020: **-0.61**; change since 2023: -0.14)

– PT WAs

- One PT WA increased in mean importance by more than 0.50 since 2023:
 - Perform and/or train patient/client/caregiver in selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)
(change since 2020: 0.41; change since 2023: **0.51**)

– **PTA WAs**

- One PTA WA decreased in mean importance by more than 0.50 since 2020, one PTA WA decreased in mean importance by more than 0.50 since 2023, and one PTA WA increased in mean importance by more than 0.50 since 2023:
 - Perform tests and measures of body composition (e.g., percent body fat, lean muscle mass, body mass index [BMI]) (change since 2020: -0.32; change since 2023: **-0.53**)
 - Perform peripheral mobilization/manipulation (thrust) (change since 2020: **-0.52**; change since 2023: -0.35)
 - Disclose financial interest in recommended products or services to patient/client (change since 2020: 0.49; change since 2023: **0.84**)
- **Selected WAs and KSRs:** FSBPT indicated special interest in tracking a number of specific WAs and KSRs over time due to relevant changes and trends in the physical therapy field. FSBPT typically indicated interest in tracking these statements by state or work setting (or both). For KSRs, we only conducted analyses of mean importance of KSRs for states or work settings where there were at least 20 respondents. For WA statements, we also only reported “percent perform” for states or work settings where there were at least 20 respondents, but reported mean importance ratings for those states or work settings if at least 10 respondents reported they had performed the activity. These analyses, reported below, included:
 - Blood-flow restriction, by state, for PT KSR, PT WA, and PTA KSR
 - Cupping, by state, for PT KSR, PT WA, and PTA KSR
 - Dry needling, by state and work setting, for PT WA
 - Telehealth, by state, for PT KSR and PTA KSR
 - Regenerative medicine, by state, for PT KSR
 - Negative pressure wound therapy, by work setting, for PT WA and PTA WA
 - Sharp debridement, by work setting, for PT WA

Blood-flow restriction, by state (PT KSR and WA, PTA KSR). Figures 3 through 5 depict our findings for blood-flow restriction by state. The mean importance rating for this KSR across the overall sample of PTs was 2.95, and most of the states we examined for the PT KSR data had mean ratings around this value, with none falling below the criticality index of 2.50. The percentage of the overall PT sample who perform the blood-flow restriction WA was 55%. For the PTA KSR sample, only Ohio was below the mean importance criticality threshold of 2.50. Most of the states examined had mean importance ratings above the overall sample’s mean value of 2.90.

Cupping, by state (PT KSR and WA, PTA KSR). Figures 6 through 8 depict our findings for cupping by state. The mean rating for this KSR across the overall sample of PTs was 2.64. Similar to blood-flow restriction, most of the states we examined were around this value, although two states (Pennsylvania and Texas) were at or below the criticality threshold. For the cupping PT WA, all states we examined except one (Illinois) had at least 50% of respondents indicating they perform this WA. The percentage performing this WA in the overall PT sample was 67%. For the PTA KSR

sample, most states had mean importance ratings near the overall mean value of 2.77. Two states (Ohio and Illinois) were at or below the criticality threshold.

Dry needling, by state and work setting (PT WA). Figures 9 and 10 depict our findings for dry needling. The mean importance rating for this WA in the PT sample was 3.17, and the percent performing this WA was 48%. There was considerable variation in the percentage of PAs performing this WA across the states that we examined, but relatively little variation across work settings.

Telehealth, by state (PT KSR, PTA KSR). Figures 11 and 12 depict our findings for telehealth by state for the PT sample. The mean importance rating for this KSR in the overall PT sample was 3.24, and most of the states that we examined had mean ratings close to that value, with none falling below the criticality index. The mean importance rating for this KSR in the overall PTA sample was 3.15, and there was more variation among states than in the PT sample. The mean rating for Massachusetts was at the criticality threshold.

Regenerative medicine, by state (PT KSR). Figures 13 and 14 depict our findings for regenerative medicine by state. There were two different PT KSRs on this topic, with results for the neuromuscular and nervous systems summarized in Figure 13 and the results for musculoskeletal diseases summarized in Figure 14. The mean importance rating in the overall PT sample for the former was 2.99, and the mean rating in the overall sample for the latter was 3.07. Most state means were close to the overall mean ratings for both topics, with none falling below the criticality index.

Negative pressure wound therapy, by work setting (PT WA, PTA WA). Figures 15 and 16 depict our findings for negative pressure wound therapy. The percentage of PT respondents who reported performing this WA was 24%, and the mean importance rating was 2.68. Although relatively few respondents reported performing this WA, those who perform it deem it to be important. Each of these metrics varied based on work setting, with suburban settings indicating the lowest percent performing and the lowest mean rating. In the PTA sample, the percentage reporting performing this WA was 32%, with a similar variation based on work setting (again with suburban respondents indicating the lowest percentage of respondents performing this WA).

Sharp debridement, by work setting (PT WA). Figure 17 depicts our findings for sharp debridement. The percentage of PT respondents who reported performing this WA was 22%, and the mean importance rating was 2.61. Similar to negative pressure wound therapy, few respondents report performing this WA, but those who do perform it rated it as important. Suburban respondents yielded the lowest percentage of PTs performing, but urban/metropolitan respondents had the lowest mean importance rating (which was just at the criticality threshold).

Figure 3. PT KSR Blood-flow Restriction by State




Figure 4. PT WA Blood-flow Restriction by State




Figure 5. PTA KSR Blood-flow Restriction by State




Figure 6. PT KSR Cupping by State




Figure 7. PT WA Cupping by State




Figure 8. PTA KSR Cupping by State




Figure 9. PT WA Dry Needling by State




Figure 10. PT WA Dry Needling by Setting





Figure 11. PT KSR Telehealth by State




Figure 12. PTA KSR Telehealth by State




Figure 13. PT KSR Regenerative Medicine (Neuromuscular and Nervous System) by State




Figure 14. PT KSR Regenerative Medicine (Musculoskeletal Disease) by State




Figure 15. PT WA Negative Pressure Wound Therapy by Setting





Figure 16. PTA WA Negative Pressure Wound Therapy by Setting






Figure 17. PT WA Sharp Debridement by Setting



Recommendations for Future Practice Analysis Survey Cycles

All results were presented during the 2024 Exam Chairs meeting or were provided to the Exam Chairs offline. During the meeting, we received feedback for future survey administrations and analyses, which we summarize here.

- Encourage item writers to develop items about more modern airway clearance techniques, as there are methods other than postural drainage that are more frequently used.
- Continue to monitor PTA WA about blood-flow restriction, as it is trending upward in mean importance. Currently, this topic is not on the test content outline.
- Consider adding sleep hygiene as an example in the PT/PTA WA “Educate patient/client and/or caregiver about lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation).”

References

- Harris, J.L., Caramagno, J.P., & Rogers, A.P. (2022a). *Analysis of practice for the physical therapy profession: Entry-level physical therapists* (No. 094). Human Resources Research Organization.
- Harris, J.L., Caramagno, J.P., & Rogers, A.P. (2022b). *Analysis of practice for the physical therapy profession: Entry-level physical therapist assistants* (No. 095). Human Resources Research Organization.
- Harris, J.L., Rogers, A.P., Caramagno, J.P. (2021). *Analysis of practice for the physical therapy profession: Report memo 2021* (No. 100). Human Resources Research Organization.
- Howald, N., Bui, T., & Harris, J. (2023). *Analysis of practice for the physical therapy profession: Report memo 2023* (No. 159). Human Resources Research Organization
- McGraw, K. O., & Wong, S. P. (1996). Forming inferences about some intraclass correlation coefficients. *Psychological Methods*, 1, 30-46.
- Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. *Psychological Bulletin*, 86, 420-428.

Appendix A. Summary of Background Questionnaire Responses

Table A.1. Descriptive Statistics for the 2024 Background Questionnaire

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q1 What is your gender?								
I prefer not to respond	16	7	6	3	1.5	1.3	1.2	1.6
Female	769	375	339	142	73.2	71.2	70.5	75.9
Male	262	143	133	41	24.9	27.1	27.7	21.9
Transgender	2	0	0	0	0.2	0.0	0.0	0.0
Gender Non-Binary	2	2	2	1	0.2	0.4	0.4	0.5
[other]	0	0	1	0	0.0	0.0	0.2	0.0
Q2 Are you Hispanic or Latino?								
I prefer not to respond	30	14	8	3	2.9	2.7	1.7	1.6
Yes	44	52	34	21	4.2	9.9	7.1	11.2
No	977	461	439	163	93.0	87.5	91.3	87.2
Q3 What is your race?								
I prefer not to respond	63	25	17	7	6.0	4.7	3.5	3.7
American Indian or Alaska Native	6	6	2	2	0.6	1.1	0.4	1.1
Asian	201	65	85	22	19.1	12.3	17.7	11.8
Black or African American	41	18	25	12	3.9	3.4	5.2	6.4
Native Hawaiian or Other Pacific Islander	6	7	1	0	0.6	1.3	0.2	0.0
White	738	407	362	143	70.2	77.2	75.3	76.5
[other]	13	13	8	8	1.2	2.5	1.7	4.3
Q4 What is the highest academic degree related to physical therapy that you have earned?								
Certificate	0	0	0	1	0.0	0.0	0.0	0.5
Associate's	0	278	0	138	0.0	52.8	0.0	73.8
Bachelor's	88	111	21	45	8.4	21.1	4.4	24.1
Master's	131	28	14	3	12.5	5.3	2.9	1.6
Doctor of Physical Therapy (DPT, clinical doctorate)	796	101	441	0	75.7	19.2	91.7	0.0
Other doctoral degree (PhD, EdD, or other)	29	2	1	0	2.8	0.4	0.2	0.0
[other]	7	7	4	0	0.7	1.3	0.8	0.0
Q5 Where did you complete your entry-level physical therapy education?								
United States	858	480	422	179	81.6	91.1	87.7	95.7
Canada	6	0	0	0	0.6	0.0	0.0	0.0
Egypt	6	2	2	0	0.6	0.4	0.4	0.0
India	43	10	20	2	4.1	1.9	4.2	1.1
Philippines	117	29	15	4	11.1	5.5	3.1	2.1
South Korea	4	0	3	0	0.4	0.0	0.6	0.0
United Kingdom	1	0	1	0	0.1	0.0	0.2	0.0
[other]	16	6	18	2	1.5	1.1	3.7	1.1

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q6 In what year were you FIRST licensed as a physical therapist in the United States, the District of Columbia, U.S. Virgin Islands, or Puerto Rico?								
Not selected	0	0	0	0	0.0	0.0	0.0	0.0
1955-1959	0	0	0	0	0.0	0.0	0.0	0.0
1960-1969	0	0	0	0	0.0	0.0	0.0	0.0
1970-1979	0	0	0	0	0.0	0.0	0.0	0.0
1980-1989	2	3	0	0	0.2	0.6	0.0	0.0
1990-1999	90	32	0	1	8.6	6.1	0.0	0.5
2000-2009	302	107	1	0	28.7	20.3	0.2	0.0
2010-2019	653	380	1	0	62.1	72.1	0.2	0.0
2020-2024	4	5	479	186	0.4	0.9	99.6	99.5
Q7 In which one of the following United States physical therapy jurisdictions do you currently have your PRIMARY clinical work setting?								
Not selected	0	0	0	0	0.0	0.0	0.0	0.0
Alabama	13	7	5	5	1.2	1.3	1.0	2.7
Alaska	2	1	1	0	0.2	0.2	0.2	0.0
Arizona	32	7	13	3	3.0	1.3	2.7	1.6
Arkansas	7	5	4	3	0.7	0.9	0.8	1.6
California	71	34	46	20	6.8	6.5	9.6	10.7
Colorado	18	7	16	1	1.7	1.3	3.3	0.5
Connecticut	17	6	6	0	1.6	1.1	1.2	0.0
District of Columbia (Washington)	4	1	3	0	0.4	0.2	0.6	0.0
Delaware	7	2	4	1	0.7	0.4	0.8	0.5
Florida	41	29	24	7	3.9	5.5	5.0	3.7
Georgia	32	18	17	8	3.0	3.4	3.5	4.3
Guam	1	0	0	0	0.1	0.0	0.0	0.0
Hawaii	6	2	2	1	0.6	0.4	0.4	0.5
Idaho	7	3	4	0	0.7	0.6	0.8	0.0
Illinois	50	30	23	10	4.8	5.7	4.8	5.3
Indiana	24	13	11	3	2.3	2.5	2.3	1.6
Iowa	8	5	4	2	0.8	0.9	0.8	1.1
Kansas	13	4	3	3	1.2	0.8	0.6	1.6
Kentucky	11	11	12	3	1.0	2.1	2.5	1.6
Louisiana	14	7	9	0	1.3	1.3	1.9	0.0
Maine	3	2	2	1	0.3	0.4	0.4	0.5
Maryland	18	14	15	4	1.7	2.7	3.1	2.1
Massachusetts	26	15	12	1	2.5	2.8	2.5	0.5
Michigan	28	20	13	10	2.7	3.8	2.7	5.3
Minnesota	24	7	13	5	2.3	1.3	2.7	2.7
Mississippi	3	3	6	3	0.3	0.6	1.2	1.6
Missouri	16	14	11	7	1.5	2.7	2.3	3.7

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Montana	7	1	2	2	0.7	0.2	0.4	1.1
Nebraska	9	5	2	1	0.9	0.9	0.4	0.5
Nevada	11	3	3	5	1.0	0.6	0.6	2.7
New Hampshire	12	8	2	1	1.1	1.5	0.4	0.5
New Jersey	64	20	8	3	6.1	3.8	1.7	1.6
New Mexico	5	2	1	1	0.5	0.4	0.2	0.5
New York	75	25	51	9	7.1	4.7	10.6	4.8
North Carolina	26	13	10	9	2.5	2.5	2.1	4.8
North Dakota	1	0	0	0	0.1	0.0	0.0	0.0
Northern Mariana Islands	0	0	0	0	0.0	0.0	0.0	0.0
Ohio	28	18	7	7	2.7	3.4	1.5	3.7
Oklahoma	8	5	5	5	0.8	0.9	1.0	2.7
Oregon	8	3	7	3	0.8	0.6	1.5	1.6
Pennsylvania	47	29	11	5	4.5	5.5	2.3	2.7
Puerto Rico	0	0	0	0	0.0	0.0	0.0	0.0
Rhode Island	6	0	1	1	0.6	0.0	0.2	0.5
South Carolina	11	12	6	3	1.0	2.3	1.2	1.6
South Dakota	4	0	2	1	0.4	0.0	0.4	0.5
Tennessee	28	16	8	6	2.7	3.0	1.7	3.2
Texas	102	59	29	12	9.7	11.2	6.0	6.4
U.S. Virgin Islands	0	1	0	0	0.0	0.2	0.0	0.0
Utah	11	7	5	2	1.0	1.3	1.0	1.1
Vermont	6	1	2	0	0.6	0.2	0.4	0.0
Virginia	30	8	17	3	2.9	1.5	3.5	1.6
Washington	20	9	11	1	1.9	1.7	2.3	0.5
West Virginia	6	4	2	2	0.6	0.8	0.4	1.1
Wisconsin	30	10	10	4	2.9	1.9	2.1	2.1
Wyoming	0	1	0	0	0.0	0.2	0.0	0.0
Q8 In which of the following United States physical therapy jurisdictions are you currently licensed (percentages may sum to more than 100%)?								
Alabama	16	7	5	5	1.5	1.3	1.0	2.7
Alaska	4	3	4	0	0.4	0.6	0.8	0.0
Arizona	33	11	19	3	3.1	2.1	4.0	1.6
Arkansas	7	5	4	5	0.7	0.9	0.8	2.7
California	86	42	55	20	8.2	8.0	11.4	10.7
Colorado	25	9	17	1	2.4	1.7	3.5	0.5
Connecticut	29	9	12	0	2.8	1.7	2.5	0.0
District of Columbia (Washington)	4	2	6	0	0.4	0.4	1.2	0.0
Delaware	15	3	4	1	1.4	0.6	0.8	0.5
Florida	55	39	30	7	5.2	7.4	6.2	3.7
Georgia	41	19	19	7	3.9	3.6	4.0	3.7

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Guam	1	0	0	0	0.1	0.0	0.0	0.0
Hawaii	7	2	3	1	0.7	0.4	0.6	0.5
Idaho	11	3	6	1	1.0	0.6	1.2	0.5
Illinois	64	36	28	10	6.1	6.8	5.8	5.3
Indiana	30	14	13	3	2.9	2.7	2.7	1.6
Iowa	10	6	5	2	1.0	1.1	1.0	1.1
Kansas	15	7	5	4	1.4	1.3	1.0	2.1
Kentucky	14	13	12	3	1.3	2.5	2.5	1.6
Louisiana	17	7	10	0	1.6	1.3	2.1	0.0
Maine	4	2	2	1	0.4	0.4	0.4	0.5
Maryland	25	14	17	4	2.4	2.7	3.5	2.1
Massachusetts	34	19	15	1	3.2	3.6	3.1	0.5
Michigan	37	20	14	10	3.5	3.8	2.9	5.3
Minnesota	26	7	15	5	2.5	1.3	3.1	2.7
Mississippi	4	4	7	3	0.4	0.8	1.5	1.6
Missouri	23	16	13	8	2.2	3.0	2.7	4.3
Montana	7	2	3	2	0.7	0.4	0.6	1.1
Nebraska	10	6	2	1	1.0	1.1	0.4	0.5
Nevada	15	3	3	6	1.4	0.6	0.6	3.2
New Hampshire	15	10	3	1	1.4	1.9	0.6	0.5
New Jersey	81	22	13	3	7.7	4.2	2.7	1.6
New Mexico	11	3	1	1	1.0	0.6	0.2	0.5
New York	97	30	60	10	9.2	5.7	12.5	5.3
North Carolina	28	15	12	9	2.7	2.8	2.5	4.8
North Dakota	2	0	0	0	0.2	0.0	0.0	0.0
Northern Mariana Islands	1	0	0	0	0.1	0.0	0.0	0.0
Ohio	31	23	8	8	2.9	4.4	1.7	4.3
Oklahoma	9	5	4	5	0.9	0.9	0.8	2.7
Oregon	16	8	9	3	1.5	1.5	1.9	1.6
Pennsylvania	58	32	17	5	5.5	6.1	3.5	2.7
Puerto Rico	0	0	0	0	0.0	0.0	0.0	0.0
Rhode Island	9	2	1	1	0.9	0.4	0.2	0.5
South Carolina	18	16	10	4	1.7	3.0	2.1	2.1
South Dakota	4	1	2	2	0.4	0.2	0.4	1.1
Tennessee	28	18	12	8	2.7	3.4	2.5	4.3
Texas	117	61	35	11	11.1	11.6	7.3	5.9
U.S. Virgin Islands	0	1	0	0	0.0	0.2	0.0	0.0
Utah	14	10	7	2	1.3	1.9	1.5	1.1
Vermont	7	2	4	0	0.7	0.4	0.8	0.0
Virginia	36	15	24	4	3.4	2.8	5.0	2.1
Washington	25	12	16	1	2.4	2.3	3.3	0.5

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
West Virginia	6	7	1	2	0.6	1.3	0.2	1.1
Wisconsin	31	12	13	4	2.9	2.3	2.7	2.1
Wyoming	0	1	0	0	0.0	0.2	0.0	0.0
Q8b In which of the following United States physical therapy jurisdictions do you currently hold a PT Compact Privilege (percentages may sum to more than 100%)?								
Alabama	1	0	1	0	0.1	0.0	0.2	0.0
Alaska	0	0	0	0	0.0	0.0	0.0	0.0
Arizona	6	1	7	0	0.6	0.2	1.5	0.0
Arkansas	2	1	1	0	0.2	0.2	0.2	0.0
California	10	12	6	2	1.0	2.3	1.2	1.1
Colorado	8	1	7	1	0.8	0.2	1.5	0.5
Connecticut	4	1	1	0	0.4	0.2	0.2	0.0
District of Columbia (Washington)	0	0	2	0	0.0	0.0	0.4	0.0
Delaware	2	0	2	0	0.2	0.0	0.4	0.0
Florida	3	7	5	3	0.3	1.3	1.0	1.6
Georgia	9	7	8	0	0.9	1.3	1.7	0.0
Guam	1	0	0	0	0.1	0.0	0.0	0.0
Hawaii	0	0	0	0	0.0	0.0	0.0	0.0
Idaho	2	0	1	0	0.2	0.0	0.2	0.0
Illinois	9	9	3	3	0.9	1.7	0.6	1.6
Indiana	5	1	5	0	0.5	0.2	1.0	0.0
Iowa	3	0	2	0	0.3	0.0	0.4	0.0
Kansas	0	0	1	0	0.0	0.0	0.2	0.0
Kentucky	5	6	3	1	0.5	1.1	0.6	0.5
Louisiana	3	1	5	0	0.3	0.2	1.0	0.0
Maine	0	0	0	0	0.0	0.0	0.0	0.0
Maryland	3	0	4	0	0.3	0.0	0.8	0.0
Massachusetts	4	2	2	1	0.4	0.4	0.4	0.5
Michigan	10	3	6	2	1.0	0.6	1.2	1.1
Minnesota	5	2	1	1	0.5	0.4	0.2	0.5
Mississippi	3	2	3	0	0.3	0.4	0.6	0.0
Missouri	2	5	4	0	0.2	0.9	0.8	0.0
Montana	2	3	5	1	0.2	0.6	1.0	0.5
Nebraska	3	1	2	0	0.3	0.2	0.4	0.0
Nevada	1	0	1	0	0.1	0.0	0.2	0.0
New Hampshire	2	1	2	0	0.2	0.2	0.4	0.0
New Jersey	6	3	3	1	0.6	0.6	0.6	0.5
New Mexico	1	0	0	0	0.1	0.0	0.0	0.0
New York	13	11	10	2	1.2	2.1	2.1	1.1
North Carolina	3	3	4	1	0.3	0.6	0.8	0.5
North Dakota	2	0	1	0	0.2	0.0	0.2	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Northern Mariana Islands	0	0	0	0	0.0	0.0	0.0	0.0
Ohio	5	3	3	1	0.5	0.6	0.6	0.5
Oklahoma	4	1	0	1	0.4	0.2	0.0	0.5
Oregon	3	2	2	0	0.3	0.4	0.4	0.0
Pennsylvania	3	6	2	1	0.3	1.1	0.4	0.5
Puerto Rico	0	0	0	0	0.0	0.0	0.0	0.0
Rhode Island	2	1	0	0	0.2	0.2	0.0	0.0
South Carolina	3	6	2	0	0.3	1.1	0.4	0.0
South Dakota	3	0	0	1	0.3	0.0	0.0	0.5
Tennessee	5	7	4	3	0.5	1.3	0.8	1.6
Texas	22	14	8	4	2.1	2.7	1.7	2.1
U.S. Virgin Islands	0	0	0	0	0.0	0.0	0.0	0.0
Utah	7	1	3	0	0.7	0.2	0.6	0.0
Vermont	0	1	0	0	0.0	0.2	0.0	0.0
Virginia	7	4	5	1	0.7	0.8	1.0	0.5
Washington	8	1	7	1	0.8	0.2	1.5	0.5
West Virginia	1	1	1	0	0.1	0.2	0.2	0.0
Wisconsin	5	2	3	0	0.5	0.4	0.6	0.0
Wyoming	0	0	0	0	0.0	0.0	0.0	0.0
Q9 Which best describes the location of your PRIMARY clinical work setting?								
Urban/Metropolitan	421	165	190	55	40.1	31.3	39.5	29.4
Suburban	466	250	230	88	44.3	47.4	47.8	47.1
Rural	164	112	61	44	15.6	21.3	12.7	23.5
Q10 What is your employment status as a physical therapist (physical therapist assistant)?								
Actively employed as a physical therapist (physical therapist assistant) full-time	755	373	425	158	71.8	70.8	88.4	84.5
Actively employed as a physical therapist (physical therapist assistant) part-time	167	100	35	24	15.9	19.0	7.3	12.8
Self-employed as a physical therapist (physical therapist assistant) full-time	79	26	6	1	7.5	4.9	1.2	0.5
Self-employed as a physical therapist (physical therapist assistant) part-time	40	13	6	1	3.8	2.5	1.2	0.5
Retired	0	0	0	0	0.0	0.0	0.0	0.0
Unemployed, seeking employment as a physical therapist (physical therapist assistant)	10	15	9	3	1.0	2.8	1.9	1.6
NOT seeking employment as a physical therapist (physical therapist assistant)	0	0	0	0	0.0	0.0	0.0	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q19 Have you ever had an extended period of time (more than three months) away from actively working as a physical therapist assistant? Includes work in clinical, administration, consultation, education, or research activities.								
No, I have never had an extended break from my work	796	385	443	175	75.7	73.1	92.1	93.6
Yes, lasting 3 to 6 months	140	71	26	9	13.3	13.5	5.4	4.8
Yes, lasting 6 to 12 months	48	22	5	3	4.6	4.2	1.0	1.6
Yes, lasting 12 to 18 months	22	19	2	0	2.1	3.6	0.4	0.0
Yes, lasting 18 to 36 months	16	14	1	0	1.5	2.7	0.2	0.0
Yes, lasting 3 to 5 years	15	12	4	0	1.4	2.3	0.8	0.0
Yes, lasting 5 to 10 years	7	3	0	0	0.7	0.6	0.0	0.0
Yes, lasting greater than 10 years	7	1	0	0	0.7	0.2	0.0	0.0
Q11 How many physical therapist (physical therapist assistant) positions/jobs have you held in the past 12 months?								
1	692	356	277	104	65.8	67.6	57.6	55.6
2 to 3	337	154	189	79	32.1	29.2	39.3	42.2
4 to 5	19	14	13	3	1.8	2.7	2.7	1.6
6 to 7	2	1	2	1	0.2	0.2	0.4	0.5
More than 7	1	2	0	0	0.1	0.4	0.0	0.0
Q12 What percentage of your time over the past 12 months was spent working in: Academic institution (post-secondary)?								
0%	941	510	463	185	89.5	96.8	96.3	98.9
1% to 10%	42	8	7	2	4.0	1.5	1.5	1.1
11% to 20%	18	1	1	0	1.7	0.2	0.2	0.0
21% to 30%	7	1	2	0	0.7	0.2	0.4	0.0
31% to 40%	2	0	1	0	0.2	0.0	0.2	0.0
41% to 50%	6	1	2	0	0.6	0.2	0.4	0.0
51% to 60%	0	0	0	0	0.0	0.0	0.0	0.0
61% to 70%	1	0	2	0	0.1	0.0	0.4	0.0
71% to 80%	5	1	2	0	0.5	0.2	0.4	0.0
81% to 90%	15	2	0	0	1.4	0.4	0.0	0.0
91% to 100%	14	3	1	0	1.3	0.6	0.2	0.0
Q12 What percentage of your time over the past 12 months was spent working in: School system (preschool/primary/secondary)								
0%	998	517	450	177	95.0	98.1	93.6	94.7
1% to 10%	9	2	7	2	0.9	0.4	1.5	1.1
11% to 20%	2	1	6	4	0.2	0.2	1.2	2.1
21% to 30%	3	3	1	2	0.3	0.6	0.2	1.1
31% to 40%	3	1	0	0	0.3	0.2	0.0	0.0
41% to 50%	2	1	2	1	0.2	0.2	0.4	0.5
51% to 60%	0	0	1	0	0.0	0.0	0.2	0.0
61% to 70%	0	0	1	0	0.0	0.0	0.2	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
71% to 80%	6	1	2	1	0.6	0.2	0.4	0.5
81% to 90%	1	0	5	0	0.1	0.0	1.0	0.0
91% to 100%	27	1	6	0	2.6	0.2	1.2	0.0
Q12 What percentage of your time over the past 12 months was spent working in: Acute care hospital								
0%	807	443	385	151	76.8	84.1	80.0	80.7
1% to 10%	57	21	22	10	5.4	4.0	4.6	5.3
11% to 20%	20	14	17	4	1.9	2.7	3.5	2.1
21% to 30%	20	8	10	6	1.9	1.5	2.1	3.2
31% to 40%	4	4	2	0	0.4	0.8	0.4	0.0
41% to 50%	18	5	6	5	1.7	0.9	1.2	2.7
51% to 60%	4	1	1	1	0.4	0.2	0.2	0.5
61% to 70%	1	5	2	0	0.1	0.9	0.4	0.0
71% to 80%	18	4	5	3	1.7	0.8	1.0	1.6
81% to 90%	11	2	4	2	1.0	0.4	0.8	1.1
91% to 100%	91	20	27	5	8.7	3.8	5.6	2.7
Q12 What percentage of your time over the past 12 months was spent working in: Health and wellness facility								
0%	1018	515	464	184	96.9	97.7	96.5	98.4
1% to 10%	8	4	10	1	0.8	0.8	2.1	0.5
11% to 20%	6	1	2	0	0.6	0.2	0.4	0.0
21% to 30%	4	3	1	0	0.4	0.6	0.2	0.0
31% to 40%	0	0	0	0	0.0	0.0	0.0	0.0
41% to 50%	8	1	2	1	0.8	0.2	0.4	0.5
51% to 60%	0	0	0	0	0.0	0.0	0.0	0.0
61% to 70%	1	1	0	0	0.1	0.2	0.0	0.0
71% to 80%	1	0	0	0	0.1	0.0	0.0	0.0
81% to 90%	2	0	0	0	0.2	0.0	0.0	0.0
91% to 100%	3	2	2	1	0.3	0.4	0.4	0.5
Q12 What percentage of your time over the past 12 months was spent working in: Outpatient facility (health system or hospital-based)								
0%	759	398	305	135	72.2	75.5	63.4	72.2
1% to 10%	24	9	8	9	2.3	1.7	1.7	4.8
11% to 20%	12	1	7	3	1.1	0.2	1.5	1.6
21% to 30%	23	13	11	3	2.2	2.5	2.3	1.6
31% to 40%	6	9	3	1	0.6	1.7	0.6	0.5
41% to 50%	21	6	18	1	2.0	1.1	3.7	0.5
51% to 60%	5	1	5	0	0.5	0.2	1.0	0.0
61% to 70%	10	3	6	2	1.0	0.6	1.2	1.1
71% to 80%	25	12	21	5	2.4	2.3	4.4	2.7
81% to 90%	32	8	12	9	3.0	1.5	2.5	4.8
91% to 100%	134	67	85	19	12.7	12.7	17.7	10.2

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q12 What percentage of your time over the past 12 months was spent working in: Outpatient facility (private)								
0%	737	369	254	85	70.1	70.0	52.8	45.5
1% to 10%	21	8	9	3	2.0	1.5	1.9	1.6
11% to 20%	11	3	4	7	1.0	0.6	0.8	3.7
21% to 30%	17	6	8	3	1.6	1.1	1.7	1.6
31% to 40%	6	4	2	3	0.6	0.8	0.4	1.6
41% to 50%	21	9	18	6	2.0	1.7	3.7	3.2
51% to 60%	4	2	3	3	0.4	0.4	0.6	1.6
61% to 70%	6	5	5	1	0.6	0.9	1.0	0.5
71% to 80%	18	11	16	10	1.7	2.1	3.3	5.3
81% to 90%	21	8	12	11	2.0	1.5	2.5	5.9
91% to 100%	189	102	150	55	18.0	19.4	31.2	29.4
Q12 What percentage of your time over the past 12 months was spent working in: Industrial Rehabilitation								
0%	1039	523	478	186	98.9	99.2	99.4	99.5
1% to 10%	5	1	2	0	0.5	0.2	0.4	0.0
11% to 20%	2	1	0	0	0.2	0.2	0.0	0.0
21% to 30%	1	0	1	0	0.1	0.0	0.2	0.0
31% to 40%	1	0	0	0	0.1	0.0	0.0	0.0
41% to 50%	0	1	0	1	0.0	0.2	0.0	0.5
51% to 60%	0	0	0	0	0.0	0.0	0.0	0.0
61% to 70%	0	1	0	0	0.0	0.2	0.0	0.0
71% to 80%	1	0	0	0	0.1	0.0	0.0	0.0
81% to 90%	1	0	0	0	0.1	0.0	0.0	0.0
91% to 100%	1	0	0	0	0.1	0.0	0.0	0.0
Q12 What percentage of your time over the past 12 months was spent working in: Inpatient Rehab Facility (IRF)								
0%	949	486	434	172	90.3	92.2	90.2	92.0
1% to 10%	24	16	12	5	2.3	3.0	2.5	2.7
11% to 20%	13	4	3	1	1.2	0.8	0.6	0.5
21% to 30%	9	5	6	4	0.9	0.9	1.2	2.1
31% to 40%	1	0	3	0	0.1	0.0	0.6	0.0
41% to 50%	10	2	6	2	1.0	0.4	1.2	1.1
51% to 60%	3	0	0	0	0.3	0.0	0.0	0.0
61% to 70%	5	0	0	0	0.5	0.0	0.0	0.0
71% to 80%	7	4	2	0	0.7	0.8	0.4	0.0
81% to 90%	6	1	2	0	0.6	0.2	0.4	0.0
91% to 100%	24	9	13	3	2.3	1.7	2.7	1.6

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q12 What percentage of your time over the past 12 months was spent working in: US Military/Veterans Administration/Indian Health Services								
0%	1029	521	474	186	97.9	98.9	98.5	99.5
1% to 10%	2	0	1	1	0.2	0.0	0.2	0.5
11% to 20%	0	0	0	0	0.0	0.0	0.0	0.0
21% to 30%	2	0	1	0	0.2	0.0	0.2	0.0
31% to 40%	0	0	0	0	0.0	0.0	0.0	0.0
41% to 50%	3	0	2	0	0.3	0.0	0.4	0.0
51% to 60%	0	0	0	0	0.0	0.0	0.0	0.0
61% to 70%	0	0	0	0	0.0	0.0	0.0	0.0
71% to 80%	3	0	0	0	0.3	0.0	0.0	0.0
81% to 90%	2	0	0	0	0.2	0.0	0.0	0.0
91% to 100%	10	6	3	0	1.0	1.1	0.6	0.0
Q12 What percentage of your time over the past 12 months was spent working in: Patient's home/home care								
0%	836	393	423	169	79.5	74.6	87.9	90.4
1% to 10%	36	20	28	3	3.4	3.8	5.8	1.6
11% to 20%	15	16	6	4	1.4	3.0	1.2	2.1
21% to 30%	16	11	4	4	1.5	2.1	0.8	2.1
31% to 40%	1	6	3	1	0.1	1.1	0.6	0.5
41% to 50%	21	6	5	0	2.0	1.1	1.0	0.0
51% to 60%	1	1	1	2	0.1	0.2	0.2	1.1
61% to 70%	7	3	0	0	0.7	0.6	0.0	0.0
71% to 80%	13	7	1	0	1.2	1.3	0.2	0.0
81% to 90%	7	3	1	1	0.7	0.6	0.2	0.5
91% to 100%	98	61	9	3	9.3	11.6	1.9	1.6
Q12 What percentage of your time over the past 12 months was spent working in: Research center								
0%	1046	527	480	187	99.5	100.0	99.8	100.0
1% to 10%	3	0	0	0	0.3	0.0	0.0	0.0
11% to 20%	0	0	1	0	0.0	0.0	0.2	0.0
21% to 30%	0	0	0	0	0.0	0.0	0.0	0.0
31% to 40%	0	0	0	0	0.0	0.0	0.0	0.0
41% to 50%	1	0	0	0	0.1	0.0	0.0	0.0
51% to 60%	0	0	0	0	0.0	0.0	0.0	0.0
61% to 70%	0	0	0	0	0.0	0.0	0.0	0.0
71% to 80%	1	0	0	0	0.1	0.0	0.0	0.0
81% to 90%	0	0	0	0	0.0	0.0	0.0	0.0
91% to 100%	0	0	0	0	0.0	0.0	0.0	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q12 What percentage of your time over the past 12 months was spent working in: Skilled Nursing Facility (SNF)								
0%	915	382	431	134	87.1	72.5	89.6	71.7
1% to 10%	29	17	17	12	2.8	3.2	3.5	6.4
11% to 20%	11	6	3	5	1.0	1.1	0.6	2.7
21% to 30%	8	5	3	3	0.8	0.9	0.6	1.6
31% to 40%	6	3	5	4	0.6	0.6	1.0	2.1
41% to 50%	10	13	3	3	1.0	2.5	0.6	1.6
51% to 60%	3	4	2	2	0.3	0.8	0.4	1.1
61% to 70%	4	2	4	0	0.4	0.4	0.8	0.0
71% to 80%	7	12	3	4	0.7	2.3	0.6	2.1
81% to 90%	7	10	2	1	0.7	1.9	0.4	0.5
91% to 100%	51	73	8	19	4.9	13.9	1.7	10.2
Q12 What percentage of your time over the past 12 months was spent working in: Assisted Living Facility (ALF)								
0%	1009	494	467	175	96.0	93.7	97.1	93.6
1% to 10%	8	9	6	1	0.8	1.7	1.2	0.5
11% to 20%	8	6	1	2	0.8	1.1	0.2	1.1
21% to 30%	10	8	4	2	1.0	1.5	0.8	1.1
31% to 40%	4	0	1	2	0.4	0.0	0.2	1.1
41% to 50%	3	2	0	2	0.3	0.4	0.0	1.1
51% to 60%	1	0	0	1	0.1	0.0	0.0	0.5
61% to 70%	0	1	0	0	0.0	0.2	0.0	0.0
71% to 80%	2	4	0	2	0.2	0.8	0.0	1.1
81% to 90%	2	2	0	0	0.2	0.4	0.0	0.0
91% to 100%	4	1	2	0	0.4	0.2	0.4	0.0
Q12 What percentage of your time over the past 12 months was spent working in: Long-term Acute Care (LTAC)								
0%	1037	505	471	181	98.7	95.8	97.9	96.8
1% to 10%	2	5	4	1	0.2	0.9	0.8	0.5
11% to 20%	6	2	2	1	0.6	0.4	0.4	0.5
21% to 30%	1	2	0	3	0.1	0.4	0.0	1.6
31% to 40%	2	1	2	0	0.2	0.2	0.4	0.0
41% to 50%	0	4	1	0	0.0	0.8	0.2	0.0
51% to 60%	0	1	0	0	0.0	0.2	0.0	0.0
61% to 70%	1	0	0	0	0.1	0.0	0.0	0.0
71% to 80%	0	0	0	1	0.0	0.0	0.0	0.5
81% to 90%	0	1	0	0	0.0	0.2	0.0	0.0
91% to 100%	2	6	1	0	0.2	1.1	0.2	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q12 What percentage of your time over the past 12 months was spent working in: Other								
0%	979	516	463	185	93.1	97.9	96.3	98.9
1% to 10%	17	3	7	0	1.6	0.6	1.5	0.0
11% to 20%	9	0	2	1	0.9	0.0	0.4	0.5
21% to 30%	5	1	3	0	0.5	0.2	0.6	0.0
31% to 40%	0	1	0	0	0.0	0.2	0.0	0.0
41% to 50%	9	1	2	0	0.9	0.2	0.4	0.0
51% to 60%	0	0	1	0	0.0	0.0	0.2	0.0
61% to 70%	1	0	0	1	0.1	0.0	0.0	0.5
71% to 80%	7	0	0	0	0.7	0.0	0.0	0.0
81% to 90%	4	1	0	0	0.4	0.2	0.0	0.0
91% to 100%	20	4	3	0	1.9	0.8	0.6	0.0
Q13 For the facility in which you work the most, what is your principal area of responsibility								
Administration/Management	282	257	219	118	26.8	48.8	45.5	63.1
Supervision	358	115	95	26	34.1	21.8	19.8	13.9
Consultation	415	113	114	15	39.5	21.4	23.7	8.0
Direct patient care	145	32	48	5	13.8	6.1	10.0	2.7
Research	51	9	15	7	4.9	1.7	3.1	3.7
Sales/Marketing	137	35	40	12	13.0	6.6	8.3	6.4
Academic education	93	21	24	10	8.8	4.0	5.0	5.3
Clinical education	315	122	137	28	30.0	23.1	28.5	15.0
[other]	52	41	12	9	4.9	7.8	2.5	4.8
Q14 Approximately what percentage of your time over the past 12 months was spent in direct patient care								
0%	17	1	0	0	1.6	0.2	0.0	0.0
1 to 25%	66	13	9	1	6.3	2.5	1.9	0.5
26 to 50%	44	24	10	0	4.2	4.6	2.1	0.0
51 to 75%	141	54	38	10	13.4	10.2	7.9	5.3
76 to 100%	783	435	424	176	74.5	82.5	88.1	94.1
Q15 What is the approximate percentage of your patient population by age: 18 years old and younger								
0%	445	271	95	68	42.3	51.4	19.8	36.4
1% to 10%	345	165	230	71	32.8	31.3	47.8	38.0
11% to 20%	91	49	71	26	8.7	9.3	14.8	13.9
21% to 30%	41	18	23	9	3.9	3.4	4.8	4.8
31% to 40%	11	5	7	3	1.0	0.9	1.5	1.6
41% to 50%	10	3	3	1	1.0	0.6	0.6	0.5
51% to 60%	3	0	2	0	0.3	0.0	0.4	0.0
61% to 70%	2	2	1	0	0.2	0.4	0.2	0.0
71% to 80%	4	1	7	2	0.4	0.2	1.5	1.1
81% to 90%	11	3	9	2	1.0	0.6	1.9	1.1

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
91% to 100%	88	10	33	5	8.4	1.9	6.9	2.7
Q15 What is the approximate percentage of your patient population by age: 19 to 64 years old								
0%	124	53	30	18	11.8	10.1	6.2	9.6
1% to 10%	115	84	50	15	10.9	15.9	10.4	8.0
11% to 20%	79	61	32	23	7.5	11.6	6.7	12.3
21% to 30%	145	94	61	31	13.8	17.8	12.7	16.6
31% to 40%	147	64	90	23	14.0	12.1	18.7	12.3
41% to 50%	186	73	84	37	17.7	13.9	17.5	19.8
51% to 60%	84	37	51	10	8.0	7.0	10.6	5.3
61% to 70%	56	22	37	16	5.3	4.2	7.7	8.6
71% to 80%	64	22	33	11	6.1	4.2	6.9	5.9
81% to 90%	30	8	9	3	2.9	1.5	1.9	1.6
91% to 100%	21	9	4	0	2.0	1.7	0.8	0.0
Q15 What is the approximate percentage of your patient population by age: 65 years old and older								
0%	124	26	43	4	11.8	4.9	8.9	2.1
1% to 10%	63	18	32	8	6.0	3.4	6.7	4.3
11% to 20%	74	32	46	16	7.0	6.1	9.6	8.6
21% to 30%	118	43	69	26	11.2	8.2	14.3	13.9
31% to 40%	97	47	58	17	9.2	8.9	12.1	9.1
41% to 50%	148	71	84	29	14.1	13.5	17.5	15.5
51% to 60%	102	39	53	20	9.7	7.4	11.0	10.7
61% to 70%	86	52	35	13	8.2	9.9	7.3	7.0
71% to 80%	99	76	31	27	9.4	14.4	6.4	14.4
81% to 90%	62	64	17	14	5.9	12.1	3.5	7.5
91% to 100%	78	59	13	13	7.4	11.2	2.7	7.0
Does not apply	9	5	1	0	0.9	0.9	0.2	0.0
Q16 Are you a current member of American Physical Therapy Association (APTA)								
Yes	305	78	174	50	29.0	14.8	36.2	26.7
No	746	449	307	137	71.0	85.2	63.8	73.3
Q17 Have you completed or are you currently completing an Advanced Proficiency Pathway through the American Physical Therapy Association (PTA Only)								
Yes	0	158	0	62	0.0	30.0	0.0	33.2
No	0	249	0	125	0.0	47.2	0.0	66.8
If you selected "Yes", which Advanced Proficiency Pathway type have you completed or are currently completing?								
Acute Care	0	6	0	2	0.0	3.8	0.0	3.2
Cardiovascular/pulmonary	0	0	0	0	0.0	0.0	0.0	0.0
Geriatrics	0	25	0	7	0.0	15.8	0.0	11.3
Neurology	0	3	0	4	0.0	1.9	0.0	6.5
Oncology	0	2	0	0	0.0	1.3	0.0	0.0
Orthopedics	0	22	0	9	0.0	13.9	0.0	14.5

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Pediatrics	0	2	0	2	0.0	1.3	0.0	3.2
Wound management	0	3	0	1	0.0	1.9	0.0	1.6
Other	0	95	0	37	0.0	60.1	0.0	59.7
Q17a Have you completed or are you currently completing a Residency in a specialized area of Physical Therapy (PT only)								
Yes	82	9	40	0	7.8	1.7	8.3	0.0
No	969	111	441	0	92.2	21.1	91.7	0.0
If you selected “Yes”, which Residency type have you completed or are currently completing?								
Acute Care	1	0	0	0	1.2	0.0	0	0.0
Cardiovascular & Pulmonary	1	0	1	0	1.2	0.0	2.5	0.0
Clinical Electrophysiology	0	0	0	0	0.0	0.0	0.0	0.0
Faculty	2	0	0	0	2.4	0.0	0.0	0.0
Geriatrics	11	1	1	0	13.4	11.1	2.5	0.0
Neurology	13	0	4	0	15.9	0.0	10.0	0.0
Oncology	1	0	2	0	1.2	0.0	5.0	0.0
Orthopaedics	37	6	23	0	45.1	66.6	57.5	0.0
Pediatrics	6	0	2	0	7.3	0.0	5.0	0.0
Sports	3	0	6	0	3.7	0.0	15.0	0.0
Women’s Health	1	1	1	0	1.2	11.1	2.5	0.0
Wound Management	3	0	0	0	3.7	0.0	0.0	0.0
Other	3	1	0	0	3.7	11.1	0.0	0.0
Q17b Have you completed or are you currently completing a Fellowship in a specialized area of Physical Therapy (PT only)								
Yes	37	3	7	0	3.5	0.6	1.5	0.0
No	1013	117	473	0	96.4	22.2	98.3	0.0
If you selected “Yes”, which type of Fellowship have you completed or are currently completing?								
Critical Care	0	0	0	0	0.0	0.0	0.0	0.0
Higher Education Leadership	3	0	0	0	8.1	0.0	0.0	0.0
Movement System	0	0	1	0	0.0	0.0	14.3	0.0
Neonatology	0	0	0	0	0.0	0.0	0.0	0.0
Neurologic Movement Disorders	0	0	1	0	0.0	0.0	14.3	0.0
Orthopaedic Manual Physical Therapy	26	1	2	0	70.3	33.3	28.6	0.0
Performing Arts	1	0	0	0	2.7	0.0	0.0	0.0
Spine	0	0	1	0	0.0	0.0	14.3	0.0
Sports Division 1	1	0	1	0	2.7	0.0	14.3	0.0
Upper Extremity Athlete	0	0	0	0	0.0	0.0	0.0	0.0
Other	6	2	1	0	16.2	66.7	14.3	0.0

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q18 Which of these statements is true regarding your experience supervising PTAs over the past 12 months								
I routinely supervise PTAs and have a good understanding of the knowledge and skills they need to provide safe and effective care	644	120	308	0	61.3	22.8	64.0	0.0
I do NOT routinely supervise PTAs and/or I do NOT have a good understanding of the knowledge and skills they need to provide safe and effective care	407	0	173	0	38.7	0.0	36.0	0.0

Note. Percentages are based on the observed values divided by the total number of usable cases. Missing data are not reported so within a question, the results may not sum to 100%. For questions 12 and 15, percentages may not sum to 100% because these items used a rate all that apply format. Question 18 was not administered to PTA respondents. The 120 respondents shown for Q18 within the PTA KSR sample are PT KSR survey respondents who were reassigned based on their response to Q18

Appendix B. Summary of Work Activity and Knowledge and Skill Requirements Survey Responses

Tables B.1-B.4: Statistics and Formatting Key

- **Sample Size (n):** Count of respondents that provided usable data
- **Mean Importance (M):** Based on responses for scale points 1 through 5
- **Standard Deviation of Importance (SD):** Based on responses for scale points 1 through 5
- **Percent Important (%_{imp}):** Sum of responses for scale points 2 through 5, divided by the total number of usable respondents

Format	Description	Example
Light red shading	Statements with mean importance rating less than 2.50 in 2024 (Criticality Threshold)	Diagnostic electrophysiology (EMG/NCV) using needle insertion
Light orange shading	Statements with mean importance rating between 2.50 (inclusive) and 3.00 (less than) in 2024 (Criticality Threshold)	Diagnostic electromyography (EMG) using surface electrodes
Red, boldface values	Statements with mean importance rating below 2.50 (Criticality Threshold)	0.53

Table B.1. PT Work Activity Survey Results

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Information Gathering & Synthesis																				
<i>Interview patients/clients, caregivers, and family to obtain patient/client history and current information (e.g., medical, surgical, medications, social, cultural, language preference, economic) to</i>																				
– establish prior and current level of function/activity	750	430	268	445	226	4.80	4.80	4.78	4.84	4.81	0.47	0.56	0.50	0.42	0.45	100	100	100	100	100
– establish general health status	750	430	268	445	226	4.53	4.53	4.51	4.58	4.43	0.69	0.70	0.70	0.65	0.71	100	100	100	100	100
– identify red flags (e.g., fever, malaise, unexplained weight change) and contraindications	750	430	268	445	226	4.73	4.61	4.72	4.71	4.63	0.60	0.71	0.64	0.60	0.64	100	100	99	100	100
– identify risk factors and needs for preventative measures	750	430	268	445	226	4.44	4.33	4.43	4.40	4.22	0.74	0.86	0.76	0.80	0.84	100	100	100	100	100
– identify patient/client's, family/caregiver's goals, values, and preferences	750	430	268	445	226	4.58	4.59	4.64	4.63	4.55	0.67	0.67	0.66	0.65	0.71	100	100	99	100	100
– determine if patient/client is appropriate for PT	750	430	268	445	226	4.61	4.63	4.62	4.63	4.62	0.69	0.69	0.68	0.66	0.72	100	100	100	100	100
– determine insurance and financial resources and issues (e.g., co-pays, deductibles, insurance limitations)	750	430	268	445	226	3.38	3.35	3.44	3.52	3.25	1.09	1.13	1.11	1.11	1.11	88	87	89	89	85
– determine impact of medications on plan of care (e.g., medication reconciliation, timing of intervention delivery, adherence)	750	430	268	445	226	3.70	3.67	3.79	3.85	3.63	1.03	1.03	1.05	0.98	1.05	98	98	96	98	97
Administer standardized questionnaires (e.g., pain inventory, fall risk assessment)	750	430	268	445	226	3.75	3.72	3.82	3.78	3.67	1.04	1.16	1.16	1.12	1.19	97	94	94	96	92
Review medical records (e.g., lab values, diagnostic tests, imaging, specialty reports, narrative, consults)	750	430	268	445	226	4.12	4.17	4.20	4.20	4.06	0.91	0.91	0.98	0.90	0.99	99	99	98	99	97

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Gather information/discuss patient/client's current health status with interprofessional/interdisciplinary team members	750	430	268	445	226	3.98	4.09	4.14	4.10	3.97	0.96	0.97	0.98	0.95	1.04	98	99	98	99	96
Identify signs/symptoms of change in patient/client's health status that require intervention by interprofessional/interdisciplinary team members	750	430	268	445	226	4.37	4.42	4.41	4.46	4.37	0.79	0.82	0.82	0.73	0.87	100	100	99	100	98
Systems Review																				
<i>Perform screen of the</i>																				
– patient/client's current affect, cognition, communication, and learning preferences (e.g., ability to convey needs, consciousness, orientation, expected emotional/behavioral responses)	750	430	268	445	226	3.95	4.03	4.00	4.01	3.92	1.03	1.00	1.07	1.00	1.06	96	96	94	96	93
– patient/client's quality of speech, hearing, and vision (e.g., dysarthria, pitch/tone, use of corrective lenses, use of hearing aids)	750	430	268	445	226	3.29	3.24	3.38	3.31	3.06	1.15	1.15	1.23	1.21	1.24	87	85	85	86	77
– vestibular system (e.g., dizziness, vertigo)	732	420	261	428	217	3.49	3.52	3.51	3.60	3.58	1.09	1.05	1.05	1.04	1.13	90	90	90	93	89
– gastrointestinal system (e.g., difficulty swallowing, nausea, change in appetite/diet, change in bowel function)	732	420	261	428	217	2.94	3.00	3.09	3.01	2.92	1.08	1.06	1.12	1.10	1.07	83	82	78	85	82
– genitourinary system (e.g., changes in bladder function, catheter complications)	732	420	261	428	217	3.06	3.10	3.14	3.14	3.12	1.08	1.13	1.13	1.12	1.10	84	81	79	86	83
– reproductive system (e.g., sexual dysfunction, menstrual dysfunction, menopause/andropause status)	732	420	261	428	217	2.52	2.56	2.57	2.68	2.68	1.07	1.11	1.21	1.19	1.21	69	65	62	72	66

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– cardiovascular/pulmonary system (e.g., blood pressure, heart rate, respiration rate)	732	420	261	428	217	4.08	4.15	4.19	4.20	4.10	0.93	0.94	0.85	0.90	0.89	96	94	95	98	97
– lymphatic system (e.g., primary or secondary lymphedema)	732	420	261	428	217	3.18	3.02	3.07	3.08	2.87	1.00	1.10	1.15	1.20	1.13	87	77	78	83	76
– integumentary system (e.g., presence of scar formation, skin integrity, discoloration)	732	420	261	428	217	3.71	3.59	3.62	3.72	3.52	0.97	1.05	1.01	1.00	1.00	95	93	94	95	94
– musculoskeletal system (e.g., gross symmetry, strength, range of motion)	732	420	261	428	217	4.82	4.80	4.81	4.80	4.80	0.44	0.46	0.41	0.47	0.47	98	98	97	100	100
– neuromuscular system (e.g., gross coordination, motor function, balance, locomotion, gross sensory function)	732	420	261	428	217	4.76	4.74	4.74	4.72	4.69	0.50	0.52	0.50	0.54	0.53	98	98	97	100	100
Tests & Measures																				
Cardiovascular/Pulmonary																				
<i>Select and perform tests and measures of</i>																				
– cardiovascular function (e.g., blood pressure, heart rate, heart sounds)	715	412	255	414	206	4.13	4.15	4.21	4.21	4.12	0.97	1.05	0.95	1.00	0.98	93	92	91	98	96
– pulmonary function (e.g., respiratory rate, breathing patterns, breath sounds, chest excursion)	715	412	255	414	206	3.61	3.71	3.82	3.75	3.47	1.15	1.19	1.16	1.22	1.19	88	87	85	92	87
– perfusion and gas exchange (e.g., oxygen saturation)	715	412	255	413	206	3.61	3.71	3.76	3.66	3.59	1.18	1.24	1.21	1.28	1.23	85	83	82	86	81
– peripheral circulation (e.g., capillary refill, blood pressure in upper versus lower extremities)	715	412	255	414	206	3.24	3.30	3.31	3.30	3.09	1.10	1.09	1.16	1.22	1.12	86	84	83	86	80
– critical limb ischemia (e.g., peripheral pulses, skin perfusion pressure)	715	412	255	414	206	3.13	3.18	3.22	3.18	2.99	1.12	1.16	1.18	1.26	1.17	82	78	79	82	76
– physiological responses to position change (e.g., orthostatic hypotension, skin color, blood pressure, heart rate)	715	412	255	413	206	3.99	4.05	4.11	4.11	3.93	1.03	1.07	0.99	1.01	1.00	93	91	91	96	95

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– aerobic capacity under maximal and submaximal conditions (e.g., endurance, exercise tolerance, metabolic equivalents, perceived exertion)	715	412	255	414	206	3.69	3.69	3.73	3.79	3.54	1.08	1.11	1.12	1.10	1.16	89	88	86	92	88
Anthropometric																				
<i>Select and perform tests and measures of</i>																				
– body composition (e.g., percent body fat, lean muscle mass, body mass index [BMI])	715	412	255	414	206	2.50	2.61	2.74	2.68	2.40	1.06	1.16	1.20	1.24	1.12	71	68	66	72	65
– body dimensions (e.g., height, weight, girth, limb length, head circumference/shape)	715	412	255	414	206	2.67	2.81	2.86	2.75	2.55	1.06	1.16	1.11	1.20	1.13	77	77	78	78	72
Quantify and qualify edema (e.g., pitting, volume, circumference)	715	412	255	414	206	3.28	3.23	3.25	3.30	2.99	1.03	1.10	1.06	1.15	1.16	88	85	85	90	80
Arousal, Attention, & Cognition																				
<i>Select and perform tests and measures of</i>																				
– arousal and orientation (e.g., level of consciousness, time, person, place, situation)	698	404	246	392	194	3.68	3.84	3.78	3.75	3.77	1.26	1.17	1.24	1.29	1.24	77	81	78	84	82
– attention and cognition (e.g., ability to process commands, delirium, confusion)	698	404	246	392	194	3.70	3.86	3.85	3.85	3.77	1.16	1.14	1.16	1.15	1.16	81	82	81	89	85
– communication (e.g., expressive and receptive skills, following instructions)	698	404	246	392	194	3.76	3.86	3.94	3.93	3.81	1.10	1.08	1.06	1.10	1.09	83	85	84	91	87
– recall (including memory and retention)	698	404	246	392	194	3.39	3.47	3.44	3.54	3.39	1.08	1.12	1.11	1.16	1.12	81	82	78	86	81
Nerve Integrity																				
<i>Select and perform tests and measures of</i>																				
– cranial nerve integrity (e.g., facial asymmetry, oculomotor function, hearing)	698	404	246	392	194	3.33	3.40	3.35	3.41	3.20	1.12	1.15	1.16	1.16	1.18	84	84	81	90	82

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– spinal nerve integrity (e.g., dermatome, myotome)	698	404	246	392	194	4.03	4.07	4.02	4.10	3.96	0.95	1.02	1.00	0.96	1.08	91	90	90	97	95
– peripheral nerve integrity (e.g., sensation, strength)	698	404	246	392	194	4.18	4.35	4.22	4.32	4.15	0.86	0.84	0.83	0.81	1.00	92	93	91	98	97
– neural provocation (e.g., tapping, tension, stretch)	698	404	246	392	194	3.52	3.59	3.52	3.56	3.51	1.08	1.14	1.14	1.14	1.21	89	88	86	92	89
Environmental & Community Integration/Reintegration (Home, Work, Job, School, Play, & Leisure)																				
Assess activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	688	395	241	387	189	4.47	4.61	4.57	4.58	4.41	0.80	0.72	0.78	0.74	0.92	91	90	88	99	96
Assess instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	688	395	241	387	189	4.17	4.21	4.24	4.33	4.15	0.95	1.00	0.94	0.90	1.03	89	88	86	98	97
Assess ability to perform skills needed for integration or reintegration into the community, work, or school	688	395	241	387	189	4.22	4.31	4.29	4.40	4.19	0.93	0.89	0.95	0.88	0.94	90	88	87	98	96
Assess barriers (e.g., social, economic, physical, psychological, environmental, work conditions and activities) to home, community, work, or school integration/reintegration	688	395	241	387	189	4.19	4.24	4.31	4.26	4.05	0.91	0.91	0.88	0.89	0.97	90	90	88	98	97
Assess safety in home, community, work, or school environments	688	395	241	387	189	4.25	4.29	4.41	4.31	4.10	0.94	0.90	0.91	0.94	0.99	88	86	85	93	92
Assess ability to participate in activities with or without the use of devices, equipment, or technologies	688	395	241	387	189	4.35	4.40	4.43	4.44	4.30	0.85	0.85	0.84	0.81	0.86	91	90	88	98	97
Ergonomics and Body Mechanics																				
<i>Select and perform tests and measures of</i>																				
– ergonomics and body mechanics during functional activities	680	391	234	374	186	4.25	4.26	4.21	4.30	4.09	0.89	0.96	0.97	0.94	0.96	89	88	85	98	99
– postural alignment and position (static and dynamic)	680	391	234	374	186	4.23	4.26	4.24	4.24	4.09	0.90	0.95	0.91	0.98	1.01	90	90	87	99	99

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– specific work conditions or activities	680	391	234	374	186	3.97	3.96	3.92	4.08	3.91	0.99	1.07	1.11	0.99	1.08	86	84	81	96	89
– tools, devices, equipment, and workstations related to work actions, tasks, or activities	680	391	234	374	186	3.68	3.69	3.69	3.84	3.54	1.08	1.14	1.23	1.12	1.10	84	81	75	91	87
Functional Mobility, Balance, & Vestibular																				
<i>Select and perform tests and measures of</i>																				
– balance (dynamic and static) with or without the use of specialized equipment	680	391	234	374	186	4.58	4.62	4.62	4.64	4.54	0.65	0.67	0.63	0.63	0.71	90	90	87	100	100
– gait and locomotion (e.g., ambulation, wheelchair mobility) with or without the use of specialized equipment	680	391	234	374	186	4.69	4.72	4.78	4.75	4.67	0.60	0.57	0.54	0.53	0.58	91	90	87	99	100
– mobility during functional activities and transitional movements (e.g., transfers, bed mobility)	680	391	234	374	186	4.65	4.72	4.79	4.71	4.57	0.66	0.58	0.53	0.58	0.68	90	90	87	100	99
– vestibular function (e.g., peripheral dysfunction, central dysfunction)	680	391	234	374	186	3.64	3.63	3.64	3.82	3.59	1.06	1.10	1.11	1.03	1.12	84	83	81	95	86
Integumentary Integrity																				
Assess skin characteristics (e.g., continuity of skin color, sensation, temperature, texture, turgor)	675	387	230	367	181	3.54	3.40	3.52	3.54	3.20	1.02	1.06	1.12	1.09	1.08	87	83	80	96	90
Assess wound characteristics (e.g., tissue involvement, depth, tunneling, burn classification, ulcer/injury classification)	675	387	230	367	181	3.18	3.16	3.13	3.19	2.96	1.18	1.20	1.25	1.17	1.16	68	67	64	77	67
Assess scar tissue characteristics (e.g., banding, pliability, sensation, and texture)	675	386	230	367	181	3.29	3.27	3.29	3.35	3.09	1.06	1.16	1.19	1.14	1.14	81	75	72	89	83
Assess activities, positioning, and postures that may produce or relieve trauma to the skin	675	386	230	367	181	3.73	3.74	3.96	3.80	3.54	1.15	1.16	1.12	1.17	1.20	78	77	76	89	80

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Assess devices and equipment that may produce or relieve trauma to the skin	675	386	230	367	181	3.62	3.56	3.84	3.64	3.41	1.16	1.19	1.17	1.17	1.23	76	75	73	86	76
Joint Integrity & Range of Motion																				
<i>Select and perform tests and measures of</i>																				
– spinal and peripheral joint stability (e.g., ligamentous integrity, joint structure)	664	381	228	362	180	4.14	4.10	4.12	4.26	4.11	1.02	1.08	1.09	1.01	1.04	87	86	80	96	97
– spinal and peripheral joint mobility (e.g., glide, end feel)	664	381	228	362	180	4.01	4.01	3.92	4.11	3.99	1.13	1.17	1.21	1.15	1.16	85	84	79	93	92
– range of motion (e.g., passive, active, functional)	664	381	228	362	180	4.57	4.68	4.60	4.64	4.66	0.67	0.58	0.74	0.70	0.58	88	89	85	100	100
– flexibility (e.g., muscle length, soft tissue extensibility)	664	381	228	362	180	4.35	4.43	4.39	4.46	4.31	0.86	0.84	0.89	0.86	0.95	88	88	84	98	99
Motor Function																				
<i>Select and perform tests and measures of</i>																				
– muscle tone (e.g., hypertonicity, hypotonicity, dystonia)	664	381	228	362	180	4.24	4.32	4.29	4.29	4.24	0.89	0.83	0.90	0.93	0.92	88	88	84	98	97
– dexterity, coordination, and agility (e.g., rapid alternating movement, finger to nose)	664	381	228	362	180	3.91	4.05	3.96	4.04	3.91	1.00	0.99	1.04	1.02	1.05	87	86	82	99	97
– ability to initiate, modify and control movement patterns and postures (e.g., catching a ball, gait)	664	381	228	362	180	4.33	4.45	4.39	4.41	4.32	0.83	0.80	0.85	0.84	0.84	88	88	84	99	99
– ability to change movement performance with practice (e.g., motor learning)	664	381	228	362	180	4.34	4.42	4.33	4.41	4.28	0.82	0.78	0.90	0.80	0.94	88	88	84	100	98
– movement quality (e.g., purpose, precision, efficiency, biomechanics, kinematics, compensatory strategies)	664	381	228	362	180	4.38	4.46	4.37	4.52	4.41	0.80	0.77	0.81	0.75	0.82	88	88	85	99	99

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Muscle Performance																				
<i>Select and perform tests and measures of</i>																				
– muscle strength, power, and endurance without specialized equipment (e.g., manual muscle test, functional strength testing)	661	377	226	358	177	4.62	4.71	4.73	4.69	4.59	0.67	0.60	0.52	0.61	0.70	88	87	84	100	100
– muscle strength, power, and endurance with specialized equipment (e.g., isokinetic testing, dynamometry)	661	377	226	358	177	3.46	3.48	3.65	3.76	3.56	1.40	1.46	1.34	1.33	1.42	68	65	64	81	77
– muscle integrity (using ultrasound imaging)	661	377	226	358	177	2.32	2.51	2.58	2.84	2.59	1.24	1.29	1.43	1.54	1.45	36	34	31	46	43
Neuromotor Development & Sensory Integration																				
<i>Select and perform tests and measures of</i>																				
– acquisition and evolution of motor skills throughout the lifespan	661	377	226	358	177	3.14	3.39	3.32	3.49	3.42	1.26	1.29	1.29	1.31	1.25	62	60	62	75	71
– sensorimotor integration (e.g., perceptual deficits, neglect)	661	377	226	358	177	3.29	3.51	3.45	3.75	3.58	1.15	1.21	1.21	1.20	1.15	68	67	66	85	81
– developmental reflexes and reactions (e.g., asymmetrical tonic neck reflex, righting reactions)	661	377	226	358	177	3.04	3.26	3.32	3.38	3.30	1.32	1.38	1.34	1.41	1.41	53	53	54	64	60
Reflex Integrity																				
<i>Select and perform tests and measures of</i>																				
– deep tendon/muscle stretch reflexes (e.g., quadriceps, biceps)	656	377	225	357	176	3.69	3.71	3.67	3.64	3.53	1.13	1.17	1.15	1.21	1.22	83	82	79	93	91
– upper motor neuron integrity (e.g., Babinski reflex, Hoffman sign)	656	377	225	357	176	3.66	3.75	3.74	3.65	3.55	1.15	1.16	1.09	1.18	1.22	82	81	80	93	90
– superficial reflexes and reactions (e.g., plantar reflex, abdominal reflexes)	656	377	225	357	176	2.84	2.91	2.93	3.31	3.25	1.28	1.34	1.31	1.27	1.24	65	62	60	85	85

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Pain & Sensory Integrity																				
<i>Select and perform tests and measures of</i>																				
– pain (e.g., location, intensity, frequency, central, peripheral, psychogenic)	656	377	225	357	176	4.42	4.48	4.54	4.44	4.42	0.84	0.80	0.74	0.82	0.80	86	87	83	99	99
– deep sensation (e.g., proprioception, kinesthesia, pressure)	656	377	225	357	176	3.79	3.82	3.75	3.80	3.60	1.04	1.07	1.06	1.09	1.13	85	84	79	95	91
– superficial sensation (e.g., touch, temperature discrimination)	656	377	225	357	176	3.93	3.92	3.83	3.89	3.68	0.97	1.03	1.06	1.04	1.06	85	86	80	96	92
– visceral organ sensitivity and integrity (e.g., palpation, auscultation)	656	377	225	357	176	2.79	2.80	2.96	2.92	2.71	1.17	1.31	1.30	1.23	1.24	65	58	58	73	66
Evaluation & Diagnosis																				
<i>Interpret each of the following types of data to determine the need for intervention or the response to intervention:</i>																				
– Cardiovascular/pulmonary system	653	375	225	354	175	4.19	4.30	4.27	4.26	3.94	0.93	0.90	0.98	0.91	1.02	84	84	79	98	96
– Lymphatic system	653	375	225	354	175	3.07	2.96	3.05	3.08	2.76	1.10	1.20	1.13	1.20	1.16	73	66	69	81	67
– Arousal, attention, cognition, and communication	653	375	225	354	175	3.73	3.82	3.91	3.80	3.67	1.13	1.13	1.13	1.12	1.21	78	79	74	90	85
– Neuromuscular system	653	375	225	354	175	4.60	4.68	4.66	4.58	4.54	0.65	0.61	0.61	0.71	0.66	86	87	84	100	99
– Functional mobility, balance, and vestibular	653	375	225	354	175	4.64	4.69	4.67	4.62	4.49	0.64	0.58	0.57	0.66	0.77	87	87	84	100	99
– Musculoskeletal system	653	375	225	354	175	4.78	4.85	4.80	4.77	4.76	0.47	0.39	0.45	0.47	0.55	87	87	84	100	100
– Integumentary system	653	375	225	354	175	3.57	3.45	3.51	3.47	3.22	1.05	1.07	1.08	1.08	1.07	82	81	78	95	87
– Anthropometric	653	375	225	354	175	2.76	2.81	2.71	2.79	2.61	1.05	1.15	1.16	1.21	1.19	70	67	60	74	65
– Gastrointestinal system	653	375	225	354	175	2.74	2.73	2.80	2.92	2.62	1.05	1.12	1.12	1.19	1.12	67	65	66	77	69
– Genitourinary system	653	375	225	354	175	2.74	2.75	2.76	2.90	2.70	1.08	1.13	1.15	1.20	1.18	66	63	64	77	68
– Need for or use of assistive and adaptive devices/technologies	645	373	222	353	173	4.42	4.51	4.58	4.49	4.47	0.82	0.76	0.80	0.84	0.78	84	85	80	98	96
– Need for or use of orthotic, protective, and supportive devices/technologies	645	373	222	353	173	4.10	4.14	4.24	4.18	4.04	0.97	0.95	0.93	0.95	1.00	84	83	82	97	93

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– Need for or use of prosthetic devices/technologies	645	373	222	353	173	3.80	3.77	3.81	3.81	3.74	1.11	1.13	1.16	1.17	1.19	72	73	73	83	77
– Barriers to home, community, work, or school integration/reintegration	645	373	222	353	173	4.17	4.19	4.43	4.26	4.09	0.94	0.96	0.86	0.95	1.02	84	83	78	96	94
– Ergonomics and body mechanics	645	373	222	353	173	4.16	4.16	4.16	4.25	3.99	0.90	0.99	0.92	0.95	1.05	85	85	82	98	97
– Pain and sensory integrity	645	373	222	353	173	4.26	4.27	4.30	4.28	4.05	0.83	0.84	0.86	0.86	0.98	85	87	82	99	98
– ADLs/IADLs and home management	645	373	222	353	173	4.47	4.49	4.58	4.46	4.44	0.74	0.82	0.71	0.83	0.78	85	85	81	99	98
– Imaging, lab values, and medications	645	373	222	353	173	3.55	3.71	3.76	3.71	3.50	1.03	1.05	1.14	1.08	1.10	82	84	76	94	92
– Electrodiagnostic test results (e.g., electromyography, nerve conduction velocity)			222	353	173			2.89	3.14	2.95			1.26	1.17	1.10			54	79	72
Evaluate the patient/client's ability to assume or resume home, community, work, school, and/or leisure activities	641	373	221	352	173	4.58	4.60	4.72	4.63	4.56	0.70	0.67	0.64	0.67	0.79	85	86	81	99	97
Develop physical therapy diagnosis by integrating system and non-system data	641	373	221	352	173	4.38	4.37	4.46	4.45	4.37	0.84	0.93	0.86	0.87	0.94	84	84	81	98	98
Development of Prognosis, Plan of Care, & Goals																				
Establish PT prognosis based on information gathered during the examination process	640	373	221	347	173	4.59	4.64	4.64	4.63	4.55	0.66	0.67	0.68	0.69	0.69	85	86	82	100	100
Develop plan of care based on data gathered during the examination process, incorporating information from the patient/client, caregiver, family members, and other professionals	640	373	221	347	173	4.79	4.80	4.79	4.80	4.76	0.47	0.54	0.51	0.47	0.49	85	87	82	100	100
Revise treatment intervention plan based on treatment outcomes, change in patient/client's health status, and ongoing evaluation	640	373	221	347	173	4.79	4.80	4.79	4.81	4.77	0.49	0.52	0.48	0.47	0.47	85	87	82	100	100

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Develop objective and measurable goals based on information gathered during the examination process, in collaboration with the patient/client, caregiver, family members, and/or other professionals	640	373	221	347	173	4.71	4.68	4.75	4.69	4.63	0.57	0.68	0.56	0.65	0.61	85	87	82	99	99
Select interventions based on information gathered during the examination process, incorporating information from the patient/client, caregiver, family members, and other professionals	640	373	221	347	173	4.77	4.82	4.81	4.77	4.71	0.51	0.45	0.46	0.53	0.54	85	87	82	100	100
Modify plan of care based on patient/client's resources (e.g., financial, transportation, time, insurance benefits, available technologies)	640	373	221	347	173	4.58	4.51	4.57	4.62	4.40	0.72	0.79	0.80	0.70	0.94	85	86	82	98	98
Procedural Interventions																				
Therapeutic Exercise/Therapeutic Activities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– aerobic capacity/endurance conditioning	828	466	282	481	255	3.97	4.01	4.07	4.00	3.92	1.02	0.97	0.92	1.02	1.04	97	98	97	95	96
– balance, coordination, and agility activities	828	466	282	481	255	4.57	4.61	4.60	4.61	4.62	0.65	0.62	0.61	0.66	0.63	100	100	100	100	100
– body mechanics and postural stabilization techniques	828	466	282	481	255	4.43	4.46	4.40	4.45	4.47	0.83	0.85	0.79	0.84	0.80	99	99	99	99	100
– flexibility techniques	828	466	282	481	255	3.69	3.78	3.59	3.80	3.75	1.10	1.08	1.13	1.08	1.06	96	97	96	95	98
– neuromotor techniques (e.g., movement pattern training, neuromuscular education or re-education)	828	466	282	481	255	4.31	4.27	4.32	4.38	4.37	0.85	0.91	0.82	0.80	0.86	100	98	100	99	99
– relaxation techniques	828	466	282	481	255	3.42	3.50	3.46	3.57	3.46	1.12	1.11	1.12	1.10	1.14	95	95	96	95	95
– strength, power, and endurance exercises	828	466	282	481	255	4.44	4.52	4.50	4.54	4.51	0.75	0.70	0.70	0.73	0.71	100	100	100	99	100

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– genitourinary management (e.g., pelvic floor exercises, bladder strategies)	828	466	282	481	255	2.62	2.83	2.94	2.91	2.97	1.23	1.31	1.25	1.30	1.25	48	52	52	52	58
– gastrointestinal management (e.g., bowel strategies, positioning to avoid reflux)	828	466	282	481	255	2.52	2.71	2.77	2.75	2.76	1.19	1.30	1.20	1.34	1.23	46	49	54	46	55
– manual/mechanical airway clearance techniques (e.g., assistive devices, assistive cough, incentive spirometer, flutter valve, percussion, vibration)	828	466	282	481	255	2.82	2.90	2.92	2.83	2.83	1.25	1.33	1.28	1.29	1.31	47	46	48	46	45
– techniques to maximize ventilation and perfusion (e.g., positioning, active cycle breathing, autogenic drainage, paced breathing, pursed lip breathing)	828	466	282	481	255	3.08	3.08	3.07	2.96	3.02	1.22	1.30	1.22	1.28	1.23	60	63	60	57	57
– mechanical repositioning for vestibular dysfunction	828	466	282	481	255	3.15	3.14	3.18	3.19	3.28	1.19	1.26	1.22	1.25	1.23	70	67	66	67	69
– habituation/adaptation exercises for vestibular dysfunction	828	466	282	481	255	3.15	3.14	3.25	3.19	3.20	1.21	1.26	1.21	1.27	1.23	71	70	68	69	74
– postural drainage	828	466	282	481	255	2.50	2.54	2.48	2.46	2.48	1.21	1.32	1.24	1.33	1.29	40	37	39	37	38
Functional Training																				
Recommend barrier accommodations or modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	828	466	282	481	255	3.67	3.63	3.80	3.70	3.72	1.21	1.27	1.20	1.26	1.27	86	84	79	79	82
<i>Perform and/or train patient/client in</i>																				
– the use of environmental modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	811	453	269	461	247	3.69	3.72	3.81	3.78	3.76	1.22	1.22	1.23	1.25	1.32	85	83	80	82	82
– activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	811	453	269	461	247	4.12	4.14	4.21	4.16	4.17	1.08	1.05	1.05	1.08	1.08	94	93	90	94	94

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– community and leisure integration or reintegration (e.g., work/school/play)	811	453	269	461	247	3.91	3.90	3.93	3.97	3.99	1.08	1.10	1.04	1.07	1.01	92	90	89	92	94
– instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	811	453	269	461	247	3.93	3.94	4.05	4.13	4.05	1.05	1.10	1.04	0.97	1.02	93	91	90	93	96
– mobility techniques	811	453	269	461	247	4.31	4.34	4.25	4.20	4.31	0.89	0.84	0.92	0.96	0.86	96	95	93	96	99
– gross motor developmental progression	811	453	269	461	247	3.51	3.43	3.49	3.53	3.42	1.28	1.37	1.32	1.33	1.36	72	69	69	68	69
– fall prevention and fall recovery strategies	811	453	269	461	247	4.37	4.41	4.43	4.40	4.45	0.92	0.87	0.85	0.93	0.84	95	94	91	96	98
– behavior modification and strategies that enhance functioning (e.g., energy conservation, pacing, pre-activity planning, reminder schedules)	811	453	269	461	247	3.80	3.76	3.82	3.80	3.74	1.12	1.12	1.10	1.14	1.17	93	91	88	91	91
Perform continuous hemodynamic monitoring and safe handling of a patient who has a mechanical circulatory device				461	247				3.31	3.26				1.46	1.43				46	48
Manual Therapy Techniques																				
Perform manual lymphatic drainage	805	446	267	453	241	2.58	2.59	2.64	2.67	2.66	1.17	1.26	1.29	1.35	1.36	36	31	34	36	42
Perform dry needling	805	446	267	453	241	2.91	2.88	2.96	3.22	3.17	1.39	1.48	1.39	1.43	1.44	32	30	30	39	39
Perform spinal and peripheral manual traction	805	446	267	453	241	3.13	3.25	3.11	3.31	3.18	1.21	1.25	1.24	1.22	1.32	70	67	62	74	71
Perform and/or train patient/client/caregiver in soft tissue mobilization (e.g., connective tissue massage, therapeutic massage, foam rolling)	804	446	267	452	241	3.45	3.50	3.34	3.46	3.40	1.19	1.24	1.23	1.23	1.27	85	83	79	84	82
Perform instrument-assisted soft tissue mobilization	804	446	267	452	241	3.21	3.15	3.11	3.39	3.24	1.26	1.28	1.32	1.25	1.30	70	67	63	73	73
Perform peripheral joint range of motion	804	446	267	452	241	4.02	4.11	4.02	4.12	4.13	1.03	0.99	1.04	1.01	1.10	94	91	88	95	93

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Perform peripheral mobilization/manipulation (thrust)	798	441	263	443	239	2.99	2.98	2.88	3.07	2.96	1.34	1.32	1.36	1.35	1.31	61	61	52	65	67
Perform peripheral mobilization (non-thrust)	798	441	263	443	239	3.68	3.83	3.61	3.78	3.83	1.23	1.18	1.25	1.19	1.22	80	79	70	81	81
Perform spinal mobilization (non-thrust)	798	441	263	443	239	3.63	3.75	3.51	3.71	3.71	1.26	1.20	1.25	1.22	1.23	76	75	68	79	81
Perform cervical spinal mobilization/manipulation (thrust)	798	441	263	443	239	2.71	2.79	2.59	2.84	2.79	1.36	1.40	1.40	1.43	1.34	51	47	42	56	60
Perform thoracic and lumbar spinal mobilization/manipulation (thrust)	798	441	263	443	239	3.19	3.23	3.10	3.13	3.06	1.32	1.32	1.37	1.35	1.35	64	63	57	69	66
Apply taping for neuromuscular reeducation	792	433	261	438	234	2.85	2.88	2.72	2.85	2.82	1.20	1.20	1.19	1.23	1.12	74	71	66	72	79
Apply taping for edema management	792	433	261	438	234	2.45	2.47	2.22	2.58	2.45	1.15	1.18	1.11	1.20	1.13	39	34	30	51	55
Apply taping for pain management	792	433	261	438	234	2.77	2.83	2.54	2.78	2.77	1.17	1.19	1.19	1.18	1.16	70	68	57	68	73
Equipment & Devices																				
<i>Fabricate, apply, and/or adjust</i>																				
- adaptive devices (e.g., seating and positioning devices, steering wheel devices)	791	433	261	438	234	2.97	3.03	3.08	3.30	3.22	1.25	1.32	1.30	1.34	1.32	51	48	49	57	66
- protective devices (e.g., braces, cushions, helmets, protective taping)	791	433	261	438	234	3.14	3.21	3.16	3.29	3.16	1.20	1.29	1.27	1.25	1.30	63	59	60	65	70
- supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars, serial casts, short-stretch bandages)	791	433	261	438	234	3.08	3.09	3.20	3.13	3.02	1.19	1.30	1.26	1.24	1.27	64	58	57	61	71
- adjust orthotic devices (e.g., braces, shoe inserts, splints)	791	433	261	438	234	3.39	3.37	3.45	3.39	3.32	1.18	1.23	1.26	1.18	1.24	75	68	70	75	79
<i>Apply and/or adjust</i>																				
- assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	777	428	261	431	231	4.33	4.35	4.41	4.27	4.43	0.95	0.95	0.88	1.02	0.86	92	89	88	96	98

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	777	428	261	431	231	3.27	3.19	3.22	3.32	3.25	1.27	1.36	1.22	1.28	1.30	59	54	56	58	65
– mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	777	428	261	431	231	3.11	3.15	3.29	3.27	3.10	1.35	1.40	1.35	1.34	1.43	53	47	46	52	53
– prescribed oxygen during interventions	777	428	261	431	231	3.50	3.40	3.71	3.61	3.52	1.35	1.36	1.31	1.34	1.37	54	48	51	50	52
<i>Train patient/client/caregiver in the use of</i>																				
– adaptive devices (e.g., utensils, seating and positioning devices, steering wheel devices)	765	420	255	423	225	3.27	3.22	3.35	3.54	3.36	1.35	1.36	1.47	1.37	1.40	50	50	47	60	58
– assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	765	420	255	423	225	4.29	4.25	4.41	4.27	4.29	0.98	1.04	0.92	1.03	0.98	89	85	83	93	96
– orthotic devices (e.g., braces, shoe inserts, splints)	765	420	255	423	225	3.74	3.67	3.81	3.78	3.69	1.15	1.21	1.17	1.16	1.17	83	79	78	87	89
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	765	420	255	423	225	3.33	3.30	3.24	3.32	3.26	1.28	1.33	1.35	1.40	1.36	54	53	49	55	53
– protective devices (e.g., braces, cushions, helmets, protective taping)	765	420	255	423	225	3.46	3.45	3.43	3.44	3.34	1.24	1.22	1.28	1.28	1.36	64	62	61	67	68
– supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars, serial casts, short-stretch bandages)	765	420	255	423	225	3.35	3.28	3.38	3.29	3.25	1.23	1.25	1.25	1.26	1.29	68	63	61	70	71

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	765	420	255	423	225	3.13	3.15	3.07	3.03	2.97	1.33	1.37	1.38	1.37	1.37	50	44	45	48	52
Integumentary Repair & Protection Techniques																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– nonselective debridement (e.g., removal of nonselective areas of devitalized tissue)	758	410	254	413	223	2.52	2.64	2.37	2.31	2.75	1.36	1.44	1.44	1.29	1.40	17	16	12	15	17
– selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)	758	410	254	413	223	2.40	2.68	2.39	2.29	2.81	1.34	1.48	1.44	1.34	1.35	15	15	12	14	16
– application of topical agents (e.g., cleansers, creams, moisturizers, ointments, sealants) and dressings (e.g., hydrogels, wound coverings)	758	410	254	413	223	2.59	2.66	2.69	2.56	2.74	1.31	1.30	1.28	1.26	1.25	26	27	25	26	30
– desensitization techniques (e.g., brushing, tapping, use of textures)	758	410	254	413	223	2.98	3.05	2.95	2.91	3.00	1.12	1.17	1.13	1.07	1.09	64	62	60	69	66
– hyperbaric therapy	758	410	254	413	223	2.25	2.15	2.07	2.04	2.45	1.29	1.27	1.29	1.15	1.25	12	11	10	12	15
– negative pressure wound therapy (e.g., vacuum-assisted wound closure)	758	410	254	413	223	2.41	2.49	2.43	2.24	2.68	1.28	1.43	1.29	1.17	1.31	16	14	17	16	18
Perform sharp debridement (e.g., removal of specific areas of devitalized tissue)	758	410	254	413	223	2.33	2.55	2.24	2.14	2.61	1.38	1.46	1.38	1.30	1.32	13	14	11	12	15
Recommend topical agents (e.g., pharmacological to physician, over-the-counter to patient) and advanced wound dressings (e.g., negative pressure wound therapy, wound coverings)	758	410	254	413	223	2.42	2.66	2.63	2.40	2.68	1.27	1.31	1.40	1.27	1.24	21	24	18	22	25

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Therapeutic Modalities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– biofeedback therapy (e.g., relaxation techniques, muscle reeducation, EMG)	746	406	253	413	221	3.14	3.15	3.10	3.11	3.02	1.20	1.28	1.18	1.22	1.31	64	61	61	73	67
– iontophoresis	746	406	253	413	221	2.22	2.18	2.22	2.15	2.13	1.18	1.19	1.23	1.24	1.23	34	32	28	29	31
– phonophoresis	743	404	253	409	220	2.03	1.87	1.84	1.86	1.87	1.27	1.15	1.18	1.18	1.21	17	17	14	16	17
– electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	746	406	253	413	221	3.12	3.18	3.08	3.12	3.30	1.22	1.27	1.25	1.28	1.25	73	70	68	78	80
– cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	746	406	253	413	221	3.20	3.27	3.10	3.22	3.23	1.20	1.23	1.22	1.27	1.33	78	72	73	82	79
– hydrotherapy using contrast baths/pools	746	406	253	413	221	2.31	2.28	2.20	2.31	2.39	1.34	1.32	1.32	1.43	1.46	25	25	23	23	25
– hydrotherapy (e.g., aquatic exercise, underwater treadmill)	746	406	253	413	221	2.85	2.93	2.89	2.86	2.70	1.36	1.37	1.49	1.49	1.34	32	34	31	31	36
– phototherapy (laser light)	746	406	253	413	221	2.10	1.96	2.16	2.14	2.09	1.24	1.23	1.36	1.36	1.35	20	18	18	19	21
– monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])	743	404	253	409	220	1.89	1.77	1.73	1.89	1.85	1.21	1.10	1.08	1.23	1.22	12	12	11	14	15
– ultrasound procedures	743	404	253	409	220	2.20	2.33	2.25	2.21	2.21	1.21	1.31	1.31	1.25	1.32	39	39	33	39	36
– diathermy	743	404	253	409	220	1.86	1.65	1.78	1.71	1.77	1.20	0.98	1.17	1.12	1.19	14	14	13	13	15
– dry heat thermotherapy (e.g., Fluidotherapy)	743	404	253	409	220	1.87	1.88	1.85	1.90	1.83	1.14	1.18	1.15	1.15	1.17	16	17	15	18	19
– hot pack thermotherapy	743	404	253	409	220	2.90	3.01	2.93	2.95	2.98	1.22	1.25	1.25	1.31	1.33	68	65	58	71	72
– paraffin bath thermotherapy	743	404	253	409	220	2.31	2.20	2.10	2.34	2.22	1.28	1.29	1.24	1.34	1.39	27	26	21	27	26
– shockwave therapy	743	404	253	409	220	1.86	1.83	1.64	1.95	1.84	1.19	1.17	1.03	1.28	1.27	12	14	10	15	15

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– blood-flow restriction training			253	409	220			2.75	3.06	3.02			1.27	1.32	1.24			34	49	48
– cupping			253	409	220			2.51	2.76	2.83			1.17	1.24	1.18			37	52	58
Mechanical Modalities																				
Apply and/or train patient/client/caregiver in																				
– intermittent pneumatic compression (e.g., sequential compression devices)	740	403	253	404	219	2.73	2.67	2.68	2.79	2.66	1.32	1.24	1.23	1.31	1.26	33	35	33	44	43
– assisted movement devices (e.g., dynamic splint, continuous passive motion devices)	740	403	253	404	219	2.68	2.58	2.46	2.64	2.62	1.20	1.22	1.18	1.21	1.33	44	41	41	43	39
– mechanical spinal traction	740	403	253	404	219	2.75	2.72	2.60	2.66	2.81	1.19	1.25	1.28	1.20	1.36	46	45	38	50	46
Non-procedural Interventions																				
Communication																				
Discuss physical therapy evaluation findings, interventions, goals, prognosis, discharge planning, and plan of care with																				
– physical therapists, physical therapist assistants, and/or support staff	739	401	253	401	218	4.66	4.70	4.73	4.70	4.78	0.66	0.65	0.66	0.66	0.59	88	85	89	98	100
– interprofessional/interdisciplinary team members	739	401	253	401	218	4.48	4.53	4.60	4.47	4.61	0.85	0.80	0.79	0.86	0.73	86	84	87	96	100
– patient/client/caregiver	739	401	253	401	218	4.80	4.84	4.82	4.82	4.84	0.51	0.44	0.49	0.50	0.42	89	86	89	99	100
Provide written, oral, and electronic information to the patient/client and/or caregiver	739	401	253	401	218	4.64	4.68	4.65	4.69	4.71	0.70	0.65	0.67	0.64	0.60	88	86	89	99	100
Documentation																				
Document																				
– examination results	733	401	253	399	217	4.79	4.83	4.83	4.83	4.78	0.51	0.48	0.43	0.47	0.52	88	86	89	99	100
– evaluation to include diagnosis, goals, and prognosis	733	401	253	399	217	4.77	4.82	4.83	4.81	4.77	0.55	0.48	0.46	0.48	0.51	88	86	89	100	100
– intervention(s) and patient/client response(s) to intervention	733	401	253	399	217	4.80	4.85	4.84	4.83	4.83	0.51	0.44	0.39	0.44	0.44	89	86	89	100	100
– patient/client/caregiver education	733	401	253	399	217	4.77	4.82	4.79	4.79	4.76	0.54	0.46	0.49	0.49	0.59	89	86	89	100	100

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– outcomes (e.g., discharge summary, reassessments)	733	401	253	399	217	4.67	4.73	4.71	4.68	4.69	0.67	0.56	0.62	0.65	0.67	88	86	89	99	100
– communication with the interdisciplinary/interprofessional team related to the patient/client's care	733	401	253	399	217	4.55	4.57	4.63	4.55	4.51	0.76	0.78	0.71	0.79	0.83	87	85	88	99	97
– rationale for billing and reimbursement	733	401	253	399	217	4.34	4.37	4.42	4.44	4.37	0.95	0.96	0.91	0.91	0.96	86	81	87	97	96
– disclosure and consent (e.g., disclosure of medical information, consent for treatment)	733	401	253	399	217	4.39	4.48	4.48	4.49	4.43	0.91	0.87	0.85	0.90	0.92	86	83	86	96	96
– letter of medical necessity (e.g., wheelchair, assistive equipment, disability parking placard)	733	401	253	399	217	3.77	3.80	3.98	3.88	3.88	1.23	1.26	1.15	1.27	1.22	73	69	72	78	78
– intervention/plan of care for specialized services and settings (e.g., individual education plan, individual family service plan, vocational transition plan)	733	401	253	399	217	4.12	4.08	4.30	4.27	4.11	1.15	1.23	1.03	1.15	1.14	65	62	65	73	71
Assign billing codes for physical therapy evaluation and treatment provided	739	401	253	401	218	4.50	4.50	4.45	4.55	4.53	0.88	0.92	0.92	0.88	0.90	85	80	86	96	96
Education																				
<i>Educate patient/client and/or caregiver about</i>																				
– the patient/client's current condition and health status (e.g., nature of the condition, prognosis, potential benefits of physical therapy interventions, potential treatment outcomes)	732	400	249	394	216	4.78	4.85	4.82	4.82	4.81	0.50	0.41	0.44	0.48	0.46	88	86	88	99	100
– the role of the physical therapist and/or physical therapist assistant in patient/client management	732	400	249	394	216	4.71	4.77	4.74	4.74	4.68	0.58	0.52	0.52	0.58	0.62	88	86	87	99	100

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	732	400	249	394	216	4.41	4.42	4.43	4.48	4.43	0.83	0.84	0.82	0.82	0.85	87	85	87	98	100
– the role of physical therapy in transitional planning (e.g., hospice, palliative care, setting changes)	732	400	249	394	216	4.03	4.08	4.09	4.07	4.03	1.16	1.16	1.15	1.17	1.20	72	67	73	78	80
Educate the healthcare team about																				
– the role of the physical therapist and/or physical therapist assistant in patient/client management	732	400	249	394	216	4.34	4.36	4.43	4.43	4.35	0.91	0.95	0.89	0.90	0.98	83	82	85	93	94
– safe patient handling (e.g., injury prevention, ergonomics, use of equipment)	732	400	249	394	216	4.37	4.40	4.41	4.44	4.41	0.92	0.97	0.94	0.91	0.97	82	79	83	92	92
Educate community groups on lifestyle and behavior changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	730	399	248	392	216	3.66	3.66	3.58	3.59	3.78	1.14	1.22	1.22	1.23	1.24	66	62	62	73	76
Participate in the clinical education of students	730	399	248	392	216	3.95	4.01	3.90	3.98	3.94	1.07	1.07	1.04	1.09	1.11	70	68	68	83	84
Patient/client & Staff Safety																				
Emergency Procedures																				
Implement emergency procedures (e.g., CPR, AED, calling a code)	730	399	248	392	216	4.00	3.99	4.04	4.04	4.21	1.12	1.16	1.15	1.14	1.08	78	74	79	90	92
Perform first aid	730	399	248	392	216	3.76	3.80	3.81	3.77	3.97	1.18	1.24	1.20	1.23	1.22	78	75	75	89	92
Implement disaster response procedures	730	399	248	392	216	3.66	3.66	3.53	3.59	3.70	1.20	1.27	1.25	1.33	1.29	71	62	66	74	79
Environmental Safety																				
Perform risk assessment of the physical environment (e.g., barrier-free environment, outlets, windows, floors, lighting)	640	373	221	347	173	4.20	4.14	4.23	4.12	3.93	0.96	1.00	1.05	1.05	1.12	80	77	74	93	88

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Prepare and maintain a safe working environment for performing interventions (e.g., unobstructed walkways, equipment availability)	640	373	221	347	173	4.40	4.42	4.50	4.47	4.28	0.87	0.84	0.87	0.85	0.89	82	83	78	97	93
Perform regular equipment inspections and/or maintenance (e.g., modalities, assistive devices)	640	373	221	347	173	3.99	4.08	4.06	4.10	3.95	1.10	1.05	1.08	1.01	1.02	76	73	69	86	81
Infection Control																				
Perform and/or train patient/client and/or caregiver on appropriate infection control practices (e.g., universal precautions, hand hygiene, isolation, airborne precautions, equipment cleaning)	640	373	221	347	173	4.15	4.08	4.13	4.06	3.92	1.06	1.10	1.12	1.14	1.19	79	78	73	90	82
Research & Evidence-Based Practice																				
Search the literature for current best evidence	639	373	221	345	173	4.05	4.08	4.13	4.03	3.98	0.91	0.89	0.89	0.91	0.92	85	86	81	98	99
Evaluate the quality of published data	639	373	221	345	173	3.88	3.87	3.92	3.87	3.80	1.02	0.99	0.98	0.95	1.03	82	83	81	96	94
Integrate current best evidence, clinical experience, and patient values in clinical practice (e.g., clinical prediction rules, patient preference, clinical practice guidelines)	639	373	221	345	173	4.27	4.35	4.36	4.32	4.30	0.82	0.79	0.81	0.85	0.77	85	87	82	98	99
Design, direct, and/or participate in research activities	639	373	221	345	173	3.10	2.91	2.96	2.93	2.76	1.23	1.25	1.35	1.26	1.25	60	60	54	70	60
Compare intervention outcomes with normative data	639	373	221	345	173	3.60	3.58	3.66	3.55	3.49	1.08	1.10	1.08	1.11	1.11	75	75	72	88	83
Professional Responsibilities																				
Supervise physical therapist assistant(s) and support personnel (licensed/unlicensed)	726	398	246	388	211	4.41	4.41	4.55	4.44	4.33	0.91	0.99	0.83	0.91	0.96	75	70	71	84	87
Assign tasks to other personnel (licensed/unlicensed) to assist with patient/client care	726	398	246	388	211	4.13	4.08	4.22	4.18	4.12	1.01	1.10	1.05	1.06	1.02	79	75	76	89	90

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Discuss ongoing patient care with the interprofessional/interdisciplinary team members	726	398	246	388	211	4.43	4.45	4.58	4.49	4.39	0.84	0.85	0.79	0.82	0.90	86	83	85	97	98
Refer patient/client to specialists or other healthcare providers when necessary	726	398	246	388	211	4.41	4.56	4.54	4.50	4.33	0.83	0.71	0.83	0.78	0.92	87	85	85	98	99
Disclose financial interest in recommended products or services to the patient/client	726	398	246	388	211	3.58	3.69	3.61	3.53	3.49	1.28	1.36	1.38	1.46	1.41	61	53	54	61	70
Provide notice and information about alternative care when the physical therapist terminates provider relationship with the patient/client	726	398	246	388	211	3.91	4.00	4.07	4.09	4.06	1.06	1.11	1.13	1.04	1.12	79	76	73	90	91
Document transfer of patient/client care to another physical therapist (therapist of record)	726	398	246	388	211	3.74	3.92	3.92	3.88	3.82	1.21	1.27	1.34	1.23	1.31	75	70	69	84	88
Report healthcare providers that are suspected to not perform their professional responsibilities with reasonable skill and safety to the appropriate authorities	726	398	246	388	211	4.07	4.15	4.24	4.25	4.17	1.09	1.09	1.05	0.98	1.16	81	78	79	93	91
Report suspected cases of abuse to the appropriate authority	726	398	246	388	211	4.41	4.49	4.49	4.46	4.41	0.95	0.89	0.89	0.89	1.00	84	83	84	96	95
Report suspected illegal or unethical acts performed by healthcare providers to the relevant authority	723	397	244	385	211	4.40	4.35	4.49	4.51	4.37	0.96	1.02	0.89	0.86	1.04	84	82	83	97	95
Advocate for public access to physical therapy and other healthcare services	723	397	244	385	211	4.26	4.19	4.25	4.25	4.11	0.98	1.04	1.04	1.02	1.11	81	81	81	95	93
Determine own need for professional development	723	397	244	385	211	4.55	4.59	4.68	4.52	4.56	0.71	0.72	0.61	0.78	0.77	87	85	85	99	100

PT WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Participate in learning and/or development activities (e.g., journal clubs, self-directed reading, continuing competence activities) to maintain the currency of knowledge, skills, and abilities	723	397	244	385	211	4.45	4.42	4.51	4.38	4.43	0.81	0.89	0.80	0.86	0.88	86	84	84	99	99
Practice within the federal and jurisdiction regulations and professional standards	723	397	244	385	211	4.70	4.72	4.73	4.68	4.74	0.64	0.67	0.70	0.67	0.60	87	85	84	99	100
Participate in professional organizations	723	397	244	385	211	3.67	3.73	3.71	3.60	3.59	1.18	1.22	1.19	1.23	1.27	83	80	80	92	90
Perform community based screenings (e.g., fall risk, posture, musculoskeletal, flexibility, sports-specific)	723	397	244	385	211	3.71	3.69	3.65	3.73	3.77	1.13	1.16	1.18	1.24	1.23	75	71	68	82	83
Participate in performance improvement and quality reporting activities (e.g., Physician Quality Reporting System, standardized outcomes measurement, application of health informatics)	723	397	244	385	211	3.85	3.77	3.81	3.82	3.91	1.13	1.17	1.17	1.25	1.19	78	76	71	85	86

Table B.2. PTA Work Activity Survey Results

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Information Gathering & Synthesis																				
<i>Interview patients/clients, caregivers, and family to obtain patient/client history and current information (e.g., medical, surgical, medications, social, cultural, language preference, economic) to</i>																				
– review prior and current level of function/activity	281	244	98	190	81	4.58	4.59	4.63	4.54	4.61	0.66	0.80	0.72	0.77	0.70	99	97	94	97	99
– establish general health status	281	244	98	190	81	4.40	4.35	4.34	4.39	4.30	0.79	0.88	0.79	0.86	0.87	99	97	95	96	96
– identify red flags (e.g., unexplained weight change, fever, malaise) and contraindications	281	244	98	190	81	4.58	4.59	4.47	4.39	4.37	0.75	0.78	0.85	0.92	0.90	98	98	96	96	99
– identify patient/client's, family/caregiver's goals, values, and preferences	281	244	98	190	81	4.42	4.22	4.33	4.37	4.28	0.75	0.87	0.84	0.83	0.83	99	97	95	97	99
– determine impact of medications on plan of care (e.g., medication reconciliation, timing of intervention delivery, adherence)	281	244	98	190	81	3.94	3.83	3.80	3.86	3.73	1.02	1.12	1.06	1.09	1.18	95	91	92	92	94
Administer standardized questionnaires (e.g., pain inventory, fall risk assessment)	281	244	98	190	81	3.76	3.88	3.95	3.64	3.79	1.00	1.07	0.94	1.13	1.10	94	94	93	89	93
Review medical records (e.g., lab values, diagnostic tests, imaging, specialty reports, narrative, consults, physical therapy documentation) prior to carrying out the PT plan of care	281	244	98	190	81	4.12	4.14	4.13	4.09	3.91	0.99	0.99	1.00	1.05	1.18	96	97	97	92	95
Gather information/discuss patient/client's current health status with interprofessional/interdisciplinary team members	281	244	98	190	81	4.14	4.15	3.98	4.02	4.08	0.96	0.97	1.06	1.05	1.12	97	98	94	96	91
Identify signs/symptoms of change in patient/client's health status that require intervention by physical therapist	281	244	98	190	81	4.59	4.56	4.55	4.46	4.51	0.68	0.69	0.69	0.83	0.81	99	100	100	99	99

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Identify signs/symptoms of change in patient/client's health status that require intervention by interprofessional/interdisciplinary team members	281	244	98	190	81	4.46	4.47	4.32	4.31	4.39	0.80	0.73	0.92	0.89	0.88	98	98	97	98	98
Systems Review																				
Check patient/client's current affect, cognition, communication, and learning preferences (e.g., ability to convey needs, consciousness, orientation, expected emotional/behavioral responses)	281	244	98	190	81	4.22	4.22	4.16	4.20	4.11	0.88	0.96	1.00	1.03	0.94	98	97	98	96	100
<i>Recognize changes in status of the</i>																				
– patient/client's quality of speech, hearing, and vision (e.g., dysarthria, pitch/tone, use of corrective lenses, use of hearing aids)	271	231	95	176	79	3.98	3.88	3.85	4.01	3.73	1.04	1.13	1.07	1.12	1.13	92	87	89	88	94
– vestibular system (e.g., dizziness, vertigo)	271	231	95	176	79	4.13	4.10	3.89	4.07	3.86	0.95	1.00	1.03	0.96	1.05	93	90	92	92	96
– gastrointestinal system (e.g., difficulty swallowing, nausea, change in appetite/diet, change in bowel function)	271	231	95	176	79	3.49	3.51	3.40	3.50	3.24	1.11	1.17	1.19	1.20	1.22	87	82	81	83	84
– genitourinary system (e.g., changes in bladder function, catheter complications)	271	231	95	176	79	3.44	3.51	3.44	3.44	3.28	1.22	1.20	1.21	1.22	1.22	82	78	78	80	80
– reproductive system (e.g., sexual dysfunction, menstrual dysfunction, menopause/andropause status)	271	231	95	176	79	2.62	2.88	2.66	2.80	2.56	1.24	1.38	1.25	1.35	1.24	66	60	61	62	59
– cardiovascular/pulmonary system (e.g., blood pressure, heart rate, respiration rate)	271	231	95	176	79	4.42	4.35	4.19	4.27	4.42	0.85	0.89	0.86	0.95	0.71	94	93	96	96	99
– lymphatic system (e.g., primary or secondary lymphedema)	271	231	95	176	79	3.86	3.64	3.52	3.56	3.41	1.03	1.17	1.18	1.16	1.31	88	79	80	85	84

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– integumentary system (e.g., presence of scar formation, skin integrity, discoloration)	271	231	95	176	79	3.99	4.01	4.07	3.93	3.83	1.06	0.97	0.89	1.07	1.08	93	92	94	95	96
– musculoskeletal system (e.g., gross symmetry, strength, range of motion)	271	231	95	176	79	4.66	4.70	4.68	4.67	4.76	0.60	0.57	0.59	0.70	0.54	96	94	97	98	100
– neuromuscular system (e.g., gross coordination, motor function, balance, locomotion, gross sensory function)	271	231	95	176	79	4.66	4.65	4.66	4.63	4.67	0.61	0.64	0.59	0.72	0.61	96	95	97	98	100
Tests & Measures																				
Cardiovascular/Pulmonary																				
<i>Perform tests and measures of</i>																				
– cardiovascular function (e.g., blood pressure, heart rate, heart sounds)	265	225	92	170	74	4.28	4.11	4.16	4.20	4.46	0.92	1.11	1.03	1.07	0.89	91	87	89	94	99
– pulmonary function (e.g., respiratory rate, breathing patterns, breath sounds, chest excursion)	265	225	92	170	74	3.94	3.91	4.00	4.01	4.07	1.08	1.21	0.96	1.08	1.02	90	84	86	90	96
– perfusion and gas exchange (e.g., oxygen saturation)	265	225	92	170	74	4.02	4.06	4.02	3.93	4.02	1.18	1.13	1.05	1.15	1.12	84	83	83	88	85
– peripheral circulation (e.g., capillary refill, blood pressure in upper versus lower extremities)	265	225	92	170	74	3.52	3.41	3.61	3.56	3.21	1.13	1.29	1.10	1.19	1.21	81	76	76	78	78
– critical limb ischemia (e.g., peripheral pulses, skin perfusion pressure)	265	225	92	170	74	3.44	3.33	3.49	3.52	3.13	1.21	1.31	1.18	1.21	1.19	78	73	71	75	80
– physiological responses to position change (e.g., orthostatic hypotension, skin color, blood pressure, heart rate)	265	225	92	170	74	4.14	4.19	4.30	4.22	4.33	1.00	0.94	0.84	1.00	0.97	91	88	88	93	97
– aerobic capacity under maximal and submaximal conditions (e.g., endurance, exercise tolerance, metabolic equivalents, perceived exertion)	265	225	92	170	74	4.07	3.96	3.97	3.95	3.97	1.01	1.09	1.04	1.09	1.04	86	84	90	89	89

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Anthropometric																				
<i>Perform tests and measures of</i>																				
– body composition (e.g., percent body fat, lean muscle mass, body mass index (BMI))	265	225	92	170	74	2.63	2.73	2.60	2.84	2.31	1.15	1.27	1.15	1.21	1.16	66	64	61	66	58
– body dimensions (e.g., height, weight, girth, limb length)	265	225	92	170	74	2.70	2.83	2.65	2.83	2.69	1.23	1.21	1.12	1.11	1.18	67	70	65	72	76
Quantify and qualify edema (e.g., pitting, volume, circumference)	265	225	92	170	74	3.53	3.42	3.47	3.53	3.32	1.15	1.22	1.03	1.09	1.19	84	81	87	84	86
Arousal, Attention, & Cognition																				
<i>Perform tests and measures of</i>																				
– arousal and orientation (e.g., level of consciousness, time, person, place, situation)	256	215	87	163	73	3.89	3.84	3.80	3.80	3.83	1.11	1.19	1.19	1.24	1.18	79	74	76	84	84
– attention and cognition (e.g., ability to process commands, delirium, confusion)	256	215	87	163	73	3.93	3.92	3.85	3.95	3.97	1.10	1.13	1.07	1.09	1.10	82	79	82	90	86
– communication (e.g., expressive and receptive skills, following instructions)	256	215	87	163	73	4.00	3.94	4.02	4.10	4.07	1.01	1.10	0.99	1.01	0.91	84	82	84	92	92
– recall (including memory and retention)	256	215	87	163	73	3.63	3.63	3.62	3.64	3.45	1.07	1.16	1.02	1.15	1.15	80	78	81	88	84
Nerve Integrity																				
<i>Perform test and measures of</i>																				
– cranial nerve integrity (e.g., facial asymmetry, oculomotor function, hearing)	256	215	87	163	73	3.40	3.31	3.25	3.39	3.25	1.19	1.20	1.06	1.24	1.23	73	69	76	77	78
– spinal nerve integrity (e.g., dermatome, myotome)	256	215	87	163	73	3.64	3.52	3.53	3.61	3.53	1.09	1.18	1.08	1.19	1.21	80	74	79	80	88
– peripheral nerve integrity (e.g., sensation, strength)	256	215	87	163	73	3.93	3.88	3.84	3.91	3.73	1.00	1.04	0.96	1.15	1.10	86	80	84	87	90

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– neural provocation (e.g., tapping, tension, stretch)	256	215	87	163	73	3.60	3.54	3.36	3.54	3.38	1.15	1.11	1.06	1.22	1.21	78	77	79	82	82
Environmental & Community Integration/Reintegration (Home, Work, Job, School, Play, & Leisure)																				
Collect data on patient/client's ability to perform activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	247	212	87	156	71	4.43	4.50	4.45	4.57	4.56	0.84	0.78	0.94	0.79	0.77	85	84	87	95	99
Collect data on patient/client's ability to perform instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	247	212	87	156	71	4.16	4.27	4.36	4.33	4.31	0.97	0.90	0.88	0.95	0.94	84	82	87	94	97
Collect data on patient/client's ability to perform skills needed for integration or reintegration into the community, work, or school	247	212	87	156	71	4.15	4.24	4.26	4.35	4.28	0.95	0.91	0.95	0.88	0.91	86	84	87	97	97
Collect data on barriers (e.g., social, economic, physical, psychological, environmental, work conditions and activities, learning, health literacy) to home, community, work, or school integration/reintegration	247	212	87	156	71	3.92	4.02	3.93	4.08	3.85	1.05	1.02	1.03	1.05	1.12	82	81	86	94	92
Collect data on safety in home, community, work, or school environments	247	212	87	156	71	4.08	4.14	4.13	4.19	4.12	1.00	0.99	0.96	1.00	0.92	82	82	83	96	96
Collect data on patient/client's ability to participate in activities with or without the use of devices, equipment, or technologies	247	212	87	156	71	4.24	4.29	4.30	4.32	4.39	0.89	0.90	0.94	0.94	0.84	86	85	85	95	99
Ergonomics and Body Mechanics																				
<i>Perform tests and measures of</i>																				
– ergonomics and body mechanics during functional activities	244	210	86	155	70	4.33	4.42	4.38	4.44	4.59	0.88	0.80	0.80	0.80	0.72	85	84	88	98	97
– postural alignment and position (static and dynamic)	244	210	86	155	70	4.38	4.49	4.44	4.42	4.54	0.78	0.72	0.73	0.83	0.77	86	85	88	99	100

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Functional Mobility, Balance, & Vestibular																				
<i>Perform tests and measures of</i>																				
– balance (dynamic and static) with or without the use of specialized equipment	244	210	86	155	70	4.60	4.67	4.60	4.62	4.74	0.60	0.54	0.66	0.65	0.58	86	85	87	99	100
– gait and locomotion (e.g., ambulation, wheelchair mobility) with or without the use of specialized equipment	244	210	86	155	70	4.67	4.72	4.60	4.70	4.83	0.62	0.52	0.71	0.57	0.42	86	85	87	99	100
– mobility during functional activities and transitional movements (e.g., transfers, bed mobility)	244	210	86	155	70	4.60	4.60	4.53	4.58	4.81	0.63	0.69	0.81	0.73	0.43	86	84	87	97	100
– vestibular function (e.g., peripheral dysfunction, central dysfunction)	244	210	86	155	70	3.78	3.82	3.77	3.90	3.90	1.05	1.15	1.01	1.07	1.14	78	76	79	91	91
Integumentary Integrity																				
Observe skin characteristics (e.g., continuity of skin color, sensation, temperature, texture, turgor)	244	206	85	151	66	3.68	3.85	3.83	3.81	3.80	1.03	1.09	1.09	1.16	1.13	82	80	82	93	95
Collect data on wound characteristics (e.g., tissue involvement, depth, tunneling, burn classification, ulcer/injury classification)	244	206	85	151	66	3.26	3.30	3.40	3.47	3.21	1.24	1.31	1.27	1.29	1.30	61	59	67	72	67
Observe scar tissue characteristics (e.g., banding, pliability, sensation, and texture)	244	206	85	151	66	3.33	3.44	3.53	3.50	3.57	1.15	1.19	1.22	1.20	1.26	74	70	77	82	82
Collect data on patient/client's activities, positioning, and postures that produce or relieve trauma to the skin	244	206	85	151	66	3.88	3.95	3.91	3.94	3.79	1.11	1.16	1.18	1.19	1.11	73	73	78	85	86
Identify devices and equipment that produce or relieve trauma to the patient/client's skin	244	206	85	151	66	3.79	3.86	3.85	3.86	3.79	1.15	1.18	1.26	1.16	1.16	73	72	72	82	82

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Joint Integrity & Range of Motion																				
<i>Perform tests and measures of</i>																				
– spinal joint stability (e.g., ligamentous integrity, joint structure)	241	205	84	148	65	3.83	3.87	3.92	3.93	4.00	1.07	1.15	1.10	1.16	1.11	75	70	70	80	86
– peripheral joint stability (e.g., ligamentous integrity, joint structure)	241	205	84	148	65	3.93	3.86	3.92	3.98	3.95	1.03	1.12	1.09	1.15	1.03	79	73	76	85	92
– spinal joint mobility (e.g., glide, end feel)	241	205	84	148	65	3.75	3.80	3.74	3.82	3.79	1.11	1.16	1.15	1.15	1.32	74	68	69	78	82
– peripheral joint mobility (e.g., glide, end feel)	241	205	84	148	65	4.01	3.93	3.77	3.94	3.94	1.00	1.11	1.11	1.13	1.23	81	73	76	83	91
– range of motion (e.g., passive, active, functional)	241	205	84	148	65	4.55	4.56	4.48	4.49	4.72	0.69	0.73	0.79	0.79	0.57	85	83	84	97	100
– flexibility (e.g., muscle length, soft tissue extensibility)	241	205	84	148	65	4.41	4.37	4.40	4.35	4.52	0.81	0.78	0.78	0.93	0.79	85	82	84	97	100
Motor Function																				
<i>Perform tests and measures of</i>																				
– muscle tone (e.g., hypertonicity, hypotonicity, dystonia)	240	202	83	147	65	4.00	4.00	4.02	4.01	4.23	1.00	0.98	0.96	1.08	1.01	80	79	83	89	92
– dexterity, coordination, and agility (e.g., rapid alternating movement, finger to nose)	240	202	83	147	65	3.70	3.77	3.76	3.86	3.77	1.09	1.07	1.09	1.11	1.39	79	73	80	88	85
– ability to initiate, modify and control movement patterns and postures (e.g., catching a ball, gait)	240	202	83	147	65	4.25	4.28	4.28	4.32	4.40	0.82	0.87	0.81	0.93	0.93	84	80	83	95	98
– ability to change movement performance with practice and feedback (e.g., motor learning)	240	202	83	147	64	4.17	4.19	4.21	4.22	4.33	0.89	0.91	0.89	0.98	0.89	83	79	83	93	100
– movement quality (e.g., purpose, precision, efficiency, biomechanics, kinematics)	240	202	83	147	64	4.20	4.26	4.19	4.29	4.42	0.90	0.88	0.92	0.91	0.81	84	80	83	96	100

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Muscle Performance																				
<i>Perform tests and measures of</i>																				
– muscle strength, power, and endurance without specialized equipment (e.g., manual muscle test, functional strength testing)	240	202	83	147	64	4.42	4.41	4.43	4.37	4.53	0.76	0.79	0.79	0.91	0.80	83	81	84	95	98
– muscle strength, power, and endurance with specialized equipment (e.g., isokinetic testing, dynamometry)	240	202	83	147	64	3.95	3.89	3.87	3.88	3.87	1.18	1.26	1.27	1.30	1.26	72	67	71	80	81
Neuromotor Development & Sensory Integration																				
<i>Perform tests and measures of</i>																				
– acquisition and evolution of motor skills throughout the lifespan	240	202	83	147	65	3.75	3.55	3.57	3.58	3.76	1.09	1.25	1.21	1.23	1.15	70	66	73	78	82
– sensorimotor integration (e.g., perceptual deficits, neglect)	240	202	82	147	65	3.63	3.60	3.53	3.72	3.88	1.06	1.13	1.25	1.18	1.12	75	70	70	85	89
– developmental reflexes and reactions (e.g., asymmetrical tonic neck reflex, righting reactions)	240	202	83	147	65	3.64	3.53	3.23	3.48	3.48	1.14	1.25	1.31	1.32	1.37	67	61	64	71	78
Reflex Integrity																				
<i>Perform tests and measures of</i>																				
– deep tendon/muscle stretch reflexes (e.g., quadriceps, biceps)	237	201	81	144	64	3.54	3.53	3.38	3.53	3.67	1.14	1.16	1.29	1.25	1.24	71	70	64	82	84
– upper motor neuron integrity (e.g., Babinski reflex, Hoffman sign)	237	201	81	144	64	3.28	3.29	3.07	3.19	3.25	1.19	1.23	1.21	1.31	1.31	65	59	62	71	73
– superficial reflexes and reactions (e.g., plantar reflex, abdominal reflexes)	237	201	81	144	64	3.12	3.10	2.81	3.28	3.37	1.19	1.29	1.20	1.33	1.26	62	55	58	74	77

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
<i>Pain & Sensory Integrity</i>																				
<i>Perform tests and measures of</i>																				
– pain (e.g., location, intensity, frequency, central, peripheral, psychogenic)	237	201	81	144	64	4.35	4.30	4.15	4.24	4.37	0.79	0.97	1.02	1.00	0.98	83	77	80	92	95
– deep sensation (e.g., proprioception, kinesthesia, pressure)	237	201	81	144	64	3.82	3.72	3.73	3.73	3.70	1.07	1.11	1.17	1.24	1.29	76	71	73	82	88
– superficial sensation (e.g., touch, temperature discrimination)	237	201	81	144	64	3.66	3.77	3.70	3.61	3.79	1.11	1.07	1.15	1.25	1.24	79	72	74	81	92
<i>Plan of Care & Goals</i>																				
Modify and/or progress within the plan of care based on patient/client's resources (e.g., financial, transportation, time, insurance benefits, available technologies)	235	199	80	143	64	4.32	4.38	4.43	4.44	4.49	0.97	0.87	0.95	0.92	0.77	79	77	77	92	95
<i>Procedural Interventions</i>																				
<i>Therapeutic Exercise/Therapeutic Activities</i>																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– aerobic capacity/endurance conditioning	386	220	123	235	106	4.13	4.15	4.22	3.97	3.85	1.00	1.01	1.01	1.03	1.19	99	95	97	96	94
– balance, coordination, and agility activities	386	220	123	235	106	4.68	4.67	4.72	4.64	4.58	0.58	0.61	0.56	0.58	0.69	100	100	99	100	98
– body mechanics and postural stabilization techniques	386	220	123	235	106	4.60	4.68	4.59	4.57	4.60	0.72	0.61	0.72	0.71	0.80	99	100	100	99	97
– flexibility techniques	386	220	123	235	106	3.91	4.01	4.02	3.84	4.01	1.06	1.03	0.96	1.03	1.03	98	97	98	97	97
– neuromotor techniques (e.g., movement pattern training, neuromuscular education or re-education)	386	220	123	235	106	4.15	4.26	4.30	4.15	4.26	0.91	0.86	0.90	0.97	0.91	99	99	99	98	97
– relaxation techniques	386	220	123	235	106	3.34	3.53	3.61	3.41	3.34	1.17	1.20	1.13	1.18	1.26	94	95	94	93	90
– strength, power, and endurance exercises	386	220	123	234	106	4.34	4.42	4.41	4.35	4.34	0.87	0.80	0.81	0.90	0.96	99	99	99	99	97

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– genitourinary management (e.g., pelvic floor exercises, bladder strategies)	386	220	123	235	106	2.80	2.68	3.17	2.75	2.90	1.22	1.25	1.37	1.33	1.24	53	53	52	46	53
– gastrointestinal management (e.g., positioning to avoid reflux, bowel function strategies)	386	220	123	235	106	2.69	2.57	2.76	2.68	2.78	1.27	1.25	1.39	1.31	1.17	45	50	49	42	47
– manual/mechanical airway clearance techniques (e.g., assistive devices, assistive cough, incentive spirometer, flutter valve, percussion, vibration)	386	220	123	235	106	2.96	2.88	2.92	2.73	2.61	1.37	1.35	1.50	1.39	1.34	47	52	46	40	41
– techniques to maximize ventilation and perfusion (e.g., positioning, active cycle breathing, autogenic drainage, paced breathing, pursed-lip breathing)	386	220	123	235	106	3.21	3.18	3.46	2.92	3.08	1.23	1.28	1.38	1.31	1.34	65	69	67	56	54
– mechanical repositioning for vestibular dysfunction	386	220	123	235	106	2.99	2.90	2.98	2.95	2.86	1.20	1.24	1.29	1.31	1.13	58	59	57	50	55
– habituation/adaptation exercises for vestibular dysfunction	386	220	123	235	106	2.99	2.98	2.98	3.00	3.00	1.20	1.18	1.28	1.32	1.17	61	64	59	56	62
– postural drainage	386	220	123	235	106	2.62	2.59	2.80	2.35	2.55	1.28	1.24	1.39	1.30	1.29	40	45	43	33	35
Functional Training																				
<i>Perform and/or train patient/client in</i>																				
– the use of environmental modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	375	217	118	224	100	3.99	3.92	4.00	3.86	3.80	1.26	1.24	1.19	1.29	1.30	83	82	85	82	83
– activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	375	217	118	225	100	4.29	4.20	4.28	4.06	4.18	1.07	1.11	1.04	1.21	1.12	92	90	89	92	95
– community and leisure integration or reintegration (e.g., work/school/play)	375	217	118	225	100	3.79	3.87	3.68	3.76	3.89	1.20	1.14	1.21	1.15	1.03	87	86	81	86	91

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	375	217	118	224	100	3.98	4.08	3.73	3.88	4.13	1.07	1.03	1.11	1.12	0.95	92	91	88	90	95
– mobility techniques	375	217	118	225	100	4.37	4.34	4.30	4.27	4.19	0.81	0.85	0.91	0.84	0.97	97	97	93	98	97
– gross motor developmental progression	375	217	118	225	100	3.83	3.70	3.73	3.67	3.55	1.14	1.17	1.15	1.18	1.16	85	85	84	82	85
– fall prevention and fall recovery strategies	375	217	118	225	100	4.46	4.47	4.45	4.31	4.34	0.88	0.80	0.89	0.99	0.83	95	96	93	98	99
– behavior modification and strategies that enhance functioning (e.g., energy conservation, pacing, pre-activity planning, reminder schedules)	375	217	118	225	100	3.86	3.80	3.87	3.75	3.74	1.15	1.07	1.15	1.22	1.10	90	89	89	86	91
Manual Therapy Techniques																				
Perform manual lymphatic drainage	365	210	112	218	96	2.68	2.63	2.60	2.74	2.80	1.24	1.26	1.45	1.37	1.42	38	39	33	34	35
Perform spinal manual traction	365	209	112	217	96	3.16	3.36	3.24	3.27	3.42	1.23	1.22	1.30	1.27	1.30	62	60	54	65	66
Perform peripheral manual traction	365	209	112	217	96	3.09	3.15	3.10	3.25	3.10	1.21	1.29	1.36	1.29	1.24	61	59	48	61	67
Perform and/or train patient/client/caregiver in soft tissue mobilization (e.g., connective tissue massage, therapeutic massage, foam rolling)	365	209	112	217	96	3.64	3.71	3.64	3.76	3.59	1.23	1.24	1.34	1.16	1.26	81	78	76	89	86
Perform instrument-assisted soft tissue mobilization	365	209	112	217	96	3.50	3.64	3.36	3.46	3.35	1.30	1.19	1.47	1.29	1.31	67	73	61	78	73
Perform peripheral joint range of motion	365	209	112	217	96	4.13	4.22	4.03	4.15	4.10	1.03	0.95	1.16	1.03	1.12	86	85	82	91	91
Perform peripheral mobilization/manipulation (thrust)	365	209	112	217	96	3.15	2.95	3.04	2.98	2.63	1.29	1.36	1.55	1.28	1.37	42	41	29	40	38
Perform peripheral mobilization (non-thrust)	365	209	112	217	96	3.52	3.64	3.61	3.57	3.49	1.27	1.24	1.39	1.27	1.18	69	67	54	72	74
Perform spinal mobilization/manipulation (thrust)	365	209	112	217	96	2.78	2.65	2.86	2.98	2.59	1.29	1.34	1.58	1.32	1.40	33	34	25	33	34
Perform spinal mobilization (non-thrust)	365	209	112	217	96	3.31	3.33	3.29	3.38	3.41	1.33	1.36	1.38	1.29	1.28	55	55	47	60	68

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
<i>Apply taping for</i>																				
– neuromuscular reeducation	364	206	108	216	96	3.94	3.95	3.79	3.77	3.86	1.21	1.19	1.30	1.34	1.32	78	76	71	78	80
– lymphatic drainage	364	206	108	216	96	3.00	3.01	2.80	2.67	2.92	1.28	1.35	1.39	1.41	1.45	45	42	36	37	42
– pain management	364	206	108	216	96	3.97	4.05	3.73	3.77	3.75	1.19	1.03	1.32	1.25	1.33	78	79	71	79	80
Equipment & Devices																				
<i>Apply and/or adjust</i>																				
– adaptive devices (e.g., seating and positioning devices, steering wheel devices)	361	200	106	208	95	3.58	3.68	3.55	3.82	3.73	1.32	1.32	1.46	1.30	1.30	65	65	51	74	72
– protective devices (e.g., braces, cushions, helmets)	361	200	106	208	95	3.66	3.69	3.70	3.69	3.60	1.22	1.21	1.18	1.29	1.26	78	77	68	79	84
– supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars)	361	200	106	208	95	3.57	3.57	3.33	3.67	3.58	1.21	1.29	1.31	1.25	1.32	77	76	66	82	84
– orthotic devices (e.g., braces, shoe inserts, splints)	361	200	106	208	95	3.78	3.82	3.69	3.70	3.89	1.16	1.16	1.22	1.26	1.09	85	84	74	87	94
<i>Apply and/or adjust</i>																				
– assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	361	200	106	208	95	4.48	4.48	4.39	4.44	4.56	0.89	0.84	1.00	0.93	0.74	92	89	84	97	98
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses)	361	200	106	208	95	3.53	3.50	3.60	3.39	3.49	1.25	1.29	1.44	1.36	1.30	67	67	59	70	73
– mechanical neuromuscular reeducation devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	361	200	106	208	95	3.12	3.16	3.34	3.17	3.21	1.40	1.48	1.57	1.46	1.52	47	47	41	51	49
– prescribed oxygen during interventions	361	200	106	208	95	3.84	3.77	3.84	3.60	3.73	1.30	1.33	1.37	1.41	1.31	63	61	57	56	62

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
<i>Train patient/client/caregiver in the use of</i>																				
– adaptive devices (e.g., seating and positioning devices, steering wheel devices)	357	197	103	202	90	3.60	3.58	3.40	3.74	3.60	1.31	1.34	1.50	1.32	1.50	60	61	47	70	66
– assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	357	197	103	202	90	4.49	4.45	4.40	4.42	4.56	0.84	0.90	0.97	0.94	0.83	91	87	82	97	98
– orthotic devices (e.g., braces, shoe inserts, splints)	357	197	103	202	90	4.06	3.93	3.88	3.86	3.99	1.10	1.13	1.17	1.20	1.09	84	82	72	86	94
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses)	357	197	103	202	90	3.73	3.74	3.59	3.60	3.54	1.25	1.29	1.46	1.34	1.37	64	63	51	68	67
– protective devices (e.g., braces, cushions, helmets)	357	197	103	202	90	3.68	3.62	3.68	3.76	3.75	1.23	1.36	1.33	1.22	1.28	74	66	62	77	78
– supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars)	357	197	103	202	90	3.67	3.64	3.44	3.66	3.69	1.18	1.33	1.33	1.21	1.17	77	71	59	79	84
– mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	357	197	103	202	90	3.22	3.26	3.28	3.28	3.25	1.45	1.45	1.60	1.52	1.53	46	47	38	46	50
Integumentary Repair & Protection Techniques																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– nonselective debridement (e.g., removal of nonselective areas of devitalized tissue)	353	193	103	198	88	2.61	2.73	2.38	2.74	2.83	1.29	1.33	1.32	1.20	1.27	19	22	15	27	23
– selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)	353	193	103	198	88	2.60	2.65	2.30	2.74	2.67	1.27	1.34	1.27	1.25	1.24	18	21	14	24	23
– application of topical agents (e.g., cleansers, creams, moisturizers, ointments, sealants) and dressings (e.g., hydrogels, wound coverings)	353	193	103	198	88	2.76	2.99	2.63	2.89	2.86	1.31	1.25	1.23	1.27	1.25	33	36	26	37	36

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– desensitization techniques (e.g., brushing, tapping, use of textures)	353	193	103	198	88	3.00	3.02	2.75	2.98	3.09	1.21	1.17	1.28	1.18	1.26	53	53	43	64	67
– hyperbaric therapy	353	193	103	198	88	2.49	2.32	2.13	2.56	2.48	1.25	1.22	1.25	1.25	1.20	15	17	14	21	20
– negative pressure wound therapy (e.g., vacuum-assisted wound closure)	353	193	103	198	88	2.62	2.67	2.37	2.68	2.43	1.34	1.30	1.33	1.38	1.20	19	22	15	22	25
Perform sharp debridement (e.g., removal of specific areas of devitalized tissue)	353	193	103	198	88	2.54	2.44	2.19	2.55	2.41	1.36	1.22	1.30	1.31	1.33	15	19	13	19	17
Therapeutic Modalities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
– biofeedback therapy (e.g., relaxation techniques, muscle reeducation, EMG)	352	191	103	194	88	3.49	3.36	3.37	3.23	3.36	1.21	1.27	1.37	1.30	1.35	68	62	56	70	69
– iontophoresis	352	191	103	194	88	2.89	2.68	2.79	2.58	2.70	1.37	1.45	1.35	1.39	1.37	45	38	43	36	42
– phonophoresis	352	189	102	193	87	2.70	2.78	2.08	2.52	2.29	1.43	1.49	1.24	1.48	1.27	29	25	16	22	22
– electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	352	191	103	194	88	3.86	3.98	3.77	3.76	4.06	1.22	1.14	1.29	1.19	1.05	78	77	71	82	89
– cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	352	191	103	194	88	3.91	3.86	3.77	3.75	3.86	1.16	1.23	1.28	1.19	1.13	82	75	72	90	92
– hydrotherapy using contrast baths/pools	352	191	103	194	88	3.03	2.84	2.63	2.61	2.70	1.47	1.50	1.47	1.45	1.55	35	32	25	34	32
– hydrotherapy (e.g., aquatic exercise, underwater treadmill)	352	191	103	194	88	3.25	3.36	3.30	2.94	3.28	1.42	1.41	1.52	1.42	1.52	35	37	30	36	35
– phototherapy (laser light)	352	191	103	194	88	2.74	2.62	2.23	2.36	2.32	1.40	1.43	1.33	1.37	1.30	29	26	20	24	23

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])	352	189	102	193	87	2.34	2.44	1.97	2.15	2.15	1.31	1.30	1.09	1.19	1.17	19	20	14	20	18
– ultrasound procedures	352	189	102	193	87	3.28	3.36	3.00	3.06	3.22	1.33	1.33	1.33	1.43	1.27	67	59	52	62	69
– diathermy	352	189	102	193	87	2.61	2.54	2.26	2.15	2.52	1.37	1.32	1.21	1.28	1.39	28	26	22	19	24
– dry heat thermotherapy (e.g., Fluidotherapy)	352	189	102	193	87	2.61	2.63	2.20	2.41	2.72	1.39	1.38	1.30	1.30	1.50	26	28	18	25	28
– hot pack thermotherapy	352	189	102	193	87	3.83	3.82	3.49	3.71	3.82	1.23	1.17	1.45	1.24	1.14	79	73	61	80	89
– paraffin bath thermotherapy	352	189	102	193	87	2.98	2.95	2.69	2.82	3.30	1.38	1.36	1.38	1.44	1.39	37	40	29	35	43
– shockwave therapy	352	189	102	193	87	2.39	2.54	1.94	2.37	2.42	1.32	1.42	1.10	1.33	1.28	19	19	15	20	17
– blood-flow restriction training			102	193	87			2.85	2.81	3.29			1.40	1.34	1.45			19	36	32
– cupping			102	193	87			3.02	3.17	3.13			1.47	1.34	1.19			19	49	54
Mechanical Modalities																				
<i>Apply and/or train patient/client/caregiver in</i>																				
– intermittent pneumatic compression (e.g., sequential compression devices)	352	189	102	191	87	2.92	3.21	2.73	2.88	3.31	1.34	1.25	1.39	1.44	1.44	36	35	28	38	44
– assisted movement devices (e.g., continuous passive motion devices)	352	189	102	191	87	3.03	3.38	3.08	2.91	3.04	1.38	1.25	1.40	1.33	1.40	46	43	35	40	43
– mechanical spinal traction	352	189	102	191	87	3.33	3.74	3.28	3.41	3.36	1.33	1.13	1.44	1.37	1.21	50	48	41	47	56
Non-procedural Interventions																				
Communication																				
<i>Discuss physical therapy evaluation findings, interventions, goals, prognosis, discharge planning, and plan of care with</i>																				
– the supervising physical therapist	351	189	102	190	87	4.76	4.77	4.80	4.72	4.87	0.63	0.64	0.62	0.69	0.40	87	83	80	98	97
– interprofessional/interdisciplinary team members	351	189	102	189	87	4.50	4.49	4.44	4.38	4.61	0.83	0.83	0.93	0.97	0.85	85	80	76	94	94
– patient/client/caregiver	351	189	102	189	87	4.73	4.66	4.66	4.73	4.86	0.62	0.70	0.70	0.62	0.41	90	85	82	98	100
Provide written, oral, and electronic information to the patient/client and/or caregiver	351	189	102	189	87	4.59	4.59	4.51	4.57	4.61	0.73	0.73	0.84	0.80	0.78	89	84	80	98	100

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Documentation																				
<i>Document</i>																				
– data collection results	350	189	101	187	87	4.49	4.55	4.56	4.52	4.45	0.85	0.85	0.84	0.87	0.99	86	81	78	96	93
– intervention(s) and patient/client response(s) to intervention	350	189	101	187	87	4.70	4.79	4.81	4.75	4.83	0.67	0.49	0.54	0.56	0.47	89	86	81	99	99
– patient/client/caregiver education	350	189	101	187	87	4.69	4.71	4.66	4.66	4.74	0.64	0.54	0.65	0.73	0.56	90	86	81	99	100
– communication with the interdisciplinary/interprofessional team related to the patient/client's care	350	189	101	187	87	4.50	4.51	4.44	4.45	4.47	0.81	0.76	0.94	0.88	0.94	87	82	77	98	97
– rationale for billing and reimbursement	350	189	101	187	87	4.40	4.55	4.40	4.35	4.39	0.96	0.79	1.01	0.99	0.93	83	80	74	94	98
– disclosure and consent (e.g., disclosure of medical information, consent for treatment)	350	189	101	187	87	4.35	4.49	4.34	4.42	4.36	0.99	0.89	1.00	0.90	1.02	82	77	74	90	97
Assign billing codes for physical therapy treatment provided	350	189	101	187	87	4.35	4.46	4.41	4.44	4.52	1.01	0.88	0.97	0.97	0.90	75	74	68	88	90
Education																				
<i>Educate patient/client and/or caregiver about</i>																				
– the patient/client's current condition and health status (e.g., nature of the condition, potential benefits of physical therapy interventions, potential treatment outcomes)	347	188	100	185	87	4.72	4.65	4.64	4.69	4.76	0.63	0.68	0.75	0.63	0.59	89	85	79	99	100
– the role of the physical therapist and/or physical therapist assistant in patient/client management	347	188	100	185	87	4.61	4.53	4.55	4.57	4.63	0.73	0.76	0.78	0.80	0.76	89	85	81	98	100
– lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	347	188	100	185	87	4.41	4.47	4.38	4.41	4.36	0.84	0.85	0.97	0.88	0.92	89	81	80	97	99
– the role of physical therapy in transitional planning (e.g., hospice, palliative care, setting changes)	347	188	100	185	87	4.03	4.09	4.15	3.99	3.99	1.21	1.20	1.15	1.21	1.32	75	68	67	82	83

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
<i>Educate the healthcare team about</i>																				
– the role of the physical therapist and/or physical therapist assistant in patient/client management	347	188	100	185	87	4.29	4.22	4.33	4.23	4.20	1.00	1.06	0.94	1.03	1.11	83	79	73	91	98
– the healthcare team about safe patient handling (e.g., injury prevention, ergonomics, use of equipment)	347	188	100	185	87	4.68	4.43	4.44	4.43	4.65	0.69	0.85	0.96	0.96	0.63	89	82	75	90	99
Educate community groups on lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	346	188	100	185	86	3.87	3.85	3.60	3.84	3.91	1.11	1.20	1.27	1.18	1.14	66	57	56	70	78
Participate in the clinical education of students	346	188	100	185	86	3.77	3.67	3.85	3.74	4.11	1.15	1.31	1.28	1.27	1.05	64	52	47	66	74
<i>Patient/client & Staff Safety</i>																				
<i>Emergency Procedures</i>																				
Implement emergency procedures (e.g., CPR, AED, calling a code)	346	188	100	185	86	4.12	3.99	4.09	4.19	4.17	1.12	1.25	1.29	1.07	1.24	75	69	63	85	86
Perform first aid	346	188	100	185	86	3.91	3.87	3.99	3.93	3.87	1.19	1.29	1.27	1.23	1.39	76	70	65	88	88
Implement disaster response procedures	346	188	100	185	86	3.69	3.70	3.90	3.82	4.00	1.20	1.30	1.28	1.27	1.35	67	62	54	74	80
<i>Environmental Safety</i>																				
Perform risk assessment of the physical environment (e.g., barrier-free environment, outlets, windows, floors, lighting)	346	188	100	185	86	3.98	4.03	4.05	4.05	3.99	1.12	1.20	1.13	1.14	1.35	71	64	59	77	76
Prepare and maintain a safe working environment for performing interventions (e.g., unobstructed walkways, equipment availability)	346	188	100	185	86	4.43	4.36	4.34	4.47	4.48	0.86	0.98	1.00	0.86	0.88	83	78	72	95	93
Perform regular equipment inspections and/or maintenance (e.g., modalities, assistive devices)	346	188	100	185	86	4.15	4.13	4.01	4.20	4.14	1.03	1.11	1.14	1.05	1.19	77	66	64	83	81

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Infection Control																				
Perform and/or train patient/client and/or caregiver on appropriate infection control practices (e.g., universal precautions, hand hygiene, isolation, airborne precautions, equipment cleaning)	235	199	80	143	64	4.12	4.06	3.96	4.05	3.98	1.06	1.15	1.21	1.15	1.13	77	70	67	85	80
Research & Evidence-Based Practice																				
Search the literature for current best evidence	235	199	80	143	64	3.83	3.82	3.74	3.89	3.71	1.01	1.01	1.15	1.14	1.12	79	73	77	86	84
Evaluate the quality of published data	235	199	80	143	64	3.56	3.63	3.42	3.81	3.52	1.09	1.17	1.25	1.28	1.28	74	65	70	74	77
Integrate current best evidence, clinical experience, and patient values in clinical practice (e.g., clinical prediction rules, patient preference, clinical practice guidelines)	235	199	80	143	64	3.88	4.04	4.03	3.98	4.25	1.01	0.96	0.95	1.24	0.99	79	74	79	87	92
Design and/or direct research activities	235	199	80	143	64	2.90	3.07	2.65	2.97	2.79	1.23	1.30	1.42	1.42	1.34	48	43	41	50	53
Participate in research activities	235	199	80	143	64	2.85	2.86	2.62	2.92	2.66	1.24	1.29	1.24	1.44	1.28	47	43	47	48	52
Compare intervention outcomes with normative data	235	199	80	143	64	3.16	3.29	2.87	3.38	3.23	1.19	1.30	1.25	1.37	1.41	55	50	53	60	59
Professional Responsibilities																				
Supervise support personnel (e.g., physical therapy aide/technician)	235	199	80	143	64	3.72	3.71	3.67	3.83	4.00	1.25	1.15	1.28	1.32	1.31	61	57	63	68	63
Assign tasks to other personnel (e.g., physical therapy aide/technician) to assist with patient/client care	235	199	80	143	64	3.62	3.61	3.54	3.71	3.82	1.23	1.17	1.23	1.32	1.24	64	59	67	70	73
Disclose financial interest in recommended products or services to patient/client	232	197	80	143	63	3.20	3.18	3.11	2.84	3.68	1.28	1.20	1.37	1.33	1.14	50	46	48	43	68
Communicate with the physical therapist when the expectations of the PTA are beyond their knowledge, skills, and abilities	232	197	80	143	63	4.61	4.58	4.64	4.61	4.75	0.71	0.72	0.75	0.77	0.57	82	80	82	97	100

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Report healthcare providers that are suspected to not perform their professional responsibilities with reasonable skill and safety to the appropriate authorities	232	197	80	143	63	4.42	4.37	4.51	4.31	4.56	0.91	0.94	0.84	1.01	0.65	78	75	78	97	94
Report suspected cases of abuse to the appropriate authority	232	197	80	143	63	4.64	4.65	4.65	4.66	4.79	0.75	0.67	0.77	0.71	0.52	81	79	80	97	98
Report suspected illegal or unethical acts performed by healthcare providers to the relevant authority	232	197	80	143	63	4.60	4.58	4.63	4.61	4.78	0.78	0.75	0.77	0.78	0.52	80	78	80	97	95
Advocate for public access to physical therapy and other healthcare services	231	195	80	142	62	4.04	4.16	4.09	4.12	4.17	1.07	1.06	0.98	1.12	1.15	74	67	76	82	79
Determine own need for professional development	231	195	80	142	62	4.33	4.43	4.38	4.43	4.45	0.85	0.83	0.76	0.87	0.77	81	78	80	94	97
Participate in learning and/or development activities (e.g., journal clubs, self-directed reading, continuing competence activities) to maintain the currency of knowledge, skills, and abilities	231	195	80	142	62	4.27	4.21	4.30	4.20	4.18	0.88	1.05	0.84	0.98	1.12	82	74	80	94	94
Practice within the federal and jurisdiction regulations and professional standards	231	195	80	142	62	4.68	4.72	4.73	4.76	4.77	0.63	0.62	0.55	0.57	0.56	82	77	82	96	100
Participate in professional organizations	231	195	80	142	62	3.49	3.48	3.45	3.52	3.34	1.22	1.18	1.16	1.30	1.40	77	69	77	84	81
Participate in performance improvement and quality reporting activities (e.g., Physician Quality Reporting System, standardized outcomes measurement, application of health informatics)	231	195	80	142	62	3.78	3.75	3.69	3.64	3.66	1.07	1.10	1.10	1.34	1.29	72	67	71	77	79

Table B.3. PT Knowledge and Skill Requirements Survey Results

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
CARDIOVASCULAR/PULMONARY SYSTEM																				
Physical Therapy Examination																				
Cardiovascular/pulmonary system tests/measures, including outcome measures, and their applications according to current best evidence	982	972	431	796	525	4.03	4.07	4.08	4.07	4.03	0.95	0.93	0.97	0.92	0.95	99	99	99	99	100
Anatomy and physiology of the cardiovascular/pulmonary system as related to tests/measures	982	972	431	796	525	4.01	4.00	4.02	4.01	4.02	0.94	0.95	0.98	0.93	0.96	100	99	100	99	99
Movement analysis as related to the cardiovascular/pulmonary system (e.g., rib cage excursion, breathing pattern)	982	972	431	796	525	3.93	3.86	3.93	3.91	3.96	0.93	0.95	1.01	0.97	0.94	100	99	99	99	99
Foundation for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the cardiovascular/pulmonary systems	982	972	431	796	525	4.07	4.00	4.05	4.00	4.00	0.89	0.90	0.93	0.92	0.96	100	100	99	99	100
Cardiovascular/pulmonary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	982	972	430	796	525	4.05	4.02	4.08	4.03	4.06	0.86	0.89	0.93	0.90	0.90	100	99	99	99	100
Non-pharmacological medical management of the cardiovascular/pulmonary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures, cardiopulmonary mechanical devices)	982	972	431	796	525	3.52	3.51	3.48	3.52	3.42	0.96	0.99	0.97	0.96	1.02	99	99	99	99	98

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Function, implications, contraindications and related precautions of mechanical circulatory devices (e.g. extracorporeal membrane oxygenation [ECMO], intraaortic balloon pump [IABP], ventricular assist devices [VAD])				796	525				3.54	3.51				1.17	1.18				96	97
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	982	972	431	796	525	3.72	3.69	3.67	3.71	3.72	0.93	0.94	0.98	0.98	0.95	99	99	99	99	100
Interventions																				
Cardiovascular/pulmonary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	982	972	431	796	525	4.13	4.13	4.16	4.15	4.15	0.89	0.89	0.90	0.89	0.91	100	99	100	99	99
Anatomy and physiology of the cardiovascular/pulmonary system as related to physical therapy interventions, daily activities, and environmental factors	982	972	431	796	525	4.20	4.13	4.15	4.19	4.19	0.87	0.90	0.87	0.87	0.90	100	99	99	99	99
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on the cardiovascular/pulmonary system	982	972	431	796	525	4.45	4.43	4.41	4.34	4.38	0.75	0.76	0.82	0.80	0.76	100	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on other systems	928	899	403	727	484	4.50	4.49	4.42	4.43	4.49	0.73	0.75	0.81	0.76	0.76	94	92	93	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
LYMPHATIC SYSTEM																				
Physical Therapy Examination																				
Lymphatic system tests/measures, including outcome measures, and their applications according to current best evidence	946	928	409	751	501	3.02	2.96	3.04	3.01	3.02	0.99	0.96	0.99	1.00	1.00	92	91	91	95	97
Anatomy and physiology of the lymphatic system as related to tests/measures	946	928	409	751	501	3.13	3.08	3.12	3.11	3.19	1.01	0.98	0.99	1.03	1.01	93	92	92	96	99
Movement analysis as related to the lymphatic system (e.g., compensatory movement, extremity range of motion)	946	928	409	751	501	3.30	3.23	3.29	3.28	3.39	1.03	1.00	1.04	1.06	1.06	93	92	91	97	98
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the lymphatic system	946	928	409	751	502	3.32	3.21	3.23	3.26	3.33	0.98	0.98	1.03	1.02	1.05	94	93	92	98	98
Lymphatic system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	946	928	409	751	501	3.26	3.17	3.23	3.23	3.30	0.98	0.97	1.01	1.00	0.99	94	93	91	97	99
Non-pharmacological medical management of the lymphatic system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	946	928	409	751	501	2.99	2.94	2.98	2.99	2.97	0.95	0.96	1.00	1.00	0.97	92	91	90	96	97
Interventions																				
Lymphatic system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	946	928	409	751	501	3.38	3.31	3.37	3.35	3.43	1.04	1.02	1.08	1.08	1.05	94	93	91	97	98
Anatomy and physiology of the lymphatic system as related to interventions, daily activities, and environmental factors	946	928	409	751	501	3.38	3.30	3.31	3.35	3.43	1.05	1.02	1.01	1.06	1.05	94	92	92	97	98

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Adverse effects or complications on the lymphatic system from physical therapy interventions	946	928	409	751	501	3.63	3.54	3.58	3.52	3.57	1.02	1.07	1.09	1.07	1.02	95	93	92	98	99
Adverse effects or complications on the lymphatic system from physical therapy interventions used on other systems	928	899	403	727	484	4.01	3.96	3.96	3.98	3.97	1.02	1.09	1.05	1.05	1.06	94	91	92	99	99
MUSCULOSKELETAL SYSTEM																				
Physical Therapy Examination																				
Musculoskeletal system tests/measures, including outcome measures, and their applications according to current best evidence	1,018	1,020	469	899	526	4.73	4.70	4.68	4.71	4.74	0.59	0.56	0.58	0.58	0.57	100	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to tests/measures	1,018	1,020	469	899	526	4.75	4.69	4.68	4.71	4.74	0.52	0.56	0.57	0.54	0.55	100	100	100	100	100
Movement analysis as related to the musculoskeletal system	1,018	1,020	469	899	526	4.71	4.67	4.66	4.68	4.72	0.53	0.55	0.57	0.57	0.57	100	100	100	100	100
Joint biomechanics and their applications	1,018	1,020	469	899	526	4.54	4.49	4.46	4.49	4.49	0.68	0.69	0.71	0.73	0.75	100	100	100	100	100
Physical therapy ultrasound imaging of the musculoskeletal system	1,018	1,020	469	899	526	2.73	2.70	2.71	2.62	2.57	1.11	1.08	1.09	1.11	1.18	87	87	87	84	80
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the musculoskeletal system	993	979	453	861	496	4.57	4.53	4.52	4.56	4.55	0.63	0.67	0.68	0.64	0.67	98	96	97	100	100
Differential diagnoses related to diseases/conditions of the connective tissue	993	979	453	861	496	4.36	4.31	4.24	4.32	4.28	0.75	0.78	0.83	0.77	0.82	97	96	97	100	100
Musculoskeletal system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	993	979	453	861	496	4.56	4.46	4.51	4.53	4.56	0.62	0.69	0.66	0.66	0.70	98	96	97	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Connective tissue diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	993	979	453	861	496	4.33	4.25	4.23	4.30	4.28	0.74	0.80	0.80	0.79	0.83	97	96	97	100	100
Non-pharmacological medical management of the musculoskeletal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	993	979	453	861	496	3.86	3.80	3.77	3.78	3.83	0.84	0.89	0.88	0.87	0.92	97	95	96	100	100
The impact of pharmacology used to treat the musculoskeletal system on physical therapy management	993	979	453	861	496	3.73	3.65	3.67	3.66	3.72	0.86	0.89	0.86	0.92	0.92	97	96	97	100	100
The impact of regenerative medicine (e.g., platelet rich plasma, stem cells) on physical therapy prognosis and interventions related to musculoskeletal diseases/conditions	993	979	453	861	496	3.15	3.14	3.07	3.15	3.07	0.95	0.94	0.94	1.02	1.01	94	94	93	96	96
Interventions																				
Musculoskeletal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,018	1,020	469	899	526	4.73	4.64	4.66	4.66	4.70	0.54	0.61	0.57	0.61	0.60	100	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to physical therapy interventions, daily activities, and environmental factors	1,018	1,020	469	899	526	4.76	4.71	4.69	4.71	4.75	0.50	0.52	0.56	0.52	0.56	100	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on the musculoskeletal system	1,018	1,020	469	899	526	4.71	4.66	4.64	4.64	4.66	0.55	0.59	0.59	0.60	0.63	100	100	100	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on other systems	928	899	403	727	484	4.81	4.78	4.76	4.74	4.78	0.46	0.49	0.53	0.54	0.47	94	92	93	100	100
NEUROMUSCULAR & NERVOUS SYSTEM																				
Physical Therapy Examination																				
Neuromuscular and nervous systems tests/measures, including outcome measures, and their applications according to current best evidence	960	933	433	835	473	4.58	4.60	4.54	4.57	4.70	0.64	0.63	0.67	0.66	0.55	94	91	92	100	100
Anatomy and physiology of the neuromuscular and nervous systems as related to tests/measures	960	933	433	835	473	4.57	4.56	4.51	4.53	4.65	0.63	0.65	0.68	0.67	0.62	94	91	92	100	100
Movement analysis as related to the neuromuscular and nervous systems	960	933	433	835	473	4.56	4.58	4.52	4.57	4.64	0.64	0.64	0.68	0.67	0.67	94	91	92	100	100
Diagnostic electromyography (EMG) using surface electrodes	960	933	433	835	473	2.58	2.59	2.61	2.57	2.54	1.00	1.04	1.01	1.11	1.09	81	79	80	83	83
Diagnostic electrophysiology (EMG/NCV) using needle insertion	960	933	433	835	473	2.45	2.45	2.43	2.41	2.38	1.03	1.06	1.04	1.11	1.08	77	75	75	78	78
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the nervous system (CNS, PNS, ANS)	960	933	433	835	473	4.33	4.24	4.23	4.25	4.35	0.81	0.85	0.84	0.88	0.80	94	91	92	100	100
Neuromuscular and nervous system (CNS, PNS, ANS) diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	960	933	433	835	473	4.44	4.30	4.32	4.37	4.44	0.76	0.81	0.82	0.79	0.74	94	91	92	100	100
Non-pharmacological medical management of the neuromuscular and nervous systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	960	933	433	835	473	3.78	3.69	3.62	3.73	3.78	0.89	0.94	0.91	0.93	0.95	94	91	91	100	99

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
The impact of pharmacology used to treat the neuromuscular and nervous systems on physical therapy management	960	933	433	835	473	3.75	3.67	3.67	3.68	3.80	0.89	0.94	0.87	0.95	0.92	94	91	92	99	100
The impact of regenerative medicine (e.g., platelet rich plasma, stem cells) on physical therapy prognosis and interventions related to the neuromuscular and nervous systems	960	933	433	835	473	3.03	3.01	2.89	2.99	2.99	0.99	1.04	1.01	1.10	1.09	89	86	86	92	92
Interventions																				
Neuromuscular and nervous systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	937	899	419	799	446	4.66	4.60	4.54	4.59	4.70	0.57	0.62	0.70	0.65	0.57	92	88	89	100	100
Anatomy and physiology of the neuromuscular and nervous systems as related to physical therapy interventions, daily activities, and environmental factors	937	899	419	799	446	4.63	4.60	4.54	4.58	4.67	0.59	0.61	0.67	0.62	0.58	92	88	89	100	100
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on the neuromuscular and nervous systems	937	899	419	799	446	4.57	4.51	4.51	4.52	4.60	0.65	0.68	0.68	0.67	0.62	92	88	89	100	100
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on other systems	928	899	403	727	484	4.80	4.77	4.74	4.71	4.76	0.45	0.48	0.54	0.57	0.49	94	92	93	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Motor control as related to neuromuscular and nervous systems physical therapy interventions	937	899	419	799	446	4.54	4.52	4.47	4.52	4.60	0.67	0.67	0.68	0.69	0.66	92	88	89	100	100
Motor learning as related to the neuromuscular and nervous systems physical therapy interventions	937	899	419	799	446	4.50	4.49	4.43	4.48	4.55	0.71	0.69	0.71	0.71	0.71	92	88	89	100	100
INTEGUMENTARY SYSTEM																				
Physical Therapy Examination																				
Integumentary system tests/measures, including outcome measures, and their applications according to current best evidence	908	867	394	699	461	3.48	3.38	3.39	3.40	3.36	0.99	0.98	1.00	1.05	1.01	91	87	90	98	98
Anatomy and physiology of the integumentary system as related to tests/measures	908	867	394	699	461	3.53	3.47	3.44	3.49	3.48	0.98	0.99	0.98	1.03	1.01	91	88	91	98	98
Movement analysis as related to the integumentary system (e.g., friction, shear, pressure, and scar mobility)	908	867	394	699	461	3.92	3.86	3.90	3.86	3.93	0.93	0.95	0.93	0.99	0.94	92	88	91	99	99
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the integumentary system	908	867	394	698	461	3.58	3.50	3.47	3.49	3.44	0.97	0.98	0.99	1.01	1.00	91	88	90	99	98
Integumentary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	908	867	394	698	461	3.57	3.51	3.52	3.52	3.48	0.94	0.96	0.98	1.02	1.00	92	88	90	99	98
Non-pharmacological medical management of the integumentary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	908	867	394	698	461	3.29	3.23	3.19	3.22	3.19	0.96	1.00	1.00	1.04	1.04	91	87	90	98	97

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
The impact of pharmacology used to treat the integumentary system on physical therapy management	908	867	394	698	461	3.31	3.26	3.27	3.32	3.26	0.99	1.03	1.00	1.07	1.01	91	86	89	98	98
Interventions																				
Integumentary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	908	867	394	698	461	3.72	3.58	3.63	3.62	3.63	0.96	0.99	1.00	1.05	1.03	92	88	90	98	99
Anatomy and physiology of the integumentary system as related to physical therapy interventions, daily activities, and environmental factors	908	867	394	698	461	3.80	3.67	3.63	3.67	3.71	0.94	1.00	1.02	1.03	1.03	92	88	90	99	98
Adverse effects or complications on the integumentary system from physical therapy and medical/surgical interventions on the integumentary system	908	867	394	698	461	3.99	3.85	3.84	3.78	3.82	0.93	0.98	0.98	1.02	1.03	92	88	90	99	99
Adverse effects or complications on the integumentary system from physical therapy interventions used on other systems	928	899	403	727	484	4.22	4.17	4.08	4.14	4.16	0.86	0.92	0.96	0.95	0.97	94	92	93	99	99
METABOLIC & ENDOCRINE SYSTEMS																				
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the metabolic and endocrine systems	924	887	412	768	438	3.67	3.63	3.65	3.59	3.69	0.94	0.97	0.98	0.94	0.94	90	86	87	99	99
Metabolic and endocrine system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	924	887	412	768	438	3.68	3.63	3.64	3.59	3.71	0.92	0.96	0.97	0.95	0.95	90	86	87	99	99

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Non-pharmacological medical management of the metabolic and endocrine systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	924	887	412	768	438	3.36	3.31	3.28	3.28	3.34	0.92	0.98	0.96	0.97	1.04	89	85	86	99	96
The impact of pharmacology used to treat the metabolic and endocrine systems on physical therapy management	924	887	412	768	438	3.41	3.37	3.31	3.32	3.44	0.95	0.99	0.96	1.00	1.02	89	85	86	98	98
Interventions																				
Metabolic and endocrine systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	924	887	412	768	438	3.67	3.60	3.66	3.59	3.71	0.98	1.01	0.99	1.00	1.04	89	85	87	99	99
Anatomy and physiology of the metabolic and endocrine systems as related to physical therapy interventions, daily activities, and environmental factors	924	887	412	768	438	3.67	3.61	3.69	3.58	3.71	0.99	1.01	1.00	1.00	1.04	89	86	86	99	99
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on the metabolic and endocrine systems	924	887	412	768	438	3.85	3.77	3.83	3.72	3.86	1.01	0.99	0.98	1.01	0.96	89	86	87	99	99
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on other systems	928	899	403	727	484	4.04	3.99	3.92	4.00	3.96	0.97	1.02	1.03	1.04	1.03	94	92	92	100	99

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
GASTROINTESTINAL SYSTEM																				
Physical Therapy Examination																				
Gastrointestinal system tests/measures, including outcome measures, and their applications according to current best evidence (e.g., bowel dysfunction impact questionnaires, Murphy test, Rovsing test, McBurney point sign)	912	870	403	746	433	3.02	3.00	3.04	3.00	3.04	1.04	1.08	1.00	1.00	1.06	85	79	82	94	94
Anatomy and physiology of the gastrointestinal system as related to tests/measures	912	870	403	746	433	3.10	3.06	3.08	3.07	3.19	1.01	1.07	0.97	1.01	1.06	86	80	82	95	97
Movement analysis as related to the gastrointestinal system (e.g., effects of muscular tension or trigger points, positioning for bowel movement)	912	870	403	746	433	3.10	3.12	3.09	3.05	3.19	1.05	1.10	1.00	1.08	1.11	86	81	82	93	95
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Gastrointestinal system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	912	870	403	746	433	3.12	3.11	3.13	3.07	3.25	1.02	1.07	1.00	1.06	1.08	86	81	82	94	97
Differential diagnoses related to diseases/conditions of the gastrointestinal system	912	870	403	746	433	3.20	3.17	3.18	3.12	3.26	1.06	1.08	1.03	1.04	1.09	86	81	83	95	95
Non-pharmacological medical management of the gastrointestinal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	912	870	403	746	433	2.86	2.88	2.93	2.84	2.93	0.96	1.02	0.93	0.99	0.99	85	80	82	92	94
The impact of pharmacology used to treat the gastrointestinal system on physical therapy management	912	870	403	746	433	3.06	3.03	3.06	2.94	3.13	0.97	1.04	0.98	1.01	1.05	87	81	83	93	95

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Interventions																				
Gastrointestinal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., positioning for reflux prevention, bowel programs)	912	870	403	746	433	3.14	3.16	3.19	3.09	3.27	1.05	1.08	1.03	1.06	1.09	86	82	82	94	95
Anatomy and physiology of the gastrointestinal system as related to physical therapy interventions, daily activities, and environmental factors	912	870	403	746	433	3.29	3.23	3.31	3.22	3.36	1.05	1.11	1.07	1.09	1.10	87	81	83	95	96
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on the gastrointestinal system	912	870	403	746	433	3.46	3.37	3.44	3.28	3.42	1.09	1.13	1.07	1.08	1.11	87	82	84	96	97
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on other systems	928	899	403	727	484	3.85	3.82	3.72	3.81	3.79	1.09	1.09	1.10	1.11	1.09	93	91	92	99	99
GENITOURINARY SYSTEM																				
Physical Therapy Examination																				
Genitourinary system tests/measures, including outcome measures, and their applications according to current best evidence	903	859	395	727	426	3.04	3.06	3.09	2.95	3.19	1.06	1.06	1.06	1.03	1.12	84	79	80	93	94
Anatomy and physiology of the genitourinary system as related to tests/measures	903	858	395	727	426	3.14	3.11	3.14	3.03	3.27	1.06	1.08	1.05	1.05	1.12	84	79	80	94	95
Physical therapy ultrasound imaging of the genitourinary system	903	858	395	727	426	2.43	2.44	2.47	2.33	2.33	1.03	1.04	1.04	1.01	1.07	72	68	68	78	76

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Genitourinary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	903	858	395	727	426	3.03	3.02	3.08	2.96	3.15	1.03	1.05	1.06	1.07	1.11	84	78	80	92	94
Differential diagnoses related to diseases/conditions of the genitourinary system	903	858	395	727	426	3.13	3.10	3.18	3.01	3.17	1.06	1.06	1.09	1.06	1.13	84	80	80	94	93
Non-pharmacological medical management of the genitourinary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	903	858	395	727	426	2.83	2.81	2.84	2.75	2.83	0.99	1.01	1.00	1.01	1.07	83	77	78	90	90
The impact of pharmacology used to treat the genitourinary system on physical therapy management	903	858	395	727	426	2.92	2.91	2.92	2.83	3.04	1.02	1.05	0.99	1.04	1.11	83	78	79	91	93
Interventions																				
Genitourinary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., bladder programs, biofeedback, pelvic floor retraining)	903	858	395	727	426	3.20	3.17	3.22	3.09	3.27	1.10	1.10	1.07	1.08	1.13	85	79	80	94	94
Anatomy and physiology of the genitourinary system as related to physical therapy interventions, daily activities, and environmental factors	903	858	395	727	426	3.25	3.21	3.29	3.16	3.32	1.09	1.10	1.07	1.08	1.13	85	80	81	95	94
Adverse effects or complications on the genitourinary system from physical therapy interventions used on the genitourinary system	903	858	395	727	426	3.37	3.30	3.35	3.19	3.34	1.13	1.13	1.13	1.11	1.13	85	80	81	95	95

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Adverse effects or complications on the genitourinary system from physical therapy interventions used on other systems	928	899	403	727	484	3.81	3.78	3.73	3.79	3.81	1.12	1.15	1.11	1.15	1.12	93	91	92	98	98
SYSTEM INTERACTIONS																				
<i>Foundations for Evaluation, Differential Diagnosis and Prognosis</i>																				
Differential diagnoses related to diseases/conditions where the primary impact is on more than one system	888	844	381	672	445	4.34	4.25	4.22	4.27	4.27	0.74	0.76	0.83	0.78	0.78	90	87	88	100	100
Diseases/conditions where the primary impact is on more than one system (e.g., cancer, multi-trauma, sarcoidosis, autoimmune disorders, pregnancy) to establish and carry out plan of care, including prognosis	888	843	381	672	445	4.29	4.24	4.19	4.26	4.29	0.76	0.76	0.85	0.79	0.78	90	87	88	100	100
The impact of co-morbidities/co-existing conditions on patient/client management (e.g., diabetes and hypertension; obesity and arthritis; dementia and hip fracture)	888	843	381	672	445	4.54	4.46	4.39	4.46	4.45	0.64	0.68	0.74	0.70	0.72	90	87	88	100	100
Psychological and psychiatric conditions that impact patient/client management (e.g., grief, depression, schizophrenia)	888	843	381	672	445	4.19	4.08	4.14	4.11	4.11	0.82	0.84	0.86	0.84	0.85	90	87	88	100	100
Dimensions of pain (acute or persistent) that impact patient/client management (e.g., psychological, social, physiological, neurological, mechanical)	888	843	381	672	445	4.41	4.31	4.41	4.39	4.37	0.73	0.72	0.74	0.77	0.73	90	87	88	100	100
Non-pharmacological medical management of multiple systems (e.g., diagnostic imaging and other medical tests, surgical procedures)	888	843	381	672	445	3.98	3.91	3.93	3.97	3.84	0.86	0.88	0.93	0.90	0.89	90	87	88	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
The impact of pharmacology used to treat multiple systems, including polypharmacy, on physical therapy management	888	843	381	672	445	3.93	3.86	3.89	3.95	3.84	0.89	0.91	0.96	0.93	0.91	90	87	88	100	100
EQUIPMENT, DEVICES, & TECHNOLOGIES																				
<i>Applications and adjustments, indications, contraindications, and precautions of:</i>																				
– assistive and adaptive devices/technologies (e.g., walkers, wheelchairs, adaptive seating systems and positioning devices, mechanical lifts)	896	854	391	719	424	4.62	4.65	4.63	4.58	4.72	0.66	0.66	0.66	0.68	0.61	88	84	83	100	100
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	896	854	391	719	424	4.08	4.12	4.10	4.00	4.07	0.98	0.99	0.97	1.00	0.98	87	83	83	99	100
– protective, supportive, and orthotic devices/technologies (e.g., braces, helmets, taping, compression garments, serial casts, shoe inserts, splints)	896	854	391	719	424	4.22	4.22	4.26	4.15	4.22	0.89	0.90	0.84	0.92	0.86	88	83	83	100	100
THERAPEUTIC MODALITIES																				
<i>Applications, indications, contraindications, and precautions of:</i>																				
– cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	886	839	380	666	440	3.70	3.68	3.62	3.56	3.62	1.18	1.16	1.19	1.18	1.12	86	83	85	96	97
– hot pack thermotherapy	886	839	380	666	440	3.70	3.68	3.62	3.49	3.55	1.18	1.16	1.19	1.20	1.16	86	83	85	95	96
– dry heat thermotherapy (e.g., Fluidotherapy)	886	839	380	666	440	3.70	3.68	3.62	2.59	2.48	1.18	1.16	1.19	1.28	1.20	86	83	85	77	75
– iontophoresis	886	839	380	666	440	2.98	2.99	2.96	2.64	2.52	1.23	1.24	1.26	1.25	1.14	80	76	77	79	80

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	886	839	380	666	440	3.80	3.77	3.75	3.50	3.55	1.09	1.07	1.13	1.13	1.11	88	85	87	96	98
– laser light therapy	886	839	380	666	440	2.85	2.65	2.66	2.45	2.42	1.23	1.23	1.28	1.24	1.15	77	69	71	73	75
– LED light therapy	886	839	380	666	440	2.85	2.47	2.52	2.35	2.30	1.23	1.21	1.25	1.22	1.08	77	65	68	70	73
– phonophoresis	886	839	380	666	440	2.69	2.61	2.59	2.36	2.24	1.29	1.27	1.29	1.22	1.13	72	67	68	71	68
– ultrasound modalities, excluding phonophoresis	886	839	380	666	440	3.15	3.15	3.00	2.82	2.75	1.31	1.31	1.34	1.31	1.27	79	75	76	81	83
– mechanical modalities (e.g., mechanical motion devices, traction devices)	886	838	380	665	436	3.73	3.63	3.61	3.53	3.55	1.10	1.12	1.18	1.15	1.15	88	84	85	95	96
– biofeedback	886	838	380	665	436	3.51	3.37	3.43	3.33	3.34	1.08	1.07	1.14	1.09	1.09	87	83	83	94	95
– diathermy	886	838	380	665	436	2.37	2.40	2.34	2.31	2.14	1.23	1.27	1.29	1.22	1.18	63	60	60	69	61
– intermittent pneumatic compression (e.g., sequential compression devices)	886	838	380	665	436	3.09	3.04	3.12	3.08	2.99	1.18	1.16	1.19	1.12	1.11	82	78	81	93	93
– shockwave therapy	886	838	380	665	436	2.30	2.24	2.31	2.28	2.20	1.20	1.15	1.21	1.19	1.14	62	59	63	69	67
– blood-flow restriction training			380	665	436			2.97	2.85	2.95			1.28	1.20	1.16			77	86	90
– cupping			380	665	436			2.71	2.69	2.64			1.20	1.20	1.14			74	82	83
SAFETY & PROTECTION																				
Factors influencing safety and injury prevention (e.g., safe patient handling, fall prevention, equipment maintenance, environmental safety)	896	854	391	719	424	4.78	4.73	4.74	4.71	4.75	0.52	0.59	0.59	0.60	0.56	88	84	83	100	100
The function and implications and related precautions of intravenous lines, tubes, catheters, monitoring devices, and mechanical ventilators/oxygen delivery devices	896	854	391	719	424	4.26	4.26	4.24	4.28	4.31	0.89	0.92	0.89	0.94	0.84	87	83	83	99	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Emergency preparedness (e.g., CPR, first aid, disaster response)	896	854	391	719	424	4.57	4.51	4.46	4.51	4.50	0.74	0.79	0.80	0.78	0.77	88	83	83	100	100
Infection control procedures (e.g., standard/universal precautions, isolation techniques, sterile technique)	896	854	391	719	424	4.70	4.62	4.57	4.56	4.65	0.63	0.71	0.74	0.73	0.65	88	83	83	100	100
Signs/symptoms of physical, sexual, and psychological abuse and neglect	896	854	391	719	424	4.48	4.45	4.40	4.43	4.41	0.76	0.79	0.78	0.79	0.81	88	83	83	100	100
PROFESSIONAL RESPONSIBILITIES																				
Standards of documentation	893	851	390	716	422	4.70	4.64	4.61	4.58	4.67	0.58	0.62	0.65	0.71	0.61	88	83	83	100	100
Standards of professional ethics	893	851	390	716	422	4.84	4.74	4.74	4.77	4.82	0.43	0.54	0.56	0.54	0.46	88	83	83	100	100
Standards of billing, coding, and reimbursement	893	851	390	716	422	4.44	4.35	4.32	4.36	4.41	0.79	0.84	0.84	0.89	0.84	88	83	83	99	100
Patient/client rights (e.g., ADA, IDEA, HIPAA, patient bill of rights)	893	851	390	716	422	4.75	4.59	4.61	4.60	4.68	0.55	0.69	0.66	0.71	0.62	88	83	83	100	100
Obligations for reporting illegal, unethical, or unprofessional behaviors (e.g., fraud, abuse, neglect)	893	851	390	716	422	4.76	4.64	4.59	4.61	4.66	0.54	0.65	0.67	0.68	0.62	88	83	83	100	100
State and federal laws, rules, regulations, and industry standards set by state and accrediting bodies (e.g., state licensing entities, Joint Commission, CARF, CMS)	893	851	390	716	422	4.63	4.48	4.42	4.43	4.48	0.67	0.75	0.80	0.85	0.79	88	83	83	99	100
Risk management and quality assurance (e.g., policies and procedures, incident reports, peer chart review)	890	851	389	713	421	3.93	3.88	3.88	3.79	3.94	0.96	0.94	0.98	1.05	0.97	87	83	82	98	99
Human resource legal issues (e.g., OSHA, sexual harassment)	890	851	389	713	421	4.03	3.87	3.92	3.88	3.96	0.97	0.99	0.96	1.04	1.03	87	83	82	98	99
The roles and responsibilities of the PT, PTA, other healthcare professionals, and support staff	890	851	389	713	421	4.56	4.45	4.48	4.43	4.53	0.67	0.74	0.74	0.81	0.71	87	83	83	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Cultural factors and/or characteristics that affect patient/client management (e.g., language differences, disability, ethnicity, customs, demographics, religion, health literacy)	890	851	389	713	421	4.34	4.23	4.26	4.21	4.30	0.81	0.89	0.89	0.90	0.90	87	83	83	99	99
Socioeconomic factors that affect patient/client management (e.g., social determinants of health)	890	851	389	713	421	4.27	4.16	4.20	4.14	4.20	0.82	0.89	0.88	0.92	0.94	87	83	83	99	100
Applications and utilization of health information technology (e.g., electronic medical records)	890	851	389	713	421	4.13	4.07	4.03	4.00	4.10	0.88	0.93	0.93	0.99	0.99	87	83	83	99	99
The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)		851	389	713	421		3.45	3.39	3.30	3.24		1.09	1.06	1.15	1.18		81	80	95	94
TEACHING & LEARNING THEORIES																				
Teaching and learning theories and techniques	886	836	378	660	435	3.93	3.92	3.97	3.93	3.96	0.99	1.00	0.98	1.00	0.95	89	85	87	99	99
Health behavior change models (e.g., social cognitive theory, health belief model)	886	836	378	660	435	3.73	3.66	3.82	3.75	3.80	1.00	1.07	1.00	1.00	0.99	89	84	86	98	99
Communication methods and techniques (e.g., motivational interviewing, health information brochures/handouts, feedback techniques)	886	836	378	660	435	4.14	4.10	4.11	4.16	4.22	0.92	0.96	0.95	0.92	0.90	89	85	87	99	100
RESEARCH & EVIDENCE-BASED PRACTICE																				
Techniques for accessing evidence (e.g., peer-reviewed publications, scientific proceedings, guidelines, clinical prediction rules)	886	836	378	660	435	4.11	4.03	4.11	4.04	4.11	0.88	0.95	0.92	0.95	0.90	90	85	87	99	99
Research methodology and interpretation (e.g., qualitative, quantitative, levels of evidence)	886	836	378	660	435	3.81	3.75	3.79	3.76	3.80	0.96	1.02	1.02	1.03	0.98	89	84	86	98	99

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Measurement science (e.g., reliability, validity)	886	836	378	660	435	3.88	3.82	3.86	3.80	3.81	0.97	0.99	1.03	1.00	0.96	89	85	86	98	99
Statistics (e.g., t-test, chi-square, correlation coefficient, ANOVA, likelihood ratio, effect size, confidence interval)	886	836	378	660	435	3.12	3.00	2.98	3.04	2.96	1.07	1.10	1.15	1.11	1.10	85	79	79	91	92
Data collection techniques (e.g., surveys, direct observation)	886	836	378	660	435	3.32	3.26	3.30	3.27	3.21	1.02	1.09	1.11	1.10	1.03	87	82	83	95	96
SKILLS																				
Active listening - Giving full attention to what other people are saying, taking time to understand the points being made, asking questions as appropriate, and not interrupting at inappropriate times	884	833	377	658	434	4.82	4.80	4.75	4.74	4.82	0.46	0.51	0.56	0.56	0.45	90	85	87	100	100
Speaking - Talking to others to convey information effectively	884	833	377	658	434	4.78	4.77	4.75	4.73	4.81	0.49	0.52	0.55	0.57	0.47	90	86	87	100	100
Reading comprehension - Understanding written sentences and paragraphs in work related documents	884	833	377	658	434	4.58	4.60	4.52	4.61	4.60	0.65	0.66	0.80	0.64	0.67	90	85	87	100	100
Critical thinking - Using logic and clinical reasoning to identify the strengths and weaknesses of alternative solutions, conclusions or approaches to problems	884	833	377	658	434	4.83	4.81	4.77	4.80	4.84	0.45	0.47	0.55	0.50	0.41	90	85	87	100	100
Social perceptiveness - Being aware of others' reactions and understanding why they react as they do	884	833	377	658	434	4.73	4.69	4.68	4.68	4.72	0.53	0.58	0.61	0.59	0.55	90	85	87	100	100
Time management - Managing one's own time and the time of others	884	833	377	658	434	4.70	4.67	4.67	4.69	4.69	0.57	0.62	0.63	0.58	0.57	90	85	87	100	100
Coordination - Adjusting actions in relation to others' actions	880	830	377	658	433	4.55	4.52	4.46	4.49	4.57	0.63	0.70	0.75	0.72	0.62	90	85	87	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Writing - Communicating effectively in writing as appropriate for the needs of the audience	880	830	377	658	433	4.44	4.48	4.39	4.48	4.43	0.71	0.71	0.77	0.70	0.70	90	85	87	100	100
Active learning - Understanding the implications of new information for both current and future problem solving and decision-making	880	830	377	658	433	4.63	4.61	4.50	4.60	4.58	0.59	0.61	0.74	0.65	0.62	90	85	87	100	100
Persuasion - Persuading others to change their minds or behavior	880	830	377	658	433	3.99	3.96	3.90	3.93	3.89	0.94	0.94	1.02	0.97	0.98	88	85	86	99	99
Negotiation - Bringing others together and trying to reconcile differences	880	830	377	658	433	4.10	4.05	4.00	4.05	4.04	0.88	0.91	1.02	0.92	0.94	89	85	85	99	99
Service orientation - Actively looking for ways to help people	880	830	377	658	433	4.37	4.30	4.29	4.29	4.27	0.79	0.85	0.94	0.84	0.86	89	85	87	100	100

Table B.4. PTA Knowledge and Skill Requirements Survey Results

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
CARDIOVASCULAR/PULMONARY SYSTEM																				
Physical Therapy Data Collection																				
Cardiovascular/pulmonary system tests/measures, including outcome measures, and their applications according to current best evidence	565	463	304	452	244	3.97	4.03	3.94	4.08	3.80	0.95	0.98	1.01	0.97	1.09	99	99	99	99	98
Anatomy and physiology of the cardiovascular/pulmonary system as related to tests/measures	565	463	304	452	244	4.02	3.97	3.94	3.98	3.76	0.94	0.97	1.00	1.02	1.04	99	100	99	99	98
Movement analysis as related to the cardiovascular/pulmonary system (e.g., rib cage excursion, breathing pattern)	565	463	304	452	244	3.93	3.89	3.85	3.93	3.82	0.93	0.95	0.95	0.98	1.00	100	99	99	99	100
Diseases/Conditions that Impact Effective Treatment																				
Cardiovascular/pulmonary system diseases/conditions and their pathophysiology to carry out the established plan of care	565	463	304	452	244	4.09	4.04	3.96	4.07	4.04	0.89	0.91	0.93	0.89	0.93	99	100	100	100	100
Non-pharmacological medical management of the cardiovascular/pulmonary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	565	463	304	452	244	3.42	3.34	3.34	3.33	3.17	1.02	0.99	1.01	1.05	1.10	98	98	97	97	95
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	565	463	304	452	244	3.56	3.49	3.47	3.50	3.46	0.97	1.00	1.00	1.02	1.04	99	98	98	98	98
Interventions																				
Cardiovascular/pulmonary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	565	463	304	452	244	4.24	4.16	4.11	4.10	4.08	0.86	0.86	0.93	0.92	0.91	99	99	100	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Anatomy and physiology of the cardiovascular/pulmonary system as related to physical therapy interventions, daily activities, and environmental factors	565	463	304	452	244	4.28	4.17	4.08	4.15	4.14	0.84	0.85	0.91	0.86	0.91	100	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on the cardiovascular/pulmonary system	565	463	304	452	244	4.50	4.41	4.36	4.35	4.36	0.74	0.80	0.82	0.81	0.79	100	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on other systems	516	426	286	394	228	4.40	4.39	4.30	4.25	4.26	0.78	0.78	0.83	0.84	0.81	90	92	94	99	100
LYMPHATIC SYSTEM																				
Physical Therapy Data Collection																				
Lymphatic system tests/measures, including outcome measures, and their applications according to current best evidence	534	435	299	416	237	3.23	3.15	3.07	3.12	2.90	0.99	1.03	1.03	1.01	0.98	91	90	94	96	94
Anatomy and physiology of the lymphatic system as related to tests/measures	534	435	299	416	237	3.31	3.25	3.16	3.21	3.02	1.00	1.02	0.99	1.01	1.01	92	92	96	97	95
Movement analysis as related to the lymphatic system (e.g., compensatory movement, extremity range of motion)	534	435	299	416	237	3.63	3.49	3.46	3.51	3.35	0.99	1.01	0.99	1.07	1.04	93	91	96	98	96
Diseases/Conditions that Impact Effective Treatment																				
Lymphatic system diseases/conditions and their pathophysiology to carry out the established plan of care	534	435	299	416	237	3.56	3.46	3.40	3.42	3.29	0.96	0.96	1.00	0.98	1.00	93	92	97	98	97
Non-pharmacological medical management of the lymphatic system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	534	435	298	416	237	3.13	3.09	2.98	3.03	2.83	0.96	1.00	0.98	1.02	1.02	90	90	94	96	93

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Interventions																				
Lymphatic system interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	534	435	299	416	237	3.61	3.50	3.37	3.45	3.34	0.97	1.03	1.02	1.03	1.05	93	92	96	98	97
Anatomy and physiology of the lymphatic system as related to interventions, daily activities, and environmental factors	534	435	299	416	237	3.69	3.54	3.43	3.49	3.35	1.00	1.00	1.04	1.04	1.01	92	92	95	97	97
Adverse effects or complications on the lymphatic system from physical therapy interventions used on the lymphatic system	534	435	299	416	237	3.95	3.77	3.72	3.64	3.57	0.98	1.04	1.04	1.06	1.07	93	92	97	98	98
Adverse effects or complications on the lymphatic system from physical therapy interventions used on other systems	518	426	286	394	228	3.86	3.72	3.71	3.65	3.64	1.05	1.07	1.04	1.05	1.08	90	90	93	98	97
MUSCULOSKELETAL SYSTEM																				
Physical Therapy Data Collection																				
Musculoskeletal system tests/measures, including outcome measures, and their applications according to current best evidence	583	521	306	480	283	4.43	4.43	4.31	4.48	4.45	0.79	0.76	0.80	0.75	0.79	99	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to tests/measures	583	521	306	480	283	4.56	4.51	4.40	4.57	4.57	0.68	0.72	0.71	0.67	0.72	100	100	100	100	100
Movement analysis as related to the musculoskeletal system	583	521	306	480	283	4.51	4.45	4.38	4.53	4.54	0.67	0.71	0.72	0.68	0.67	100	100	100	100	100
Joint biomechanics and their applications	583	521	306	480	283	4.40	4.34	4.31	4.45	4.49	0.77	0.78	0.77	0.74	0.70	100	100	100	100	100
Diseases/Conditions that Impact Effective Treatment																				
Musculoskeletal system diseases/conditions and their pathophysiology to carry out the established plan of care	561	499	291	457	267	4.36	4.28	4.20	4.30	4.31	0.72	0.77	0.80	0.76	0.76	96	96	95	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Connective tissue diseases/conditions and their pathophysiology to carry out the established plan of care	561	499	291	457	267	4.19	4.11	4.04	4.17	4.16	0.79	0.83	0.87	0.81	0.81	96	95	95	100	100
Non-pharmacological medical management of the musculoskeletal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	561	499	291	457	267	3.52	3.57	3.57	3.65	3.59	0.93	0.90	0.94	0.91	0.93	95	95	94	100	99
The impact of pharmacology used to treat the musculoskeletal system on physical therapy management	561	499	291	457	267	3.51	3.50	3.48	3.59	3.49	0.90	0.90	0.95	0.93	0.93	96	95	95	100	99
Interventions																				
Musculoskeletal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	583	521	306	480	283	4.63	4.59	4.48	4.60	4.64	0.60	0.62	0.67	0.64	0.61	100	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to physical therapy interventions, daily activities, and environmental factors	583	521	306	480	283	4.68	4.58	4.48	4.63	4.66	0.58	0.62	0.67	0.61	0.59	100	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on the musculoskeletal system	583	521	306	480	283	4.67	4.60	4.51	4.56	4.59	0.57	0.60	0.67	0.66	0.66	100	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on other systems	516	426	286	394	228	4.49	4.47	4.42	4.36	4.37	0.74	0.74	0.75	0.80	0.81	91	92	94	99	99
NEUROMUSCULAR & NERVOUS SYSTEM																				
Physical Therapy Data Collection																				

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Neuromuscular and nervous systems tests/measures, including outcome measures, and their applications according to current best evidence	561	499	291	457	267	4.08	4.03	3.99	4.09	4.00	0.85	0.88	0.89	0.88	0.92	96	95	95	100	100
Anatomy and physiology of the neuromuscular and nervous systems as related to tests/measures	561	499	291	457	267	4.17	4.10	4.09	4.18	4.10	0.83	0.85	0.83	0.85	0.87	96	96	95	100	100
Movement analysis as related to the neuromuscular and nervous systems	561	499	291	457	267	4.27	4.21	4.23	4.27	4.33	0.79	0.80	0.80	0.78	0.76	96	96	95	100	100
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Neuromuscular & nervous systems (CNS, PNS, ANS) diseases/conditions and their pathophysiology to carry out the established plan of care	561	499	291	457	267	4.11	3.98	3.97	4.09	4.09	0.87	0.87	0.92	0.85	0.90	96	95	95	100	99
Non-pharmacological medical management of the neuromuscular and nervous systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	561	499	291	457	267	3.59	3.55	3.51	3.63	3.58	0.94	0.91	0.92	0.92	0.96	95	95	94	100	99
The impact of pharmacology used to treat the neuromuscular and nervous systems on physical therapy management	561	499	291	457	267	3.63	3.52	3.54	3.63	3.58	0.93	0.94	0.96	0.91	0.90	96	95	94	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Interventions																				
Neuromuscular and nervous systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	545	474	275	420	254	4.42	4.33	4.26	4.37	4.33	0.72	0.77	0.81	0.74	0.74	93	91	90	100	100
Anatomy and physiology of the neuromuscular and nervous systems as related to physical therapy interventions, daily activities, and environmental factors	545	474	275	420	254	4.42	4.31	4.29	4.38	4.37	0.71	0.79	0.74	0.73	0.73	93	91	90	100	100
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on the neuromuscular and nervous systems	545	474	275	420	254	4.45	4.34	4.28	4.30	4.30	0.71	0.75	0.76	0.74	0.78	93	91	90	100	100
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on other systems	516	426	286	394	228	4.46	4.50	4.40	4.36	4.33	0.75	0.71	0.77	0.79	0.84	91	92	94	99	99
Motor control as related to neuromuscular and nervous systems physical therapy interventions	545	474	275	420	254	4.36	4.32	4.24	4.34	4.34	0.73	0.76	0.75	0.74	0.75	93	91	90	100	100
Motor learning as related to the neuromuscular and nervous systems physical therapy interventions	545	474	275	420	254	4.34	4.26	4.20	4.31	4.31	0.75	0.79	0.74	0.75	0.78	93	91	90	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
INTEGUMENTARY SYSTEM																				
<i>Physical Therapy Data Collection</i>																				
Integumentary system tests/measures, including outcome measures, and their applications according to current best evidence	506	414	278	381	226	3.52	3.46	3.44	3.40	3.14	1.01	0.98	1.01	1.05	1.04	87	88	91	97	95
Anatomy and physiology of the integumentary system as related to tests/measures	506	414	278	381	226	3.62	3.52	3.52	3.48	3.24	1.02	0.99	1.01	1.02	1.07	88	88	90	98	96
Movement analysis as related to the integumentary system (e.g., friction, shear, pressure, and scar mobility)	506	414	278	381	226	4.03	3.94	3.95	3.93	3.96	0.93	0.92	0.94	0.96	0.96	89	88	91	99	99
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Integumentary system diseases/conditions and their pathophysiology to carry out the established plan of care	506	414	278	381	226	3.83	3.71	3.73	3.68	3.55	0.92	0.98	0.91	1.00	1.01	89	89	91	98	98
Non-pharmacological medical management of the integumentary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	506	414	278	381	226	3.36	3.31	3.25	3.25	3.01	0.99	1.02	1.00	1.04	1.03	87	87	89	96	94
The impact of pharmacology used to treat the integumentary system on physical therapy management	506	414	278	381	226	3.41	3.32	3.31	3.25	3.14	1.00	1.02	1.04	1.06	1.08	87	87	90	97	95
<i>Interventions</i>																				
Integumentary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	505	414	278	381	226	3.85	3.74	3.74	3.66	3.53	0.96	0.98	0.96	1.02	1.08	88	89	91	98	96
Anatomy and physiology of the integumentary system as related to physical therapy interventions, daily activities, and environmental factors	505	414	278	381	226	3.97	3.80	3.76	3.74	3.60	0.95	0.97	0.96	1.03	1.06	88	89	91	98	96

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Adverse effects or complications on the integumentary system from physical therapy and medical/surgical interventions used on the integumentary system	505	414	278	381	226	4.06	3.94	3.92	3.86	3.72	0.94	0.96	0.92	1.02	1.06	88	89	91	99	97
Adverse effects or complications on the integumentary system from physical therapy interventions used on other systems	516	426	286	394	228	4.14	4.11	4.03	3.99	3.80	0.93	0.89	0.93	0.96	0.99	90	92	93	99	99
METABOLIC & ENDOCRINE SYSTEMS																				
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Metabolic and endocrine system diseases/conditions and their pathophysiology to carry out the established plan of care	535	464	268	411	245	3.49	3.39	3.39	3.45	3.44	0.94	0.93	0.94	0.95	0.92	91	88	85	99	99
Non-pharmacological medical management of the metabolic and endocrine systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	535	464	268	411	245	3.27	3.17	3.20	3.26	3.20	0.94	0.92	0.93	0.98	0.95	91	86	84	97	98
The impact of pharmacology used to treat the metabolic and endocrine systems on physical therapy management	535	464	268	411	245	3.31	3.20	3.23	3.27	3.17	0.97	0.94	0.97	0.98	0.97	90	86	85	98	98
<i>Interventions</i>																				
Metabolic and endocrine systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	535	464	268	411	245	3.58	3.47	3.44	3.47	3.43	0.97	0.98	1.01	0.98	0.98	91	88	85	98	99
Anatomy and physiology of the metabolic and endocrine systems as related to physical therapy interventions, daily activities, and environmental factors	535	464	268	411	245	3.64	3.47	3.50	3.53	3.51	0.97	0.97	1.00	1.01	1.02	91	87	85	99	99

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on the metabolic and endocrine systems	535	464	268	411	245	3.77	3.67	3.63	3.60	3.61	0.96	0.97	1.02	1.00	0.98	91	88	86	99	99
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on other systems	516	426	286	394	228	3.88	3.87	3.71	3.73	3.56	1.00	0.99	1.03	1.04	1.03	90	91	92	98	97
GASTROINTESTINAL SYSTEM																				
Physical Therapy Data Collection																				
Gastrointestinal system tests/measures, including outcome measures, and their applications according to current best evidence (e.g., bowel dysfunction impact questionnaires, Murphy test, Rovsing test, McBurney point sign)	528	451	266	405	240	2.88	2.84	2.89	2.87	2.82	0.96	1.03	1.02	1.02	1.03	85	78	79	92	91
Anatomy and physiology of the gastrointestinal system as related to tests/measures	528	451	266	405	240	3.00	2.92	2.97	2.96	2.95	0.98	1.06	0.99	1.00	1.06	87	79	81	94	93
Movement analysis as related to the gastrointestinal system (e.g., effects of muscular tension or trigger points, positioning for bowel movement)	528	451	266	405	240	3.17	3.03	3.02	3.08	3.04	1.00	1.05	1.02	1.03	1.06	88	80	81	95	95
Diseases/Conditions that Impact Effective Treatment																				
Gastrointestinal system diseases/conditions and their pathophysiology to carry out the established plan of care	528	451	266	405	240	3.19	3.04	2.98	3.04	3.08	0.99	1.04	0.99	1.01	1.03	88	80	81	95	94
Non-pharmacological medical management of the gastrointestinal system (e.g., surgical procedures, diagnostic imaging, laboratory test values, other medical tests)	528	451	266	405	240	2.92	2.86	2.85	2.93	2.86	0.95	1.02	0.95	0.98	1.05	86	80	81	95	93

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
The impact of pharmacology used to treat the gastrointestinal system on physical therapy management	528	451	266	405	240	3.02	2.93	2.98	2.97	2.91	0.97	1.04	1.01	1.01	1.03	87	80	80	94	93
Interventions																				
Gastrointestinal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., positioning for reflux prevention, bowel programs)	528	451	266	405	240	3.22	3.12	3.14	3.12	3.13	1.03	1.05	1.04	1.04	1.06	88	81	82	96	95
Anatomy and physiology of the gastrointestinal system as related to physical therapy interventions, daily activities, and environmental factors	528	451	266	405	240	3.31	3.20	3.21	3.19	3.21	1.02	1.04	1.04	1.03	1.11	88	82	83	96	94
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on the gastrointestinal system	528	451	266	405	240	3.46	3.35	3.33	3.24	3.29	1.03	1.07	1.08	1.03	1.12	89	83	83	97	95
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on other systems	516	426	286	394	228	3.75	3.70	3.61	3.59	3.33	1.06	1.07	1.06	1.08	1.12	89	90	92	98	96
GENITOURINARY SYSTEM																				
Physical Therapy Data Collection																				
Genitourinary system tests/measures, including outcome measures, and their applications according to current best evidence	519	438	263	399	235	2.90	2.83	2.84	2.86	2.90	1.02	1.04	0.96	1.03	1.01	83	75	80	92	91
Anatomy and physiology of the genitourinary system as related to tests/measures	519	438	263	399	235	2.95	2.88	2.86	2.91	2.99	1.03	1.05	1.00	1.04	1.07	83	76	80	93	92

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Genitourinary system diseases/conditions and their pathophysiology to carry out the established plan of care	519	438	263	399	235	3.02	2.95	2.95	2.94	3.07	1.03	1.04	1.01	1.03	1.05	84	78	80	93	94
Non-pharmacological medical management of the genitourinary system (e.g., surgical procedures, diagnostic imaging, laboratory test values, other medical tests)	519	438	263	399	235	2.84	2.79	2.80	2.83	2.86	0.98	1.01	0.95	1.01	1.04	82	76	80	92	91
The impact of pharmacology used to treat the genitourinary system on physical therapy management	519	438	263	399	235	2.95	2.87	2.88	2.84	2.88	1.01	1.03	0.98	0.98	1.06	83	77	80	92	90
<i>Interventions</i>																				
Genitourinary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., bladder programs, biofeedback, pelvic floor retraining)	519	438	263	399	235	3.17	3.08	3.09	3.10	3.18	1.09	1.06	1.03	1.07	1.10	85	79	82	95	93
Anatomy and physiology of the genitourinary system as related to physical therapy interventions, daily activities, and environmental factors	519	438	263	399	235	3.23	3.12	3.10	3.10	3.18	1.08	1.07	1.05	1.09	1.09	85	79	82	94	94
Adverse effects or complications on the genitourinary system from physical therapy interventions used on the genitourinary system	519	438	263	399	235	3.31	3.25	3.19	3.11	3.21	1.13	1.11	1.09	1.08	1.13	85	80	82	95	93
Adverse effects or complications on the genitourinary system from physical therapy interventions used on other systems	516	426	286	394	228	3.67	3.65	3.53	3.52	3.27	1.11	1.11	1.10	1.13	1.15	88	90	91	97	94

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
SYSTEM INTERACTIONS																				
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Diseases/conditions where the primary impact is on more than one system (e.g., cancer, multi-trauma, sarcoidosis, autoimmune disorders, pregnancy) to carry out the established plan of care	497	402	270	374	223	4.24	4.22	4.16	4.22	4.09	0.83	0.77	0.80	0.80	0.91	88	87	88	99	100
The impact of co-morbidities/co-existing conditions on patient/client management (e.g., diabetes and hypertension; obesity and arthritis; dementia and hip fracture)	497	402	270	374	223	4.46	4.49	4.34	4.40	4.33	0.69	0.67	0.74	0.73	0.78	88	87	89	100	100
Psychological and psychiatric conditions that impact patient/client management (e.g., grief, depression, schizophrenia)	497	402	270	374	223	4.09	4.14	4.00	4.05	4.03	0.86	0.81	0.86	0.87	0.88	88	87	89	99	100
Dimensions of pain (acute or persistent) that impact patient/client management (e.g., psychological, social, physiological, neurological, mechanical)	497	402	270	374	223	4.30	4.30	4.22	4.24	4.26	0.79	0.75	0.76	0.84	0.83	88	87	89	99	100
Non-pharmacological medical management of multiple systems (e.g., diagnostic imaging and other medical tests, surgical procedures)	497	402	270	374	223	3.74	3.76	3.68	3.70	3.58	0.95	0.94	0.97	0.96	1.06	87	86	88	99	97
The impact of pharmacology used to treat multiple systems, including polypharmacy, on physical therapy management	497	402	270	374	223	3.74	3.71	3.71	3.70	3.56	0.98	0.98	0.93	0.97	1.07	87	86	88	99	98

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
EQUIPMENT, DEVICES, & TECHNOLOGIES																				
<i>Applications and adjustments, indications, contraindications, and precautions of:</i>																				
– assistive and adaptive devices/technologies (e.g., walkers, wheelchairs, adaptive seating systems and positioning devices, mechanical lifts)	515	434	262	395	235	4.71	4.69	4.62	4.67	4.71	0.54	0.59	0.61	0.61	0.57	88	83	86	100	100
– prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses)	515	434	262	395	235	4.30	4.21	4.25	4.33	4.34	0.90	0.90	0.87	0.84	0.89	88	83	86	100	100
– protective, supportive, and orthotic devices/technologies (e.g., braces, helmets, compression garments, shoe inserts, splints)	515	434	262	395	235	4.32	4.25	4.28	4.33	4.38	0.84	0.88	0.81	0.81	0.82	88	83	85	100	100
THERAPEUTIC MODALITIES																				
<i>Applications, indications, contraindications, and precautions of:</i>																				
– cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	494	395	269	372	221	4.31	4.12	4.04	3.89	3.85	0.92	1.03	1.05	1.07	1.12	86	84	88	97	99
– hot pack thermotherapy	494	395	269	372	221	4.31	4.12	4.04	3.87	3.87	0.92	1.03	1.05	1.09	1.11	86	84	88	97	99
– dry heat thermotherapy (e.g., Fluidotherapy)	494	395	269	372	221	4.31	4.12	4.04	2.82	2.65	0.92	1.03	1.05	1.29	1.34	86	84	88	82	77
– paraffin bath thermotherapy				372	221				2.73	2.65				1.27	1.22				80	82
– iontophoresis	494	395	269	372	221	3.37	3.25	3.10	2.86	2.76	1.24	1.28	1.28	1.26	1.26	81	77	80	85	82
– electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	494	395	269	372	221	4.29	4.17	4.07	3.87	3.95	0.90	1.01	1.06	1.12	1.05	87	84	87	97	98
– laser light therapy	494	395	269	372	221	3.16	2.85	2.75	2.63	2.58	1.30	1.31	1.26	1.28	1.25	77	70.19	71	78	78
– LED light therapy	494	395	269	372	221	3.16	2.68	2.55	2.51	2.42	1.30	1.27	1.22	1.20	1.21	77	67.60	69	77	76

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
– phonophoresis	494	395	269	372	221	3.11	2.90	2.77	2.63	2.37	1.31	1.33	1.32	1.27	1.25	76	71	71	78	71
– ultrasound modalities, excluding phonophoresis	494	395	269	372	221	3.95	3.66	3.59	3.44	3.33	1.15	1.23	1.25	1.27	1.26	85	80	83	92	93
– mechanical modalities (e.g., mechanical motion devices, traction devices)	494	395	269	372	221	3.93	3.73	3.72	3.58	3.52	1.10	1.11	1.16	1.20	1.20	85	83	84	95	94
– biofeedback	494	395	269	372	221	3.54	3.41	3.25	3.23	3.11	1.11	1.17	1.16	1.17	1.20	85	80	83	91	91
– diathermy	494	395	269	372	221	3.05	2.80	2.68	2.58	2.44	1.33	1.38	1.34	1.32	1.36	74	66	67	73	66
– intermittent pneumatic compression (e.g., sequential compression devices)	494	395	269	372	221	3.55	3.30	3.25	3.16	3.10	1.10	1.23	1.22	1.16	1.14	84	78	81	93	92
– blood-flow restriction training			269	372	221			2.95	2.95	2.90			1.26	1.25	1.28			76	86	83
– cupping			269	372	221			2.68	2.74	2.77			1.21	1.22	1.23			72	82	85
SAFETY & PROTECTION																				
Factors influencing safety and injury prevention (e.g., safe patient handling, fall prevention, equipment maintenance, environmental safety)	515	434	262	395	235	4.83	4.72	4.64	4.71	4.77	0.44	0.58	0.62	0.59	0.54	88	83	86	100	100
The function and implications and related precautions of intravenous lines, tubes, catheters, monitoring devices, and mechanical ventilators/oxygen delivery devices	515	434	262	395	235	4.38	4.27	4.28	4.26	4.39	0.82	0.88	0.85	0.95	0.80	88	83	86	100	100
Emergency preparedness (e.g., CPR, first aid, disaster response)	515	434	262	395	235	4.62	4.49	4.41	4.47	4.51	0.67	0.75	0.82	0.83	0.82	88	83	86	100	100
Infection control procedures (e.g., standard/universal precautions, isolation techniques, sterile technique)	515	434	262	395	235	4.74	4.65	4.58	4.55	4.63	0.54	0.64	0.67	0.74	0.69	88	83	86	100	100
Signs/symptoms of physical, sexual, and psychological abuse and neglect	515	434	262	395	235	4.47	4.37	4.37	4.36	4.40	0.77	0.85	0.79	0.84	0.82	88	83	86	100	100
PROFESSIONAL RESPONSIBILITIES																				
Standards of documentation	512	431	262	394	234	4.69	4.60	4.58	4.59	4.66	0.57	0.61	0.64	0.64	0.58	88	83	86	100	100
Standards of professional ethics	512	431	262	394	234	4.82	4.72	4.67	4.70	4.74	0.45	0.57	0.60	0.56	0.53	88	83	86	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Standards of billing, coding, and reimbursement	512	431	262	394	234	4.23	4.16	4.09	4.33	4.19	0.88	0.93	0.93	0.84	0.94	87	82	86	100	98
Patient/client rights (e.g., ADA, IDEA, HIPAA, patient bill of rights)	512	431	262	394	234	4.70	4.64	4.58	4.63	4.58	0.59	0.65	0.69	0.63	0.68	88	82	86	100	100
Obligations for reporting illegal, unethical, or unprofessional behaviors (e.g., fraud, abuse, neglect)	512	431	262	394	234	4.69	4.67	4.60	4.63	4.63	0.63	0.57	0.72	0.64	0.66	88	83	86	100	100
State and federal laws, rules, regulations, and industry standards set by state and accrediting bodies (e.g., state licensing entities, Joint Commission, CARF, CMS)	512	431	262	394	234	4.57	4.54	4.44	4.47	4.38	0.72	0.70	0.82	0.75	0.82	87	83	86	100	100
Risk management and quality assurance (e.g., policies and procedures, incident reports, peer chart review)	512	431	262	394	234	4.25	4.16	4.19	4.16	4.02	0.87	0.90	0.92	0.92	0.96	87	83	85	99	98
Human resource legal issues (e.g., OSHA, sexual harassment)	512	431	262	394	234	4.22	4.19	4.10	4.12	4.08	0.90	0.89	0.98	0.96	0.98	87	83	84	100	99
The roles and responsibilities of the PT, PTA, other healthcare professionals, and support staff	512	431	262	394	234	4.73	4.65	4.60	4.63	4.56	0.53	0.61	0.66	0.60	0.69	88	83	86	100	100
Cultural factors and/or characteristics that affect patient/client management (e.g., language differences, disability, ethnicity, customs, demographics, religion, health literacy)	510	430	262	393	234	4.22	4.11	4.08	4.04	4.15	0.81	0.86	0.90	0.93	0.93	87	82	85	99	99
Socioeconomic factors that affect patient/client management (e.g., social determinants of health)	510	430	262	393	234	4.09	3.99	3.94	3.95	3.97	0.86	0.88	0.90	0.94	0.95	87	82	85	99	99
Applications and utilization of health information technology (e.g., electronic medical records)	510	430	262	393	234	4.00	4.05	4.02	4.02	4.00	0.90	0.89	0.86	0.89	0.94	87	82	85	100	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)		430	262	393	234		3.30	3.22	3.15	3.15		1.05	1.12	1.14	1.19		80	81	94	92
TEACHING & LEARNING THEORIES																				
Teaching and learning theories and techniques	510	430	262	393	234	3.96	3.86	3.87	3.83	3.91	0.93	0.94	0.90	0.98	1.01	87	82	85	99	99
Health behavior change models (e.g., social cognitive theory, health belief model)	510	430	262	393	234	3.82	3.63	3.75	3.71	3.71	0.95	1.00	0.94	1.04	1.08	86	82	85	98	99
Communication methods and techniques (e.g., motivational interviewing, health information brochures/handouts, feedback techniques)	510	430	262	393	234	3.94	3.77	3.83	3.74	3.81	1.00	0.97	0.94	1.02	1.08	86	82	85	99	97
RESEARCH & EVIDENCE-BASED PRACTICE																				
Techniques for accessing evidence (e.g., peer-reviewed publications, scientific proceedings, guidelines, clinical prediction rules)	494	395	268	369	217	3.64	3.59	3.61	3.73	3.51	1.04	1.07	0.99	1.02	1.10	86	84	86	98	95
Research methodology and interpretation (e.g., qualitative, quantitative, levels of evidence)	494	395	268	369	217	3.46	3.40	3.36	3.53	3.38	1.06	1.07	1.00	1.03	1.09	85	83	85	98	95
Measurement science (e.g., reliability, validity)	494	395	268	369	217	3.64	3.56	3.59	3.69	3.54	1.03	1.03	1.00	1.00	1.08	86	84	87	98	96
Data collection techniques (e.g., surveys, direct observation)	494	395	268	369	217	3.55	3.37	3.38	3.50	3.39	1.09	1.06	1.05	1.09	1.15	85	82	85	96	94

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
SKILLS																				
Active listening - Giving full attention to what other people are saying, taking time to understand the points being made, asking questions as appropriate, and not interrupting at inappropriate times	493	394	268	367	214	4.83	4.81	4.76	4.77	4.78	0.46	0.47	0.52	0.52	0.52	87	85	88	100	100
Speaking - Talking to others to convey information effectively	493	394	268	367	214	4.80	4.76	4.71	4.74	4.78	0.45	0.52	0.58	0.54	0.46	87	85	88	100	100
Reading comprehension - Understanding written sentences and paragraphs in work related documents	493	394	268	367	214	4.72	4.67	4.66	4.67	4.61	0.55	0.60	0.60	0.57	0.63	87	85	88	100	100
Critical thinking - Using logic and clinical reasoning to identify the strengths and weaknesses of alternative solutions, conclusions or approaches to problems	493	394	268	367	214	4.83	4.74	4.73	4.77	4.79	0.43	0.51	0.53	0.49	0.50	87	85	88	100	100
Social perceptiveness - Being aware of others' reactions and understanding why they react as they do	493	394	268	367	214	4.76	4.69	4.60	4.69	4.74	0.51	0.57	0.61	0.56	0.51	87	85	88	100	100
Time management - Managing one's own time and the time of others	493	394	268	367	214	4.73	4.70	4.62	4.66	4.74	0.55	0.56	0.62	0.60	0.52	87	85	88	100	100
Coordination - Adjusting actions in relation to others' actions	492	393	267	366	214	4.57	4.53	4.49	4.52	4.56	0.64	0.64	0.68	0.63	0.64	87	85	88	100	100
Writing - Communicating effectively in writing as appropriate for the needs of the audience	492	393	267	366	214	4.58	4.53	4.47	4.54	4.48	0.62	0.66	0.71	0.66	0.71	87	85	88	100	100
Active learning - Understanding the implications of new information for both current and future problem solving and decision-making	492	393	267	366	214	4.64	4.57	4.53	4.58	4.55	0.57	0.62	0.68	0.61	0.65	87	85	88	100	100
Persuasion - Persuading others to change their minds or behavior	492	393	267	366	214	4.02	3.91	3.84	3.95	3.88	0.97	0.93	1.02	0.99	0.99	86	85	86	98	100

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024
Negotiation - Bringing others together and trying to reconcile differences	492	393	267	366	214	4.13	4.04	3.91	4.05	3.89	0.92	0.92	0.97	0.93	1.01	86	84	87	99	98
Service orientation - Actively looking for ways to help people	492	393	267	366	214	4.53	4.43	4.31	4.40	4.35	0.71	0.75	0.89	0.77	0.84	87	85	87	100	99

Appendix C. Notable Mean Differences Across Years

Table C.1.: Statistics and Formatting Key

- **Sample Size (n):** Count of respondents that provided usable data
- **Mean Importance (M):** Based on responses for scale points 1 through 5
- **Standard Deviation of Importance (SD):** Based on responses for scale points 1 through 5
- **Mean Difference (M-Diff):** Difference between mean importance ratings across years (Y1=2020, Y2=2021, Y3=2022, Y4=2023, Y5=2024)

- **Boldface Mean (Red):** Mean importance rating was less than 2.50 (Criticality Threshold)
- **Boldface M-Diff (Green):** Mean difference rating increased by at least 0.50
- **Boldface M-Diff (Red):** Mean difference rating decreased by at least 0.50

Format	Description	Example
Boldface Mean (Red)	Mean importance rating was less than 2.50 (Criticality Threshold)	0.53
Italicized M-Diff (Green)	Mean difference rating increased by at least 0.50	<i>0.61</i>
Italicized M-Diff (Red)	Mean difference rating decreased by at least 0.50	<i>-0.70</i>

Table C.1. Notable Mean Differences Across Years

	Importance															M-Diff	
	n					M					SD						
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2024 - 2020	2024 - 2023
PT KSRs																	
Applications, indications, contraindications, and precautions of dry heat thermotherapy (e.g., Fluidotherapy)	886	839	380	666	440	3.70	3.68	3.62	2.59	2.48	1.18	1.16	1.19	1.28	1.20	-1.22	-0.22
Applications, indications, contraindications, and precautions of LED light therapy	886	839	380	666	440	2.85	2.47	2.52	2.35	2.30	1.23	1.21	1.25	1.22	1.08	-0.55	-0.05
PTA KSR																	
Applications, indications, contraindications, and precautions of dry heat thermotherapy (e.g., Fluidotherapy)	494	395	269	372	221	4.31	4.12	4.04	2.82	2.65	0.92	1.03	1.05	1.29	1.34	-1.66	-0.18
Applications, indications, contraindications, and precautions of iontophoresis	494	395	269	372	221	3.37	3.25	3.10	2.86	2.76	1.24	1.28	1.28	1.26	1.26	-0.61	-0.10
Applications, indications, contraindications, and precautions of laser light therapy	494	395	269	372	221	3.16	2.85	2.75	2.63	2.58	1.30	1.31	1.26	1.28	1.25	-0.58	-0.05
Applications, indications, contraindications, and precautions of LED light therapy	494	395	269	372	221	3.16	2.68	2.55	2.51	2.42	1.30	1.27	1.22	1.20	1.21	-0.75	-0.09
Applications, indications, contraindications, and precautions of phonophoresis	494	395	269	372	221	3.11	2.90	2.77	2.63	2.37	1.31	1.33	1.32	1.27	1.25	-0.74	-0.26
Applications, indications, contraindications, and precautions of ultrasound modalities, excluding phonophoresis	494	395	269	372	221	3.95	3.66	3.59	3.44	3.33	1.15	1.23	1.25	1.27	1.26	-0.62	-0.12

	Importance															M-Diff	
	n					M					SD						
	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2020	2021	2022	2023	2024	2024 - 2020	2024 - 2023
Applications, indications, contraindications, and precautions of diathermy	494	395	269	372	221	3.05	2.80	2.68	2.58	2.44	1.33	1.38	1.34	1.32	1.36	-0.61	-0.14
PT WAs																	
Perform and/or train patient/client/caregiver in selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)	758	410	254	413	223	2.40	2.68	2.39	2.29	2.81	1.34	1.48	1.44	1.34	1.35	0.41	0.51
PTA WAs																	
Perform tests and measures of body composition (e.g., percent body fat, lean muscle mass, body mass index [BMI])	265	225	92	170	74	2.63	2.73	2.60	2.84	2.31	1.15	1.27	1.15	1.21	1.16	-0.32	-0.53
Perform peripheral mobilization/manipulation (thrust)	365	209	112	217	96	3.15	2.95	3.04	2.98	2.63	1.29	1.36	1.55	1.28	1.37	-0.52	-0.35
Disclose financial interest in recommended products or services to patient/client	232	197	80	143	63	3.20	3.18	3.11	2.84	3.68	1.28	1.20	1.37	1.33	1.14	0.49	0.84